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Stellingen 
1. Suppletie met een enkel nutrient in gebieden waar meerdere nutrienttekorten naast 
elkaar bestaan, zal niet leiden tot verbeteringen in geboortegewicht of 
zuigelingengroei (Dit proefschrift). 
Vergeleken met suppletie tijdens de zuigelingenperiode, is suppletie met zink tijdens 
de zwangerschap een effectievere manier om de gezondheid van zuigelingen jonger 
dan 6 maanden te verbeteren (Dit proefschrift). 
Een verbetering van de status van vrouwen in de maatschappij is de beste lange-
termijn strategie vooreen verlaging van de kindersterfte. (UNICEF, 1999). 
De effecten van het langdurig geven van borstvoeding op de voedingstoestand van 
moeders in populaties waar de meeste moeders ondervoed zijn verdienen meer 
aandacht. 
Een laag geboortegewicht is geen oorzaak maar een indicatie voor postnatale 
gezondheidsrisico's. 
De gevolgen van luchtvervuiling op de voedings- en gezondheidstoestand van 
kinderen in stedelijke gebieden in ontwikkelingslanden wordt onderschat. 
7. Het huidige Nederlandse ontwikkelingssamenwerkingsbeleid om hulpontvangende 
landen te selecteren op basis van criteria voor armoede en goed bestuur zal in de 
praktijk niet werken aangezien in de meeste landen deze twee zaken negatief met 
elkaar gecorreleerd zijn. 
Het verdient aanbeveling om enige praktijkervaring op te doen met zwangerschap en 
lactatie alvorens een onderzoek te ontwerpen bij zwangere en lacterende vrouwen. 
Stellingen behorende bij het proefschrift getiteld: "Zinc supplementation in Bangladeshi 
women and infants: Effects on pregnancy outcome, infant growth, morbidity and immune 
response". 
Saskia Josepha Maria Osendarp 
Wageningen, 19 juni 2001 
Propositions 
1. Supplementation with a single nutrient will not improve birthweight or infant growth in 
areas where multiple nutrient-deficiencies are prevalent (This dissertation). 
2. Compared to infant supplementation, is zinc supplementation during pregnancy a 
more effective way to improve health in infants below 6 months of age (This 
dissertation). 
3. Improving the status of women in the society is the best long-term strategy for 
improvement of child survival (UNICEF, 1999). 
A. The impact of prolonged breast feeding on maternal nutritional status in populations 
where most mothers are malnourished deserves more attention. 
5. Low birthweight is not a cause but rather an indicator of risk for postnatal morbidity 
and mortality. 
6. The effect of air-pollution on health and nutritional status of children in urban 
communities in developing countries is underestimated. 
7. The present Dutch foreign policy to prioritize aid-receiving countries based on criteria 
for poverty and good governance, can not apply this in reality since in most countries 
these two issues are negatively correlated. 
8. Personal experience with pregnancy and lactation before designing a study in 
pregnant and lactating women is preferred. 
Propositions belonging to the dissertation entitled: "Zinc supplementation in Bangladeshi 
women and infants: Effects on pregnancy outcome, infant growth, morbidity and immune 
response". 
Saskia Josepha Maria Osendarp 
Wageningen, 19 June 2001 
To the women of Bangladesh 
Abstract 
Zinc supplementation in Bangladeshi women and infants: 
Effects on pregnancy outcome, infant growth, morbidity and immune response. 
Ph.D. thesis by Saskia Osendarp, Division of Human Nutrition and Epidemiology, Wageningen 
University, the Netherlands. June 19, 2001. 
Zinc plays an essential role during periods of rapid growth and development, 
and is therefore important during the periods of gestation, fetal life, and early 
infancy. In this thesis two intervention studies are described to evaluate the effect of 
zinc supplementation during the last six months of pregnancy or between 1 and 6 
months of age in infancy on pregnancy outcome, infant growth, morbidity from 
infectious diseases and immune response to childhood vaccines during the first six 
months of life. The study was performed in the urban slum areas of Dhaka, 
Bangladesh; an area where low birth weight (LBW) is prevalent and zinc deficiency is 
assumed to be common. 
The results showed that supplementation with 30 mg elemental zinc/day during 
the last two trimesters of pregnancy, did not improve intra-uterine or postnatal 
growth but resulted in a reduced morbidity from diarrheal diseases and impetigo in 
the infants during the first six months of life, particularly in infants born with LBW. 
These effects were most likely due to improved cellular immunity in these infants as 
indicated by a higher proportion of positive responses to the tuberculin skin test at 6 
months of age. Supplementation of infants with 5 mg elemental zinc/day from 4 to Z4 
weeks of age improved linear and ponderal growth and reduced morbidity from Acute 
Lower Respiratory Infections (ALRI) but only in a small proportion of infants that were 
zinc deficient at 4 weeks of age. In most infants however, supplementation with zinc 
did not have any effect on growth or morbidity. There was no clear effect of zinc 
supplementation on infant's immune response. Zinc improved the antibody response 
to certain specific Pneumococcal serotypes whereas a very small but negative effect 
of zinc on the response to the tuberculin skin test was observed. 
In conclusion, the findings of this study suggest that child health and survival 
programs in less developed countries should consider the inclusion of zinc in antenatal 
multiple micronutrient supplements especially in regions where LBW is prevalent. 
More research is required to enable formulation of policy directions regarding the use 
of zinc supplements in infants during the first six months of life. 
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General introduction 
Chapter 1 
Despite impressive achievements in the area of nutrition during the last 
decade, undernutrition remains a major public health problem in many parts of 
the world with South Asia, and Bangladesh in particular, being especially affected. 
It is estimated that 55% of all Bangladeshi children under five years of age are 
moderately or severely stunted while 56% are underweight.1 The prevalence rate 
of low birth weight (LBW; < 2500 g) is estimated at 40 to 50% of all live births, the 
highest in the world. As is the case in most developing countries, the vast majority 
of these LBW cases are due to intrauterine growth retardation (IUGR). 
Infants born with IUGR have extreme rates of morbidity and mortality from 
infectious disease and malnutrition and are estimated to account for 
approximately one third of all deaths occurring in the first year of life.2 These 
children are also more likely to experience abnormal cognitive development, 
neurologic impairment, and poor school performance.3 There is increasing 
evidence that retarded fetal growth is associated with increased risks for chronic 
diseases in adulthood.4 Barker's fetal origin of disease hypothesis proposes that 
nutritional deprivation during fetal life may result into an adaptation of the body 
to limited resources. As a consequence, the body will be more prone to obesity 
and related chronic diseases such as diabetes, hypertension and heart disease later 
in life during periods of relative affluence.5 
The great majority of LBW is believed to be directly due to abnormalities 
that extend throughout the life cycle and is, therefore, considered an 
intergenerational problem. LBW infants grow up to be undernourished and stunted 
children and adolescents and, ultimately, undernourished women of childbearing 
age and undernourished pregnant women (figure 1). The life cycle approach 
currently adopted by the United Nations Sub-Committee on Nutrition (ACC/SCN)6 
has led to the recognition of maternal malnutrition as the most important 
determinant of childhood malnutrition.7 In particular, decreased maternal height 
and below normal prepregnancy weight and pregnancy weight gain, are among the 
strongest predictors of delivery of a LBW infant.8 
Undernutrition was long thought to be due to inadequate and insufficient 
dietary protein and energy intake. During the last decades however, it has been 
recognized that the problem of undernutrition is more complex and usually 
involves concurrent deficiencies of micronutrients as well. Since then, research 
and public health interventions were directed to deficiencies of the three most 
prominent micronutrients: iodine, iron and vitamin A. This recognition has led to 
great progress in the control of these deficiencies world-wide.6 
It was only in 1997 that the ACC/SCN officially recognized the importance of 
other micronutrient deficiencies and in particular acknowledged that zinc 
deficiency may be widely prevalent in many developing countries and may have 
broad, adverse consequences on public health.9 
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Source: Prepared by Nina Seres for the ACC/SCN-appointed Commission on the Nutrition Challenges of the 21" Century. 
Figure 1. Women's nutrition throughout the life cycle 
ZINC STATUS AND ZINC DEFICIENCY 
Zinc has been known as an essential trace element since the 1930s.10 In the 
1960s in Iran, Prasad et al.11 for the first time identified zinc deficiency as the 
underlying cause for stunting and delayed sexual maturation. More recently, zinc 
deficiency has not only been associated with reduced growth and development, 
but also with impaired immunity and increased morbidity from infectious 
diseases.12,13 As a constituent of over 200 metallo-enzymes in the human body, zinc 
is known to play an important molecular role in processes of gene replication, 
activation and repression, as well as DNA transcription and translation and protein 
synthesis.14 The physiological role of zinc during periods of rapid growth and 
development emphasizes its importance during periods of gestation, fetal life, and 
early infancy. 
Although zinc deficiency is thought to be wide-spread in most developing 
countries, there is no reliable information on the magnitude of zinc deficiency 
mainly because of the existing controversy on reliable and feasible indicators to 
assess body zinc status. Till date, plasma and serum zinc are still considered to be 
the best available indicators for assessment of zinc status on a group level.15 
However, it represents only 0.1% of the total body zinc.16 Furthermore, 
plasma/serum levels are known to vary by 15-20% within individuals throughout the 
day17 and are affected by physiological conditions such as infections.15 In 
populations where the habitual dietary intake of zinc is low, plasma and serum 
13 
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zinc levels may reflect a possible adaptation to these low intakes and are 
therefore not an adequate measure of marginal zinc status.18 Inverse relationships 
between dietary zinc supply and serum zinc status have been observed in several 
studies,16 probably because of reduced excretion of endogenous zinc.19 
More recently stable isotope techniques were developed20 which yield more 
reliable estimates of an individual's zinc status. These techniques however, are 
still relatively expensive, difficult to perform, and require frequent drawing of 
blood which make them less feasible for use in larger cohort studies especially 
when infants or young children are involved. 
It has been suggested that an effect on growth after zinc supplementation 
may be used as a proxy for zinc deficiency in a population.12 However, recent 
studies in Mexican21, Jamaican22 and Ugandan children23 were not able to 
demonstrate a growth effect after zinc supplementation, indicating that zinc might 
not be the primary limiting nutrient for growth in populations with multiple 
nutrient deficiencies.24 Therefore, growth performance after supplementation has 
limitations as an indicator of zinc deficiency in such populations.25 
ZINC IN THE DIET 
Zinc is available in a wide variety of foods but its bioavailability may vary 
depending on the source of origin as well as other components of the diet. The 
primary inhibitor of zinc absorption is phytic acid, which is present in significant 
amounts in staple foods like cereals, corn and rice. Inositol hexaphosphates and 
pentaphosphates are the phytate forms that exert these negative effects, whereas 
the lower phosphates have no or little effect on zinc absorption.26 The amount of 
protein in a meal has a positive effect on zinc absorption and animal proteins in 
particular have been shown to counteract the inhibitory effect of phytate on zinc 
absorption.27 In contrast, high concentrations of calcium in the diet may 
exacerbate the inhibitory effect of phytate although the calcium content of most 
plant-based diets in less developed countries is considered to be too low to 
influence the effects of phytate.28 Based on these considerations, a model has 
been developed for categorizing diets according to the potential high (i.e., >50%), 
moderate (i.e., 30%) or low (i.e. < 15%) availability of zinc.16 This model takes into 
account the dietary content of animal or fish protein, daily intakes of calcium and 
daily molar ratios of phytate to zinc. In developing countries, where most dietary 
zinc originates from cereals rich in phytate, the bioavailability of zinc is thought to 
be only 10-20%, based on a phytate:zinc molar ratio exceeding 15.16 The current 
dietary recommendations take this into account and provide estimates of required 
basal and normative intakes for diets with different levels of bio-availability.29 The 
basal requirement is the amount needed to prevent clinically detectable signs of 
14 
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functional impairment whereas the normative requirements reflect the amount 
needed to maintain tissue stores or reserve capacity. 
Table 1. Zinc and phytate daily intakes in selected regions in the world1 
Sub-Saharan 
W Europe USA & Canada SEAsia Africa South Asia World 
10 46 6 178 
504 581 1297 5882 
9.0 ±0.9 9.3 ±2.0 7.6 ±0.6 10.0 ±2.0 
2248 ±586 2530 ±645 2068 ±263 2045 ± 504 
24.5 ±4.6 26.9 ±3.7 26.9 ±1.7 21.3 ±6.0 
1.1 ±0.2 1.0 ±0.2 0.8 ±0.1 1.5 ±0.9 
71.2 ±14.2 68.0 ±25.9 95.4 ±2.1 48.9 ± 36.8 
1
 Values in mean ± SD 
2Amount of zinc available for absorption estimated as 50% if phytate:zinc molar ratio <5, 35% if phytate:zinc 
molar ratio = 5-15, and 15% if phytate:zinc ratio >15.16 
3Risk of low intake was based on theoretical mean requirements for respective national population distributions, 
assuming a 25% coefficient of variation in zinc intake. 
Adapted from: Brown KM, Wuehler SE, Peerson JM. The importance of zinc in human nutrition and estimation of 
the global prevalence of zinc deficiency. Food and Nutrition Bulletin (supplement; in Press)30 (Reproduced with 
permission). 
Number of 
countries 
Population 
(millions) 
Zinc (mg/d) 
Phytate (mg/d) 
Phytate: 
Zinc ratio 
Absorbable zinc 
(mg/d)2 
Estimated % 
population at risk 
of low zinc 
intake3 
20 
457 
12.4 ±1.3 
1596 ±391 
13.2 ±4.8 
3.2 ±1.2 
8.0 ±17.1 
2 
305 
12.2 ±0.5 
1542 ±58 
12.5 ±0.1 
2.9 ±0.1 
0.9 ± 0.2 
Assumptions on levels of zinc deficiency have been made based on 
comparisons of observed dietary zinc intake with recommended dietary intakes for 
zinc. In an attempt to estimate the global prevalence of zinc deficiency, national 
food balance sheets compiled by the Food and Agriculture Organization of the 
United Nations (FAO) were used. Absorbable zinc in the food supplies were 
calculated based on the phytate:zinc molar ratio's and risk of low intake was based 
on theoretical mean requirements for respective national population 
distributions.30 The estimated mean per capita amount of absorbable zinc in the 
national food supplies and proportion of the population at risk of low intake are 
shown in table 1. This table indicates that zinc deficiency is likely to be a major 
public health problem, particularly in South Asia with an estimated 95% of the 
population at risk of low dietary zinc intake. 
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ZINC DEFICIENCY DURING PREGNANCY 
Despite the difficulties described in measuring zinc status validly, it is 
estimated that about 82% of all pregnant women worldwide are likely to suffer 
from zinc deficiency.31 During the last two trimesters of pregnancy, a net intake of 
3 mg elemental zinc/day is recommended which translates into an intake of 15 mg 
zinc/day assuming a bioavailability of 20%.16 Median dietary zinc intakes of 8-14 
mg/day have been reported from pregnant women in developed countries31 while 
intakes of 6.2-7.0 mg/day were observed in studies in Malawi32 and Brazil.33 These 
figures are well below the recommended intakes for pregnant women and support 
the hypothesis that zinc deficiency is widely prevalent in pregnancy, especially 
among women from less developed countries. 
The possible mechanisms and pathways of maternal zinc deficiency and 
adverse health effects to the mother and fetus have been previously reviewed.31 
Maternal zinc status during pregnancy may have a direct effect on fetal growth and 
infant birth weight. Moderate maternal zinc deficiency has also been related to 
complications during labor and delivery that may in turn affect pregnancy 
outcome. It is further possible that maternal zinc status during pregnancy 
influences infant growth and morbidity beyond the neonatal period through its 
effect on intra-uterine growth and development of the immune system34 and 
possibly through an interaction with vitamin A metabolism.35 This theoretical 
framework has been supported by the results of many cross-sectional studies 
suggesting that low dietary zinc intake or low maternal plasma zinc are associated 
with an increased risk of LBW and preterm delivery.36"38 
Low plasma zinc has also been reported to correlate with pregnancy complications 
such as prolonged labor, hypertension, postpartum hemorrhage, spontaneous 
abortion, and congenital malformation.39 Despite these associations, the evidence 
from zinc supplementation trials in pregnant women to improve pregnancy 
outcome has been less convincing. 
Till date, most randomized controlled trials have been performed in developed 
countries and the results have been described and summarized.40,41 Nine of these 
trials are presented in table 2. The studies differed substantially in number of 
participants, duration of supplementation and dosages used while their results 
have been inconclusive. A clinically and statistically significant increase of 126 g in 
birth weight and 0.4 cm in head circumference after zinc supplementation was 
observed in the United States among African-American women, in which only 
women with low plasma zinc concentrations at enrollment were included.49 
Based on the results of this study it was hypothesized that in less developed 
countries where diets low in zinc are likely to result in zinc deficiency and where 
the prevalence of LBW is high, the positive effects of maternal zinc 
supplementation on pregnancy outcome would even be larger. 
16 
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Table 2. Double blind, randomized-controlled intervention trials on the effect of 
maternal zinc supplementation on pregnancy outcome in developed countries. 
Reference 
Hambidge et al. 
(1983) USA(42) 
Hunt et al. 
(1984) USA<43) 
Hunt et al. 
(1985) USA<44) 
Cherry et al. 
(1989) USA(45) 
Mahomed et al. 
(1989) UK(46> 
Simmer et al. 
(1991) UK(47) 
Jameson et al. 
(1993) Sweden m 
Goldenberg et al. 
(1995) USA<49) 
Jonsson et al. 
(1996) Denmark(50) 
N 
46 
213 
138 
556 
494 
56 
1231 
580, 
low 
plasma 
-Zn 
1206 
Duration1 
9-7 mo 
from< 
27 wk 
gestation 
last 3 
mo. 
last 3 
mo. 
last 4 
mo. 
from >19 
wk 
gestation 
from <20 
wk 
gestation 
mgZn/ 
day 
15 
20 
20 
30 
20 
22.5 
15-90 
(depen-
ding 
serum 
Zn) 
25 
25 
Growth Effect 
None 
Not measured 
No sign, effect 
on birth weight 
Longer 
gestational 
length (only in 
underweight) 
No sign, effect on 
birth weight 
Lower incidence 
IUGR 
Fewer preterm (= 
<33 wk) 
Higher 
birthweight & 
larger head 
circumference 
None 
Other Responses 
None 
Decreased number of 
low serum zinc 
None 
Reduced rates 
prematurity 
None 
Labor induced+C-
section less often. 
Reduced perinatal 
death + spont. 
abortions 
None 
None 
1
 Duration of supplementation 
Unfortunately, at the time of the onset of the study described in this thesis, 
very few trials had been performed in these settings (table 3). Garg et al.52 showed 
a significant increase in birth weight after zinc supplementation in India, whereas 
a study carried out in South Africa51 did not show any effect. However, both 
studies suffered from methodological flaws as they did not use a double-blind 
design and lacked a placebo group. 
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Table 3. Intervention trials on the effect of zinc supplementation during pregnancy on 
pregnancy outcome performed in less developed countries. 
Reference 
Ross et al. 
(1985) 
South 
Africa*(51) 
Garg et al. 
(1993) 
India**(52) 
n 
127 
168 
Duration1 
before 20th 
week 
different 
duration 
mg Zn/ day 
30-90 mg Zn 
gluconate 
(4 cell trial 
with food 
supplements) 
45 (as zinc 
sulphate) 
Pregnancy 
outcome 
No effect on birth 
weight or length 
of gestation 
Higher birth 
weight and 
longer 
gestational age 
Other Responses 
Not investigated 
Higher Apgar score 
in zinc group 
= Duration of supplementation 
* = Not designed as zinc supplementation trial; **= No double-blind design 
ZINC DEFICIENCY DURING INFANCY 
In developed countries zinc deficiency is thought to be relatively rare among 
term breast-fed infants during the first months of life53' This is due to large 
concentrations of highly bioavailable zinc in early breastmilk and utilization of 
hepatic metallothionein as a source of zinc during the first six months of life.54 
Breastmilk zinc concentrations are quite high in the first weeks postpartum, 
averaging > 3ml/L but then decline rapidly over the early months postpartum, 
resulting in a longitudinal decline in dietary zinc intake. Zinc requirements also 
decrease as growth velocity declines during the first months of life, with 
requirements falling from approximately 8 mg elemental zinc/day for male infants 
at 1 month of age to 5 mg elemental zinc/day by 5 months. Zinc intakes from 
breastmilk are therefore thought to be adequate until approximately 6 months of 
age.55 However, the situation might be different among infants in less developed 
countries where inadequate milk supplies, poor substitution of nutrients and 
increased losses of zinc during infections all contribute to an increased 
requirement. Infants born with low birth weight may be especially at risk for 
developing zinc deficiency because of their relatively faster growth rate, smaller 
liver stores and because they are at-risk for reduced intake of breastmilk. In 
addition, the bioavailability of preterm breast-milk zinc may not be adequate for 
LBW preterm infants.56 
Zinc deficiency in infants and children has been associated with reduced 
growth, impaired immunity, increased prevalence and incidence of infectious 
diseases and delayed cognitive and motor development.12,13,57,58 Evidence for a 
causal relationship has been provided by randomized controlled intervention trials 
in infants above 6 months of age and children in both industrialized and developing 
countries showing improved immune functions,59,60 reduced morbidity13 and a small 
18 
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but significant effect on growth12 after zinc supplementation. The effects on 
morbidity are now thought to be more attributable to a correction of the zinc 
deficiency status that causes an impaired immunity and intestinal mucosal 
damage61 rather than to a pharmacologic effect of zinc.62 The effect of zinc on 
growth may be due to a direct role of zinc in protein synthesis and gene 
expression, but there may also be a secondary impact of zinc on growth resulting 
from reductions in morbidity and increased appetite. Predictors for a positive 
effect of zinc on growth in children are low height-for-age and low plasma zinc 
values on enrollment.12 A study on zinc supplementation among 6-12 month old 
infants in Ethiopia observed more pronounced effects on weight and length growth 
in stunted compared to non-stunted infants after zinc supplementation.63 
Only limited and inconclusive information is available on the effect of zinc 
supplementation in young infants, when interventions may be especially effective 
due to high requirements in this age group. Beneficial effects on growth and 
morbidity were observed after zinc supplementation among low birth weight (LBW) 
and small for gestational age (SGA) infants in Brazil64 and Chile65 respectively. 
However, in India no effect of zinc supplementation on diarrheal morbidity was 
observed in children between 6-11 months of age whereas strong beneficial effects 
were observed among older children.66 The varying responses to zinc 
supplementation in very young infants may be due to different prevalences of zinc 
deficiency among younger age groups caused by varying rates of IUGR, breast-
feeding practices and early morbidity. 
OBJECTIVES OF THE STUDY. 
As outlined above zinc deficiency has a marked effect on maternal and 
infant health. Zinc supplementation of pregnant women and infants might help to 
improve the health status of women and children especially in areas where zinc 
deficiency is common. Unfortunately, very few randomized-controlled trials have 
been performed in these settings. Therefore, two studies were performed in an 
urban, poor area of Bangladesh and the results are described in this thesis. The 
objective of the first study was to evaluate the effect of zinc supplementation 
during the last six months of pregnancy on pregnancy outcome, infant growth, 
morbidity from infectious diseases and immune response to childhood vaccines 
during the first six months of life. The second study aimed to evaluate the effect 
of zinc supplementation between 1 and 6 months of life on infant growth, 
morbidity from infectious diseases and immune response to childhood vaccines. 
The studies were performed in a population at high risk of growth faltering and 
increased morbidity in an area where LBW is highly prevalent and zinc deficiency is 
assumed to be common. 
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F/gure 2. Bangladesh in South Asia 
DESCRIPTION OF THE STUDY SITE. 
The study was conducted between March 1996 and January 1998 in three 
selected areas of Dhaka, Bangladesh (figure 2). With a per capita GNP of US$273 
and a population of an estimated 124 million,67 Bangladesh is still one of the 
poorest and most densely populated countries in the world. The average life 
expectancy in Bangladesh in 1998 was 61 years.67 During the last decades the 
success of public health interventions contributed to improvements in child 
survival. However the infant- and under-five-mortality rates remain high with 79 
and 106 per thousand live births respectively in 1998.1 Even though the majority 
of its population still lives in rural areas, the process of urbanisation seems 
irreversible with 20% of the population currently living in cities which is expected 
to grow to about 40% in 2020.68 With an estimated population of 10 million,67 the 
nation's capital Dhaka is rapidly becoming one of the most populated cities in the 
world. Most of the urban population, an estimated 85%,68 live in temporary or 
makeshift housing in the ever expanding city's slum areas. The population 
20 
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described in this study came from a representative sample of households from 
Dhaka's slum population.69 The slum areas are characterised by high population 
density, poor housing, multi-family water sources and latrines, poor sewerage and 
drainage facilities and irregular garbage collection. The population is relatively 
young and mostly illiterate.69 The 1996 infant mortality rate in the slum areas was 
estimated to be 138 per 1000 live births,70 substantially higher than the national 
average. Malnutrition is known to be widely prevalent and prevalences of 
malnutrition among children of the urban slums are even higher than among 
children of the rural poor.71 
OUTLINE OF THE THESIS 
Chapter 2 describes the dietary intake during pregnancy and the 
relationship with pregnancy outcome in women from the urban slums of Dhaka. No 
data were available on dietary zinc intake during pregnancy in this population and 
the assumption that zinc deficiency was highly prevalent was primarily based on 
reports of a low intake of foods from animal origin in urban slums.72 To enable a 
more precise description of the dietary intake during pregnancy in the urban slum 
population, dietary intake assessments were collected during each month of 
pregnancy. 
In Chapter 3 the effects are evaluated of a supplementation with 30 mg 
elemental zinc per day or a daily placebo during the last two trimesters of 
pregnancy on infant birth weight and gestational age and maternal weight gain 
during pregnancy. The effects on infant growth and morbidity during the first six 
months of life are presented in Chapter 4 while Chapter 5 describes the effect of 
maternal zinc supplementation on infant's immune response to childhood vaccines 
during the first six months of life. 
Subsequently, an additional cohort of infants was supplemented with daily 5 
mg elemental zinc or placebo from 4 to 24 weeks of age and the effects on growth 
and morbidity during the first six months of life are evaluated in Chapter 6. 
Chapter 7 describes the effects of infant supplementation on infant's immune 
response to childhood vaccines and in particular to the recently developed 
pneumococcal conjugate vaccine. 
Finally, in Chapter 8 the main findings of this dissertation are discussed and 
the effects of the two interventions are compared. Possible implications for public 
health programs and future research are discussed. 
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Abstract 
Background: Little is known about the association between energy and zinc intake and 
pregnancy outcome and the effect of maternal zinc supplementation on dietary intake. 
Objective: To evaluate energy and zinc intakes during the last two trimesters of 
pregnancy, the relation with pregnancy outcome and the effect of zinc supplementation 
on dietary intake in Bangladeshi women from Dhaka slums. 
Design: A total of 224 women had five monthly dietary intake assessments by means of 
24h-recalls. The women were randomly allocated to 30 mg daily elemental zinc or placebo 
from 12 to 16 weeks gestation until delivery. Anthropometric measurements were 
performed monthly. Birth weight, length and gestational ages were measured within 72h 
and infants were followed until 6 months for growth measurements. 
Results: Median daily intakes of energy (6065 kJ/d) and zinc (6.1 mg/d) at 4 months 
gestation were low although intakes increased between 4 and 8 months of pregnancy by 
11% for energy and 23% for zinc. An increased risk (OR:2.22) for premature delivery was 
observed among women with energy intakes below the median. There was no relationship 
with birth weight or post-partum nutritional status despite the positive associations 
between energy intake and maternal weight- and mid- upperarm circumference (MUAC)-
gains. Dietary zinc intakes were not related to pregnancy outcome. Supplementation with 
zinc did not have an impact on dietary intake. 
Conclusions: These women were at-high risk for inadequate energy and zinc intakes. 
Larger energy- but not zinc- intakes were related to greater maternal weight gains and 
reduced risk of premature deliveries. 
INTRODUCTION 
Maternal pre-pregnancy nutritional status and maternal weight gain during 
pregnancy are among the most important predictors of pregnancy outcome and 
subsequent infant health and survival.1 Energy balance during pregnancy is 
affected by complex and highly interrelated biological, social and cultural factors,2 
including dietary energy and nutrient intake. Several studies however, failed to 
observe associations between dietary intake and/or dietary supplementation 
during pregnancy and pregnancy outcome.3 It has been suggested that the effect 
of prenatal dietary supplementation is dependent on maternal nutritional status, 
such that supplementation would benefit the infant of moderately malnourished 
women and benefit the mother in severely malnourished women. In well-nourished 
women supplementation would have no effects.4,5 
Women in developing countries are known to consume only two-thirds of the 
recommended daily intake of energy while actual energy and nutrient intakes for 
pregnant women tend to be only slightly higher than those of non-pregnant 
women,6 despite the large estimated energy requirements of about 1.2 MJ/day 
during pregnancy.7 There have been reports from developing countries, including 
India and Bangladesh, that women may restrict their food intake during pregnancy 
deliberately in order to have smaller infants.8,9 
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Evidence is accumulating that intake of several micro-nutrients, including 
zinc, might also determine pregnancy outcome independent of energy intake.10,11 
Low dietary zinc intakes during pregnancy have been associated with preterm 
deliveries10 and lower birth weights11 in the USA and Egypt respectively. Zinc 
might, at least in children, also affect the intake of other nutrients through an 
effect on appetite.12,13 The results of prenatal zinc supplementation trials on 
pregnancy outcome however, have been inconclusive.14,15 We previously reported 
that zinc supplementation during pregnancy had no effect on infant's birth weight 
or gestational age.16 
In Bangladesh, poor maternal nutritional status17 and low pregnancy weight 
gains18 contribute to extremely high incidences of low birth weight (LBW; < 2500g) 
and subsequent childhood malnutrition. In this report we evaluate the association 
between dietary energy and zinc intake during the last 2 months of pregnancy, and 
maternal nutritional status, weight gain and infant's nutritional status. We also 
evaluate the effect of zinc supplementation on dietary intake during pregnancy, as 
part of a prospective study on the effect of zinc supplementation among pregnant 
women from an urban slum area in Dhaka, Bangladesh .16 
SUBJECTS AND METHODS 
Study design and population. 
The study was conducted between March 1996 and October 1997 as part of a 
community-based, double-blind randomized controlled trial, to evaluate the effect 
of zinc supplementation during pregnancy on birth weight, infant growth and 
morbidity from infectious diseases.16,19 The study was approved by the Ethical 
Review Committee of the International Centre for Diarrhoeal Disease Research, 
Bangladesh (ICDDR,B). Details on the study population, intervention and data 
collection procedure have been reported elsewhere.16 
A total of 559 pregnant women from selected areas of Dhaka city slums 
were enrolled in the study between 12 and 16 weeks gestation. Women were 
stratified by parity and randomly assigned to two treatment groups, to receive 
either 30 mg elemental zinc per day (twice the RDA, as zinc acetate) or a cellulose 
placebo. Supplementation continued until delivery and compliance with tablet 
consumption was 86% as assessed by counting remaining tablets in bubble packs 
during weekly compliance visits. Maternal weight, height and mid upper arm 
circumference (MUAC) and maternal dietary intake were measured monthly until 8 
months gestation during home visits and serum zinc and blood hemoglobin were 
assessed at 4 and 7 months gestation.16 Gestational age assessment, birth-weight 
measurements and infant anthropometric measurements were performed by 
trained physicians within 72 h of birth. Infants were followed until 6 months of age 
for monthly anthropometric measurements.19 
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Dietary intake 
Information on a woman's dietary intake was collected every four weeks 
from 4 to 8 months gestation by a 24-h recall using standardized methods.20 The 
interviews were conducted by trained health workers between March and October 
1996 corresponding with the spring and monsoon season in Bangladesh. This time-
period usually reflects a period of pre-harvest food scarcity.21 Women were asked 
to recall all foods and beverages consumed during the previous 24 h, including 
snacks. Women were asked to provide information on the ingredients of composite 
dishes as much as possible. Separate questions were asked on the use of vitamin 
and mineral supplements and on the amount of oil used for cooking in the 
household. To estimate the amount of oil consumed by the woman, the total 
amount of oil consumed in the household was divided by the number of persons 
that had been eaten in the household during the previous day. Adults were 
counted as one person and children as K person to compensate for the smaller 
amounts consumed by children. Portion sizes were estimated by using standard 
household measures. The quantities in grams equivalent for the uncooked foods 
were estimated by repeated measurements of 10 independent samples for each 
household measure and each food. 
A computerized food-composition table was developed especially for this 
study on the basis of nutrient values taken primarily from the Hyderabad table for 
Indian foods,22 and completed with values from other sources.23"25 To estimate the 
composition of common recipes and composite dishes, separate interviews and 
cooking sessions were performed in a representative sample of 38 women and 
average composition of recipes were calculated. The table contained energy, 
protein, carbohydrate and fat concentrations for 295 common foods and recipes. 
Iron and zinc concentrations were available for 92 and 65% of the foods 
respectively while only 38% of the foods had values for phytate. All dietary data 
forms were coded by trained nurses following standardized procedures. The 
conversion of foods into nutrients was done using the package KOMEET, developed 
at Wageningen University, Wageningen, The Netherlands (Bware, 1997). 
Anthropometry 
The weights of the women were measured by trained field workers to the 
nearest 0.1 kg on an electronic bathroom weighing scale (model 770; Seca, 
Hamburg, Germany), and height was measured to the nearest 0.1 cm with a 
locally-made height board. Midupper arm circumference (MUAC) was measured to 
the nearest millimeter with numeral-insertion tapes. 
Infants were weighed at home within 72 h of birth by physicians using a 
portable beam-balance scale (model 725; Seca) to the nearest 10 g and then 
monthly by trained field workers until six months of age. The scales were regularly 
calibrated against standard weights. Infants' length and head, arm, and chest 
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circumferences were measured to the nearest millimeter. Gestational age was 
calculated by using the last date of menstrual period (LMP) as recalled on 
enrollment. The Capurro method26 was used for 72 infants (18%) for whom LMPs 
were considered invalid (ie, <26 or >46 completed weeks or a difference between 
the LMP and the results of the Capurro method of >4 wk). Underweight (low 
weight-for-age), stunting (low length-for-age) and wasting (low weight-for-length) 
were defined as standard deviation scores (Z-scores) of < -2.00 compared with 
the sex-specific US NCHS reference charts using EPI Info software (version 6.1, 
1994, CDC, Atlanta, GA, USA).27 All anthropometric measurements were done in 
duplicate. Intra- and interobserver variation were regularly assessed and found to 
be acceptable, with CVs <2% for all anthropometric measures. 
Blood analysis 
Nonfasting venous blood was obtained during morning hours for serum zinc 
determination by using trace-mineral-free plastic syringes, stainless steel needles, 
and trace-mineral-free plastic tubes. Serum was separated at a maximum of 6 h 
after collection and stored at -20°C until analyzed. Before analysis, the serum 
samples were diluted (1:12) with 0.03% polyoxyethylene 23 lauryl ether and 10 
mmol HN03/L. Zinc concentration was measured by using flame atomic absorption 
spectrophotometry.28 A standard curve was established using a commercial zinc 
reference (BDH Laboratory Supplies, London, UK) in concentrations of 0.1, 0.25, 
0.5 and 1.0 mg/l. Commercial serum with known concentrations of zinc were used 
as a measure of quality control. The coefficient of variation of the measurements 
was always < 5%. 
Hemoglobin was measured by using a commercial kit (Sigma Diagnostics, St 
Louis). According to general practice in Bangladesh, iron supplements (200 mg 
ferrous sulfate plus 200 ug folate/d) were provided by the study team to women 
with a hemoglobin concentration <90 g/L at 4 mo (n = 14; 2.5%) and 7 mo (n = 40; 
8.5%) of gestation. The women were specifically instructed not to consume iron 
tablets together with the zinc supplements to avoid potential competition for 
intestinal absorption.29 
Data analysis and statistical methods 
Basal metabolic rates (BMR) were predicted based on women's self-reported 
age and baseline weight, and were multiplied with a factor 1.64 for moderate 
activity levels to predict woman's pre-pregnancy energy requirements.7 Pregnancy 
energy requirements were increased by 1.2 MJ/d to compensate for the additional 
energy required during pregnancy. Subsequently, the average daily energy intakes 
of the women were compared to the corresponding recommended intakes. Energy-
adjusted nutrient intakes were computed as the residuals from the regression 
model with total energy intake as the independent variable and absolute nutrient 
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intake as the dependent variable.30 The average daily nutrient intakes for protein, 
fat and iron were compared to the Indian recommended dietary intakes during 
pregnancy.22 Dietary zinc intakes with or without the supplemental zinc were 
compared to the WHO recommended basal and normative requirements during 
pregnancy, assuming a low bio-availability of the dietary zinc.31 The basal 
requirement is the amount needed to prevent clinically detectable signs of 
functional impairment whereas the normative requirements reflect the amount 
needed to maintain tissue stores or reserve capacity. The percentage of women at-
risk for inadequate intakes was calculated using the probability approach.20 
An analysis of variance (ANOVA) for repeated measures was used to examine 
within-women trends in energy and nutrient intakes during pregnancy. Differences 
between energy and nutrient intakes at different months in pregnancy were then 
tested with the Wilcoxon signed rank-test for non-normally distributed data 
(SPSS7.5 FOR WINDOWS; SPSS Inc, Chicago). Differences in dietary intake between 
women supplemented with zinc or placebo were compared by ANOVA for repeated 
measures. To examine the association between dietary intake during pregnancy 
and pregnancy outcome we first calculated nonparametric Spearman correlation 
coefficients. Linear regression models were then made with the variable for 
pregnancy outcome as dependent and the nutrient of interest as independent 
variable. Potential confounders were identified by means of a multiple step-wise 
regression and added to the main regression models. Logistic regression models 
were used to evaluate the association between low caloric and zinc intakes during 
pregnancy and preterm delivery or low birth weight (LBW; < 2500g) after 
controlling for confounding factors. P-values of <0.05 were considered statistically 
significant. 
RESULTS 
Of the 559 women (269 zinc, 290 placebo) enrolled in the study at 4 months 
gestation a total of 113 (20.2%) were lost-to-follow-up before delivery, primarily 
(n=60) due to out-migration during the course of the study.16 Reasons and numbers 
of lost-to-follow-up were not different for women of zinc or placebo groups. Of the 
446 women who completed the follow-up until delivery, 224 (115 zinc, 109 
placebo) had complete dietary intake data on all five measurement occasions 
during pregnancy. Baseline demographic and nutritional status characteristics of 
the 224 women with complete dietary intake data and the 335 excluded from the 
dietary intake analysis were not different (table 1). There were no significant 
differences in energy intake or in any of the nutrient intakes. The women with 
incomplete dietary data had a non-significant higher carbohydrate intake (270 vs. 
247 g/day), and as a consequence a lower fat and carbohydrate intake per MJ 
energy intake than women with complete dietary intake data (table 1). 
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Table 1. Baseline (12-16 weeks' gestation) characteristics of 559 pregnant Bangladeshi 
women with or without complete dietary intake data.' 
Age at enrollment (yr) 
Nulliparous (%) 
Socioeconomic status {%? 
Poor 
Very poor 
Years of completed 
education 
Family income (tk/month)4 
Weight (kg) 
Height (cm) 
BMI (kg/m2) 
MUAC (mm) 
Hemoglobin (g/L) 
Serum zinc (nmol/L) 
Energy intake (kJ/d) 
Fat intake (g/d) 
Crude 
Per MJ energy intake 
Carbohydrate intake (g/d) 
Crude 
Per MJ energy intake 
Protein intake (g/d) 
Crude 
Per MJ energy intake 
Dietary zinc intake (mg/d) 
Crude 
Per MJ energy intake 
Iron intake (mg/d) 
Crude 
Per MJ energy intake 
Women with incomplete 
dietary intake data (n=335) 
23.5 (5.6)' 
24.5 
38.8 
42.1 
1.3 (2.4) 
3068 (1520) 
41.8 (6.5) 
148.7 (5.7) 
18.8 (2.4) 
225 (25) 
115 (13) 
15.3 (4.5) 
6291 (4543-8521 )5 
31.3 (19.2-43.8) 
5.0 (3.5-7.2) 
270 (185-397) 
43.4 (38.3-47.3) 
40.4 (24.1-62.3) 
6.2 (4.9-8.0) 
6.8 (4.3-9.6) 
1.0 (0.9-1.3) 
11.3 (5.8-21.2) 
1.8 (1.1-2.9) 
Women with complete 
dietary intake data 
(n=224) 
22.8 (5.4) 
23.7 
39.3 
36.6 
1.5 (2.3) 
3235 (1817) 
41.9 (6.1) 
148.6 (4.8) 
18.9 (2.4) 
227 (23) 
116 (13) 
15.6 (4.3) 
6065 (4297-7727) 
31.1 (22.9-43.3) 
5.7 (3.8-7.5)* 
247 (164-397) 
41.9 (37.2-45.4)* 
38.9 (25.7-59.6) 
6.7 (5.4-8.1)* 
6.1 (4.1-8.9) 
1.0 (0.8-1.3) 
10.9 (6.2-21.4) 
1.8 (1.1-2.9) 
1
 BMI= Body Mass Index, MUAC= midupper arm circumference 
2
 mean (SD) 
3
 Based on an index of household assets15 
4
 One Bangladesh Taka (Tk) * US $ 0.02 
5
 Median (1st-3rd quartile) 
* Significantly different from women with incomplete dietary intake data, P < 0.05 (Mann-Whitney U-test) 
During pregnancy the 224 women that were included in the analyses gained 
an average of 5.0 kg (SD 2.2) between 4 and 8 months gestation while the mean 
increase in mid upper arm circumference (MUAC) was 4.6 cm (SD 11.1). Mean 
serum zinc and hemoglobin concentrations at 7 months gestation were 15.6 u.mol/1 
(SD 0.29) and 10.8 g/dL (SD1.3) respectively. 
A total of 209 singleton infants were born to these women. The mean birth 
weight was 2.53 kg (SD 0.40) and 43% of the infants were classified as low birth 
weight (LBW, < 2500 g). Mean birth length was 46.7 cm (SD 2.2) and the mean 
gestational age was 38.7 weeks (SD 2.2). A total of 193 infant-mother pairs 
completed the follow-up until 6 months post-partum. Mean maternal weight at one 
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Table 2. 
pregnancy. 
Energy and nutrient intakes of 224 poor urban Bangladeshi women during 
Per day 
4 months 
gestation 
5 months 
gestation 
6 months 
gestation 
7 months 
gestation 
8 months 
gestation 
Energy (kJ/d) 
Protein (g/d) 
Fat(g/d) 
Carbohydrate 
(g/d) 
Iron (mg/d) 
Zinc (mg/d) 
Phytate (mg/d) 
60651 
(4297-7727) 
38.9 
(25.7-59.6) 
31.1 
(22.9-43.3) 
247 
(164-342) 
10.9 
(6.2-21.4) 
6.1 
(4.1-8.9) 
238 
(146-341) 
6456* 
(4981-8309) 
43.9 
(32.2-61.4) 
31.8 
(20.8-45.8) 
282* 
(202-365) 
11.5 
(7.1-22.0) 
7.1* 
(5.4-9.6) 
278* 
(198-394) 
6478 
(4972-8055) 
40.6 
(30.1-57.5) 
33.2 
(23.6-44.8) 
279 
(200-359) 
11.1 
(6.6-18.8) 
7.3* 
(5.0-9.8) 
279* 
(193-371) 
65608* 
(4856-8631) 
41.7 
(28.8-61.2) 
35.4*' 
(26.0-46.9) 
273* 
(193-369) 
9.5' 
(6.0-17.1) 
7.4* 
(4.9-10.6) 
274* 
(172-355) 
6751** 
(5067-8667) 
44.9* 
(32.9-61.8) 
35.6* 
(24.8-47.8) 
280* 
(207-389) 
10.0 
(6.5-18.5) 
7.5* 
(5.2-10.0) 
276* 
(179-381) 
' Median (1st-3rd quartile) 
* Significantly different from value at 4 
11 Significantly different from value at 5 
# Significantly different from value at 6 
mo gestation, P<0.05 (Wilcoxon signed-rank test) 
mo gestation, P <0.05 (Wilcoxon signed rank test) 
mo gestation, P < 0.05 (Wilcoxon signed rank test) 
and six months post-partum were 42.9 kg (SD 6.0) and 41.9 kg (SD 5.6) 
respectively. 
Dietary intake during pregnancy 
Median energy and nutrient intakes during pregnancy are presented in table 
2. Intakes of energy, fat, carbohydrate, zinc and phytate were significantly 
different within women between 4 and 8 months gestation. However, median 
energy and zinc intakes during the second half of pregnancy (at 5, 6, 7, and 8 
months gestation) were not different within women. 
Energy (6677 kJ/d vs. 6065 kJ/d, respectively) and zinc intakes (7.5 mg/d 
vs. 6.1 mg/d, respectively) during the second half of pregnancy were significantly 
higher compared to intakes at 4 months gestation (P < 0.001; Wilcoxon signed 
rank-test). Significantly higher intakes of energy, fat, carbohydrate, zinc and 
phytate were observed at 5, 7 and 8 months gestation compared to the median 
intakes at 4 months gestation (table 2). The intake of protein at 8 months 
gestation was also significantly higher than the protein intakes at 4 months 
gestation. There were no differences within women over time for energy-adjusted 
intakes of protein, fat and carbohydrates (table 3). Energy-adjusted zinc intakes, 
excluding the supplement were significantly higher in the second half of pregnancy 
(at 5, 6, 7 and 8 months gestation) compared to 4 months gestation (table 3). 
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Table 3. Nutrient intakes per MJ energy intake of 224 poor urban Bangladeshi women 
during pregnancy. 
PerMJ 
Protein (g/MJ) 
Fat (g/MJ) 
Carbohydrate 
(g/MJ) 
Iron (mg/MJ) 
Zinc (mg/MJ) 
Phytate (mg/MJ) 
4 months 
gestation 
6.71 
(5.4-8.1) 
5.7 
(3.8-7.5) 
42 
(37-45) 
1.8 
(1.1-2.9) 
1.0 
(0.8-1.3) 
40 
(32-47) 
5 months 
gestation 
6.7 
(5.4-8.4) 
5.3 
(3.5-6.8) 
43 
(39-47) 
1.9 
(1.2-3.0) 
1.1* 
(0.9-1.3) 
43* 
(38-49) 
6 months 
gestation 
6.4 
(5.3-7.9) 
5.2 
(3.7-7.5) 
43 
(38-46) 
1.7 
(1.1-2.6) 
1.1* 
(0.9-1.3) 
43*' 
(35-48) 
7 months 
gestation 
6.5 
(5.1-8.3) 
5.6 
(4.2-7.7) 
42 
(37-46) 
1.4*1* 
(1.0-2.3) 
1.1* 
(0.9-1.4) 
41 * 
(34-46) 
8 months 
gestation 
6.5 
(5.4-8.4) 
5.4 
(3.8-7.3) 
42 
(39-46) 
1.4*1 
(1.0-2.4) 
1.1* 
(0.9-1.4) 
41 ' 
(33-48) 
1
 Median (1st-3rd quartile) 
* Significantly different from value at 4 mo gestation, P <0.05 (Wilcoxon signed-rank test) 
D Significantly different from value at 5 mo gestation, P < 0.05 (Wilcoxon signed-rank test) 
# Significantly different from value at 6 mo gestation, P < 0.05 (Wilcoxon signed-rank test) 
Energy-adjusted dietary iron intakes were significantly lower at the end of 
pregnancy (7 and 8 months gestation) compared to early in pregnancy (4 and 5 
months gestation). 
Overall during pregnancy, carbohydrates supplied 72% of the daily energy 
intake, whereas fat and protein contributed 20% and 12% respectively. Most (61%) 
of the energy intake came from cereals and only 10% came from animal products. 
Cereals and pulses contributed to 72% of the daily zinc intake. 
Overall during pregnancy, 88.8% of the women (n=199) had energy intakes 
below the recommended energy intakes for their age and bodyweights (table 4). 
The percentage of women estimated to be at risk for inadequate dietary zinc 
intake based on normative requirements was 98.2% while 94.2% were at risk for 
inadequate iron intake. If the supplement of 30 mg elemental zinc/d was added to 
the daily dietary zinc intake, an estimated 54.9% of the population was at risk for 
inadequate intakes (8.3% in the zinc supplemented and 97.9% in the placebo 
supplemented group). A total of 41% of the population was estimated to be at risk 
for inadequate intake of protein while the intake of fat was apparently more 
adequate with an average estimate of 16% at risk for inadequate intakes. There 
were no differences in percentages of women at risk of inadequate intakes for 
energy and nutrients between the second and third trimester of pregnancy. 
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Table 4. Percentages (%) of the population of pregnant urban Bangladeshi women 
estimated at-risk of inadequate intakes. 
Energy1 
Protein2 
Fat2 
Iron2 
Zinc3 
-basal requirements 
-normative 
Total zinc4 
requirements 
-basal requirements 
-normative requirements 
All women (n=224) 
Second 
trimester 
87.1 
46.3 
14.7 
92.1 
78.6 
94.5 
42.5 
52.8 
Third 
Trimester 
79.0 
43.6 
13.8 
92.1 
90.0 
97.4 
46.2 
50.8 
Zinc group (n=118) 
Second 
trimester 
89.6 
50.5 
13.4 
92.8 
81.2 
95.1 
6.1 
8.2 
Third 
trimester 
82.6 
45.0 
14.7 
93.3 
92.0 
97.8 
0 
0 
Placebc group 
(n=109) 
Second 
trimester 
84.4 
41.9 
16.1 
91.4 
76.2 
93.9 
76.2 
93.9 
Third 
trimester 
75.2 
42.2 
12.9 
91.1 
88.2 
97.0 
88.2 
97.0 
1
 Proportion below recommended intakes for age and kg bodyweight0 
2
 Estimates at-risk calculated with probability approach1' using the recommended intakes for Indians21 
3
 Estimates at-risk calculated with probability approach19 using the basal and normal requirements by 
trimester according to WHO30 
* Total zinc » dietary zinc plus supplemental zinc 
The effects of zinc supplementation on dietary intake 
There were no significant differences between women supplemented with 
zinc or placebo for energy intake (figure 1) during pregnancy or for crude and 
energy-adjusted protein, fat, carbohydrate and iron intakes during pregnancy 
(ANOVA for repeated measurements, data not shown). Dietary zinc intakes 
excluding the supplemental zinc at any measurement occasion were also not 
different between women from zinc or placebo group (figure 2). There were no 
differences between treatment groups for percentage of women at risk of 
inadequate intakes for energy and nutrients (table 4). When the supplemental zinc 
was added to the dietary zinc intakes, the proportion of women at risk for 
inadequate zinc intakes decreased dramatically in the zinc group (table 4). With 
the additional 30 mg zinc per day all women were able to meet the requirements 
for zinc during the third trimester of pregnancy whereas the vast majority (92.5%) 
was able to meet the requirements during the second trimester as well. 
Dietary energy and zinc intake and pregnancy outcome 
A higher mean energy intake during pregnancy was associated with higher 
maternal weight gains (P=0.16, P=0.02) and MUAC gains (p=0.20, P=0.003) during 
gestation. Higher mean energy intake during pregnancy was also associated with 
higher serum zinc concentrations as measured at 7 months gestation (P=0.13, 
P=0.05). These associations remained statistically significant after controlling for 
woman's age, the household's socio-economic status and family income, baseline 
maternal weight, and baseline hemoglobin and serum zinc concentrations. 
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Figure 1. Median energy intake (kJ/d) over pregnancy for women in the zinc (n=115) and 
placebo group (n=109). 
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Figure 2. Median dietary zinc intakes (mg/d) excluding the zinc supplement over 
pregnancy for women in the zinc (n=115) and placebo group (n=109). 
35 
Chapter 2 
Energy intakes during pregnancy were also associated with higher hemoglobin 
concentrations at 7 months gestation. However, this association was not 
statistically significant anymore after controlling for the above-mentioned 
confounding factors (p=0.03, P=0.54). 
Higher mean dietary zinc intakes adjusted for total energy intake during the 
third trimester of pregnancy were associated with lower maternal weight gains (P= 
-0.15, P=0.02). Higher crude dietary zinc intakes during the third trimester of 
pregnancy were associated with larger increases in MUAC during pregnancy 
(P=0.15, P=0.02) and with higher serum zinc concentrations at 7 months gestation 
(P=0.15, P=0.03). The association between crude dietary zinc intake and 
hemoglobin concentrations at 7 months gestation was not statistically significant 
anymore (P=0.04, P=0.42), after controlling for the confounding factors. 
Women with low energy intakes during pregnancy (< 6569 kJ/d=median) had 
an increased risk for preterm delivery (OR: 2.22; [95%CI: 1.05-4.67]) even after 
controlling for confounding factors compared to women with higher energy 
intakes. The risk for delivering a LBW infant (< 2500g) was not different between 
women with lower or higher energy intakes (table 5). Dietary zinc intakes during 
pregnancy (excluding supplement) were not associated with infant birth weight or 
prematurity (table 5). Energy and dietary zinc intakes during pregnancy were not 
associated with infant or maternal nutritional status post-partum as measured at 
one or six months of age. 
Table 5. Association of low dietary energy and zinc intakes during pregnancy with low 
birth weight (LBW) and preterm delivery. 
LBW Preterm delivery 
OR (95% CI)1 OR (95%) 
Energy intake' 
Above median (n=113) 1.00 1.00 
Lower than median (n=111) 1.53 (0.88-2.65) 2.22 (1.05-4.67)* 
Dietary zinc intake3 
Above median (n=114) 1.00 1.00 
Lower than median (n=110) 1.01 (0.58-1.74) 1.28 (0.64-2.58) 
' OR= Odd Ratio (95% Confidence Interval) adjusted for baseline weight, baseline height and socio-economic 
status. 
2
 Energy intake in kJ/d; med1an=6569 kJ/d 
3
 Dietary zinc intake (excluding supplement) in mg/d; median=7.3 mg/d 
DISCUSSION 
The incidence of Low Birth Weight (LBW) in Bangladesh is reported to be the 
highest in the world with 40-50% of all live births classified as LBW in both urban32 
and rural33 Bangladesh. We previously reported an incidence of 43% LBW and 17% 
premature deliveries among a population of pregnant women from urban Dhaka 
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slums.16 The results of the current study in the same cohort of women, indicate 
that women's energy intakes during pregnancy may have contributed to the 
number of premature deliveries but had no impact on birth weight in this 
community. An increased risk for premature delivery was observed among women 
with energy intakes below the median compared to women with higher energy 
intakes. There was no relationship between energy intake during pregnancy and 
infant birth weight, length or post-partum nutritional status even though positive 
associations between energy intake and maternal weight and MUAC gains were 
observed. Dietary zinc intake during pregnancy was not related to pregnancy 
outcome independent of energy intake, except for a negative association between 
maternal pregnancy weight gain and energy-adjusted zinc intakes. 
Supplementation with daily 30 mg elemental zinc did not alter these associations 
nor did it have an impact on dietary intake during the last 2 trimesters of 
pregnancy. 
Dietary intake in our study was assessed by means of a 24h dietary recall at 
five different time locations during the last two trimesters of pregnancy. The 
limitations of the 24h recall method in estimating an individual's dietary intake are 
well known although it is considered to be a reasonable estimator of usual group's 
intakes.30 In a study among pregnant women in Malawi, a repeated, interactive 
24h dietary recall was found to slightly overestimate intakes of minerals including 
zinc and slightly underestimate intakes of energy, protein and fat as compared to 
intakes assessed by weighed records.34 We checked for a possible underestimation 
of energy intake in our population by calculating the ratio of energy intake (El) and 
estimated basal metabolic rate (BMR). It is assumed that a ratio EI/BMR below 1.27 
is incompatible with long-term survival.7,35 In our study on all measurement 
occasions, none of the women had energy intakes below this level. In addition, the 
final sample size of 224 women should have been sufficient to provide estimates 
on any single measurement occasion within 7% of the true intakes for energy and 
within 9% of the true intakes for zinc.20 We therefore believe that the estimates as 
presented in our study were reasonably reflecting true group intakes. 
In our population energy intakes during pregnancy were found to be 
extremely low (6065 kJ/d at 4 months gestation) but comparable to energy intakes 
observed in other studies from Bangladesh in pregnant36 and lactating37,38 women. 
The low energy intakes in our population are consistent with poor pregnancy 
outcomes and with the observation that 26% of these women had a decrease in 
MUAC during pregnancy, while 1.5% lost weight between 4 and 8 months gestation. 
The fact that energy intake during pregnancy was associated with maternal weight 
gain but not with infant birth weight might indicate that differences in energy 
intake in this population of extremely malnourished women, primarily are 
reflected in benefits to the mother. This is consistent with observations from East 
Java4, and Guatemala,5 where maternal energy supplementation was found to be 
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beneficial to the mother in severely malnourished women (« < 42 kg bodyweight) 
while it would benefit the infant on expense of the mother in moderately 
malnourished women (« 42-50 kg). 
It is interesting to note that energy intake in our population was related to 
premature delivery, despite the lack of effect on mean gestational age or low birth 
weight. In an overview of clinical trials on balanced energy and protein 
supplementation a similar reduced risk for preterm delivery was found while there 
was no effect on mean gestational age.3 The author contributed this inconsistency 
to problems in gestational age measurements. The fact that we did not observe an 
effect on LBW despite the effects on preterm deliveries, is most likely due to the 
fact that the LBW cases in this population were primarily (75%) term deliveries and 
caused by intra-uterine growth retardation (IUGR). 
Although observations from India8 and Bangladesh9 reported the practice of 
"down-eating" during pregnancy, i.e., eating less on purpose in order to have 
smaller babies and presumably smoother deliveries, we did not found evidence for 
this practice in these urban Bangladeshi women. Instead, women in our study 
tended to increase their caloric intakes during pregnancy and energy intakes at 8 
months of gestation (6751 KJ/d) were significantly higher compared to the intakes 
at 4 months (6065 KJ/d). 
On average women were consuming only 75% of their required energy 
intakes although we do not know whether the proportion of women at-risk of low 
energy intakes might have been overestimated in our population. The fixed 
incremental requirements of 1.2 MJ/d during pregnancy, as recommended by the 
WHO7 have been questioned recently.39 BMR is known to increase over time during 
pregnancy while the costs for energy deposition also vary throughout gestation and 
therefore lower increments, varying by trimester of pregnancy have been 
recommended instead. Prentice et al.39 further recommends the use of Physical 
Activity Levels (PAL) into calculations of energy requirements during pregnancy. In 
rural Bangladesh, PAL levels of > 1.75 were measured in lactating housewives 
while levels of > 2.10 were recorded for female, lactating tea-pluckers.38 PALs of 
women in our study were not known but it could be argued that activity levels of 
these women, almost exclusively housewives from a poor, urban community, may 
be different from the traditional rural activity patterns. The energy required for 
household activities may be less in an urban environment where women usually 
don't have to walk long distances to collect water or fuel-woods and we therefore 
assumed a moderate PAL (1.64) for the women in our study. 
The median dietary zinc intake in our population was 6.1 mg/d at 4 months 
gestation and 7.5 mg/d at 8 months gestation, lower than intakes observed in 
pregnant women from developed countries10,40 but comparable to intakes observed 
in Malawian women.41 Unfortunately, we were not able to calculate phytate:zinc 
molar ratio's because the phytate concentrations of many of the foods consumed 
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were not known. However, dietary zinc in our study was assumed to be poorly 
bioavailable since it came mainly from cereals that are known to be rich in 
phytate.31 
Dietary zinc intake was not related to zinc status or pregnancy outcome. 
Dietary zinc intakes during pregnancy have been related to birth weight in some 
studies,10,11 although others did not find evidence for such an association.40 The 
poor nutritional status and low overall energy intake in our population may have 
prevented the detection of any association between individual nutrients and 
pregnancy outcome. 
The negative association observed between dietary zinc intake adjusted for 
total caloric intake and pregnancy weight gain might be artificial. Positive 
associations between pregnancy weight gain, body weight and energy intake have 
been often observed in other studies,1 and might have resulted in a negative 
association between pregnancy weight gain and energy-adjusted zinc intakes. On 
the other hand, zinc is known to compete for intestinal absorption with other 
essential trace elements like iron and copper29 and a higher intake of zinc in the 
diet may have reduced the bioavailability of these other minerals, especially when 
consumed together in one meal. 
Zinc supplementation during pregnancy did not have an effect on dietary 
intake although in children zinc status or zinc supplementation has been associated 
with improved appetite12 and reduced anorexia.13 We are not aware of any reports 
in adults on the association between food intake and zinc. Dietary intake in adults 
is likely to be influenced by many different factors and, compared to young 
children, adult's food intake and/or taste acuity may be less responsive to zinc 
supplementation. 
In conclusion, the overall low energy and zinc intakes in this population of 
pregnant urban Bangladeshi women indicate a population at risk for poor maternal 
nutritional status and poor pregnancy outcomes. Larger energy -but not zinc-
intakes were related to greater maternal weight gains and a reduced risk of 
premature deliveries. Maternal zinc supplementation did not have an impact on 
dietary intake. 
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ABSTRACT 
Background: Maternal zinc supplementation has been suggested as a potential intervention 
to reduce the incidence of low birth weight in developing countries. To date, placebo-
controlled trials have all been performed in industrialized countries and the results are 
inconsistent. 
Objective: The objective of this study was to evaluate whether zinc supplementation in 
Bangladeshi urban poor during the last 2 trimesters of pregnancy was associated with 
pregnancy outcome. 
Design: We conducted a double-blind, placebo-controlled trial in which 559 women from 
Dhaka slums, stratified by parity between 12 and 16 wk of gestation, were randomly 
assigned to receive 30 mg elemental Zn/d (n = 269) or placebo (n = 290). Supplementation 
continued until delivery. Serum zinc was estimated at baseline and at 7 mo of gestation. 
Dietary intake was assessed at baseline and anthropometric measurements were made 
monthly. Weight, length, and gestational ages of 410 singleton newborns were measured 
within 72 h of birth. 
Results: At 7 mo of gestation, serum zinc concentrations tended to be higher in the zinc-
supplemented group than in the placebo group (15.9 ± 4.4 compared with 15.2 ± 4.3 
umol/L). No significant effect of treatment was observed on infant birth weight (2513 ± 
390 compared with 2554 ± 393 g; NS) or on gestational age, infant length, or head, chest, 
or midupper arm circumference. The incidence and distribution of low birth weight, 
prematurity, and smallness for gestational age also did not differ significantly after zinc 
supplementation. 
Conclusions: Supplementation with 30 mg elemental Zn during the last 2 trimesters of 
pregnancy did not improve birth outcome in Bangladeshi urban poor. These results 
indicate that interventions with zinc supplementation alone are unlikely to reduce the 
incidence of low birth weight in Bangladesh. 
INTRODUCTION 
South Asia, and Bangladesh in particular, has among the highest incidences 
of low birth weight (LBW; <2500 g) in the world. An estimated 40-50% of all live 
births in Bangladesh are classified as LBW, 70-80% of which are the result of 
intrauterine growth retardation (IUGR).1"3 Infants born with IUGR have higher 
mortality rates and are at higher risk of growth retardation, poor cognitive 
development, increased morbidity, and impaired immunity later in life than are 
their normal-birth-weight counterparts.4,5 Effective interventions aimed at 
preventing LBW are therefore particularly important potential strategies for 
reducing childhood malnutrition and improving infant health. Recently, maternal 
zinc supplementation was suggested as one possible nutritional intervention during 
pregnancy to improve pregnancy outcome in developing countries.6 
The results of cross-sectional studies suggest that low dietary zinc intake or 
low maternal plasma zinc are associated with an increased risk of LBW and 
preterm delivery.7"9 Low plasma zinc has also been reported to correlate with 
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pregnancy complications such as prolonged labor, hypertension, postpartum 
hemorrhage, spontaneous abortion, and congenital malformation.10 However, the 
results of zinc-supplementation trials in pregnant women to improve pregnancy 
outcome are not consistent,11'18 possibly reflecting the use of insufficient sample 
sizes11,13,16 or the fact that populations have varying risks of LBW and zinc 
deficiency.19 A clinically and statistically significant effect on birth weight and 
head circumference was observed in one controlled intervention trial in which only 
women with low plasma zinc concentrations at enrollment were selected.17 These 
results strengthened the hypothesis that zinc supplementation during pregnancy 
might be beneficial only in populations that are zinc deficient and at high risk of 
poor fetal growth.19'20 Although women from developing countries are more likely 
to be zinc deficient and to have a greater risk of producing LBW infants, we are 
aware of only 2 published supplementation trials from developing countries.21,22 
One trial in India showed a significant increase in birth weight after zinc 
supplementation,21 whereas the other study, which was carried out in South Africa, 
showed no effect.22 However, neither of these studies used a double-blind design 
and both were lacking a true placebo group. 
It is in this context that we performed a double-blind, placebo-controlled 
zinc-intervention trial among pregnant women from the urban slums of Dhaka, 
Bangladesh. These women belonged to a very poor and deprived part of the 
population in which LBW is highly prevalent and the poor quality of diets is likely 
to result in zinc deficiency. 
SUBJECTS AND METHODS 
Study population 
Between March and June 1996, a total of 559 pregnant women from 
selected areas of Dhaka city slums were identified between 12 and 16 wk of 
gestation through an established pregnancy-identification system. Gestational age 
on enrollment was determined by the women's recalled date of their last 
menstrual period (LMP). Women were included in the study if they planned to 
remain at or near their residences in Dhaka for the delivery, did not have an 
established medical risk for reduced or excessive birth weight (eg, hypertension, 
renal disease, or diabetes), and provided informed consent. The study was 
approved by the Ethical Review Committee of the International Centre for 
Diarrhoeal Disease Research, Bangladesh (ICDDR,B). The final sample size required 
to enable detection of a difference of 250 g in birth weight with 80% power and a 
type I error of 5%, assuming an SD of 500 g, was estimated to be 300 (150 per 
treatment group). 
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Study design 
The study was double blind and women were stratified by parity and 
randomly assigned to receive either 30 mg elemental Zn/d as zinc acetate (n = 
269) or a cellulose placebo (n = 290). Before randomization, information was 
collected on the socioeconomic status of the women's households and the 
reproductive history of the women. Categories for socioeconomic status were 
defined according to an index for urban populations that was developed on the 
basis of ownership of household durable goods.23 The amount of zinc given was 
based on twice the recommended daily intake for zinc during the last 2 trimesters 
of pregnancy, assuming low or moderate bioavailability,24,25 and was used 
previously in pregnant women without reports of adverse effects.26 The zinc 
content of the zinc tablets (: 31.0 mg Zn/tablet; range: 28.6-32.6; n = 20) and 
placebo tablets (: 0.0 mg Zn/tablet; range: 0.0-0.1; n = 20) was verified in our 
laboratory and confirmed in a second independent laboratory. The placebo was a 
cellulose tablet indistinguishable from the zinc supplement in both appearance and 
taste. Health workers provided a 1 -wk supply of zinc or placebo tablets (ACME Ltd, 
Dhaka) to the houses of the women weekly and instructed the women to consume 
one tablet daily between meals and not together with other vitamin or mineral 
supplements. Compliance with this regimen was assessed by counting the 
remaining tablets in each strip at the next visit. Unannounced compliance checks 
between regular visits were performed monthly in subsamples of 10% of the study 
participants. The women were prospectively followed up and supplementation 
continued until delivery. Randomization was achieved by computer-generated 
random-letter assignment, and the codes remained unknown to both investigators 
and participants until the study was completed. Serum zinc concentrations, 
hemoglobin concentrations, and blood pressure were assessed at baseline and 
again at 7 mo of gestation during visits to the ICDDR,B Clinical Research and 
Service Centre. Information on dietary intake was collected at baseline and 
anthropometric measurements were made monthly from baseline until 8 mo of 
gestation during home visits. Gestational age assessment, birth-weight 
measurements, and infant anthropometric measurements were performed by 
trained physicians within 72 h of birth. 
Blood analyses and blood pressure 
Nonfasting venous blood was obtained during morning hours for serum zinc 
determination by using trace-mineral-free plastic syringes, stainless steel needles, 
and trace-mineral-free plastic tubes. Serum was separated at a maximum of 6 h 
after collection and stored at -20°C until analyzed. Before analysis, the serum 
samples were diluted (1:12) with 0.03% polyoxyethylene 23 lauryl ether and 10 
mmol HN03/L. Zinc concentration was measured by using flame atomic absorption 
spectrophotometry.27 For quality control, a commercial zinc reference (Utak 
Laboratories, Inc, Los Angeles) was used in concentrations of 0.1, 0.25, 0.5, and 
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1.0 mg/L. The CV of the analyses was always <5%. Hemoglobin was measured by 
using a commercial kit (Sigma Diagnostics, St Louis). According to general practice 
in Bangladesh, iron supplements (200 mg ferrous sulfate plus 200 ug folate/d) were 
provided by the study team to women with a hemoglobin concentration <90 g/L at 
4 mo (n = 14; 2.5%) and 7 mo (n = 40; 8.5%) of gestation. The women were 
specifically instructed not to consume iron tablets together with the zinc 
supplements to avoid potential competition for intestinal absorption.28 The blood 
pressure of the women was measured at 4 and 7 mo of gestation by registered 
nurses following standard procedures. 
Anthropometry and dietary intake during pregnancy 
The weights of the women were measured to the nearest 0.1 kg on an 
electronic bathroom weighing scale (model 770; Seca, Hamburg, Germany), and 
height was measured to the nearest 0.1 cm with a height stick. Midupper arm 
circumference (MUAC) was measured to the nearest millimeter with numeral-
insertion tapes. Intra- and interobserver variation were regularly assessed and 
found to be acceptable, with CVs <1% for all anthropometric measures. 
Dietary intake was assessed by a 24-h dietary recall and separate questions 
on the use of vitamin or mineral supplements. Portion sizes were estimated by 
using standard household measures quantified in grams by repeated measurements 
of 10 independent samples representative of the food concerned. A computerized 
food-composition table was developed especially for this study on the basis of 
nutrient values taken primarily from the Hyderabad table for Indian foods29 and 
completed with values from other sources.30'33 All anthropometric measurements 
and assessments of dietary intake were performed by trained fieldworkers who 
were closely supervised. 
Pregnancy outcome 
Newborns were weighed by physicians on a portable beam-balance scale 
(model 725; Seca) to the nearest 10 g during a home visit within 72 h of birth. The 
scales were regularly calibrated against standard weights. The period of 72 h was 
considered feasible and valid as a measure of birth weight in a field setting and 
was used in previous studies conducted at the ICDDR,B.2 In our study, the average 
time between measurement and birth was found to be similar in both groups. 
Infants' length and head, arm, and chest circumferences were measured to the 
nearest millimeter. Gestational age was calculated by using the LMP as recalled on 
enrollment. The Capurro method34 was used for 72 infants (18%) for whom LMPs 
were considered invalid (ie, <26 or >46 completed weeks or a difference between 
the LMP and the results of the Capurro method of >4 wk). Infants were classified as 
small for gestational age or appropriate for gestational age by using the 10th 
percentile of a US fetal growth curve as a cutoff.35 
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Statistical methods 
Differences between the zinc-supplemented and placebo groups for the 
main outcome variables were tested by using Student's t test, a chi-square test, or 
the Wilcoxon signed-rank test (SPSS 7.5 FOR WINDOWS; SPSS Inc, Chicago). 
Multiple stepwise regression was performed to identify variables that contributed 
significantly to the variation in outcome variables and that required adjustment as 
covariates during multivariate analyses on the effect of supplementation. 
Analysis of covariance (ANCOVA) was used to test for differences after 
adjustment for the effect of the covariates with the different outcome measures 
as dependent variables and treatment as the independent variable. For maternal 
weight and maternal MUAC during gestation, ANCOVA for repeated measurements 
was used. Some of the confounding variables had to be transformed into dummy 
variables36 to enable the mathematical model for ANCOVA to be expressed as a 
model for multiple regression. For serum zinc, log-transformed values were used 
because the distribution approached normality only after log transformation. The 
distribution of other variables did not violate the assumption of normality. P values 
<0.05 were considered significant. 
RESULTS 
Of the 559 women enrolled, 113 (20.2%) were lost to follow-up before 
delivery [55 (20.4%) in the zinc-supplemented group and 58 (20.0%) in the placebo 
group; NS]. As anticipated for this highly mobile population and despite the 
restrictions at enrollment, most losses to follow-up (n = 60) were due to out-
migration during the course of the study or to women leaving the area to deliver in 
their home villages. No differences in reasons for women being lost to follow-up 
were observed between the 2 groups. 
A higher percentage of nulliparity was observed among the women who 
were lost to follow-up because nulliparous women were more likely to go back to 
their home villages for delivery. No differences in other relevant baseline 
characteristics were observed (Table 1). 
Of the 446 women who completed the follow-up until delivery, 19 (12 in the 
zinc-supplemented and 7 in the placebo group; NS) delivered a stillborn infant or 
an infant that died shortly after birth. Four deliveries (2 in the zinc-supplemented 
and 2 in the placebo group; NS) took place outside Dhaka and 6 birth weights (3 in 
the zinc-supplemented and 3 in the placebo group; NS) were obtained >72 h after 
delivery and were excluded from further analyses. Another 7 women (3 in the zinc-
supplemented and 4 in the placebo group; NS) delivered twins and were excluded 
from the birth-weight analyses. The final sample size for the analyses of birth 
weight and gestational age therefore consisted of 410 singleton infants. 
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Table 1. Maternal baseline characteristics'. 
Women lost-to-follow-up Women who completed the 
(n=113) follow-up (n=446) 
Age at enrollment (yr) 
Nulli-parae 
Multi-parae only: 
- Previous SGA infant 
- Previous preterm 
- Previous miscarriage 
Socio-economic status4: 
- Poor 
- Very poor 
Weight (kg) 
Height (cm) 
BMI (kg/m2) 
MUAC (mm) 
Hemoglobin (g/L) 
Serum zinc (u,mol/L) 
23.6 ± 5.8Z 
32.7% 
9.1% 
13.0% 
30.9% 
41.6% 
41.6% 
41.6 ± 6.3 
148.9 ± 5.9 
18.7 ± 2.3 
224 ± 24 
117 ± 13 
15.8 ± 4.6 
23.1 ± 5.5 
22.0%3 
13.2% 
9.5% 
26.5% 
38.3% 
39.5% 
41.8 ± 6.3 
148.6 ± 5.1 
18.9 ± 2.5 
226 ± 24 
114 ± 13 
15.3 ± 4.3 
SGA: Small for Gestational Age; MUAC: Mid Upper Arm Circumference 
2
 means ± SD 
3
 Differed significantly from lost-to-follow-up group (P < 0.05; Chi-square test) 
4
 As based on an index of household assets23 
Overall, 79% of the women came from households classified as "poor" or 
"very poor" on the basis of an index of the household assets.23 Median dietary 
intakes of energy (6073 kJ/d) and zinc (6.5 mg/d) at baseline were not 
significantly different between the zinc-supplemented and placebo groups (Table 
2). Carbohydrates supplied 67.8% of the daily energy intake, whereas fat and 
protein contributed 19.8% and 12.4%, respectively. Most (74%) of the daily zinc 
intake came from cereals (rice) and pulses. Consumption of iron and vitamin or 
mineral supplements was not common in this population, with only 11 women (2%) 
reporting intake of iron supplements and 45 (8%) reporting intake of other vitamin 
or mineral supplements during the previous 14 d at 4 mo of gestation. 
Table 2. Maternal daily intake of energy and selected nutrients at baseline' 
Zinc supplemented women Placebo supplemented women 
(n=214) (n=232) 
Energy (kJ) 5881 (4386 - 7726)a 6252 (4357 - 8488) 
Protein (g) 40 (24 - 58) 39 (26 - 69) 
Fat (g) 31 (21 - 43) 32 (21 - 45) 
Carbohydrate (g) 240 (179 - 349) 263 (168 - 379) 
Iron(mg) 11.3(6.0-19.5) 11.7(6.0-23.4) 
Zinc (mg) 6.3 (4.2 - 8.8) 6.4 (4.3 - 10.2) 
1
 All values are expressed in median (1st quartile - 3™ quartile). 
None of the differences was statistically significant 
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The mean compliance with supplementation as calculated by the 
percentage of days during follow-up that a woman reported having consumed a 
supplement was 86%, and the mean (±SD) duration of supplementation of the 446 
women who completed the follow-up until delivery was 24.6 ± 3.5 wk. No 
differences in compliance with and duration of supplementation were observed 
between the 2 groups. 
Pregnancy and maternal characteristics 
At 7 mo of gestation, serum zinc concentrations tended to be higher in the 
zinc-supplemented group (15.9 ± 4.4 umol/L) than in the placebo group (15.2 ± 4.3 
umol/L; P = 0.065; Student's t test) (Table 3). The zinc-supplemented women 
tended to have higher mean serum zinc concentrations at 7 mo of gestation than 
at 4 mo of gestation, whereas zinc concentrations in the placebo group tended to 
be lower at 7 mo of gestation than at 4 mo of gestation. The difference in response 
(1.08 umol/L) was not significant. After 4 mo of supplementation (at 8 mo of 
gestation) there were no significant differences in mean maternal weight and 
MUAC between women in the zinc-supplemented and placebo groups who 
completed the follow-up (ANCOVA for repeated measurements). Mean weight gain 
between 4 and 8 mo of gestation was 4.9 ± 2.2 kg (4.7 ± 2.3 kg in the zinc-
supplemented group compared with 5.1 ±2 .1 kg in the placebo group; NS, 
ANCOVA). The mean change in MUAC was 3 ± 11 mm (3 ± 12 mm in the zinc-
supplemented group compared with 4 ± 11 mm in the placebo group; NS, ANCOVA). 
Mean blood pressure and hemoglobin concentrations at 7 mo of gestation were also 
not significantly different between groups. 
Table 3. Maternal characteristics at baseline and at 7 or 8 mo of gestation1 
Zinc supplemented group Placebo group (n=214) (n=232) 
Weight (kg) 
MUAC (mm) 
Bloodpressure : 
Diastolic (mm Hg) 
Systolic (mm Hg) 
Hemoglobin (g/L) 
Serum zinc (u,mol/L) 
4 months 
gestation 
41.7 ± 6.2 
226 ± 24 
54.0 ± 7.8 
86.6 ±11.1 
114 ± 14 
15.3 ± 4.1 
7/8 months 
gestation 
46.4 ± 6.0 
229 ± 23 
53.8 ± 6.6 
84.4 ± 8.7 
108 ± 13 
15.9 ± 4.4 
4 months 
gestation 
42.0 ± 6.5 
226 ± 24 
53.7 ± 7.1 
85.1 ± 10.1 
115 
11 
15.5 ± 4.4 
7/8 months 
gestation 
47.1 ± 6.6 
231 ± 22 
54.6 ± 6.7 
84.7 ± 8.7 
108 ± 11 
15.2 ± 4.3 
Means ± SD. Values were controlled for maternal height, age and parity. There were no significant 
differences between zinc and placebo groups. 
MUAC= Mid Upper Arm Circumference. 
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Infant characteristics 
No significant effect of treatment was observed for weight, gestational age, 
length, head or chest circumference, or MUAC at birth in the 410 singleton infants 
with valid anthropometric measures. The incidence and distribution of LBW 
(<2500, <2000, and <1500 g), prematurity (<37 and <32 wk), and smallness for 
gestational age also did not differ significantly between infants of the zinc-
supplemented and placebo groups (Table 4). 
Infant birth weight was significantly correlated with maternal body mass 
index (BMI; in kg/m2) at baseline, socioeconomic status of the mother's household, 
and parity of the mother. We therefore examined the effect of zinc 
supplementation on women from different subgroups. Overall, nulliparous women 
(n = 92) delivered infants with a significantly lower birth weight than did 
multiparous women (n = 318) (2446 ± 325 and 2560 ± 405 g, respectively; P = 0.01). 
Likewise, women with a baseline BMI <18.5 (n = 194) had significantly smaller 
infants than did women with a higher initial BMI (n = 211) (2461 ± 400 and 2598 ± 
375 g, respectively; P = 0.00), whereas infants from very poor households (n = 160) 
had significantly lower birth weights than did infants from middle-income 
households (n = 93) (2466 ± 392 and 2605 ± 419 g, respectively; P = 0.001). No 
treatment effects of zinc or placebo were observed for any of the outcome 
variables in women from the different subgroups. A total of 45 pregnancies (20 in 
the zinc-supplemented group and 25 in the placebo group; NS) resulted in 
miscarriage, stillbirth, or early neonatal death. 
Table 4. Birth characteristics of sin$leton infants of the zinc-supplemented and placebo 
groups* 
Weight (g) 
Low Birth Weight: 
<2500g 
<2000g 
<1500g 
Gestational age (wk) 
Prematurity : 
<37wk 
<32wk 
Small-for-Gestational-Age: 
Length (cm) 
Head circumference (cm) 
Chest circumference (cm) 
MUAC (mm) 
Zinc supplemented group 
(n=194) 
2513 ± 390* 
45.9% 
8.9% 
1.0% 
38.8 ± 2.4 
17.5% 
1.0% 
74.7% 
46.8 ± 2.3 
32.6 ±1.4 
30.2 ± 1.8 
92 ± 8 
Placebo supplemented group 
(n=216) 
2554 ± 393 
40.3% 
8.8% 
0.5% 
38.9 ± 2.1 
15.7% 
0.9% 
74.5% 
47.0 ± 2.2 
32.7 ± 1.5 
30.4 ± 1.9 
91 1 8 
Values were controlled for baseline maternal weight, parity and socio-economic status. There were no 
significant differences between groups. MUAC= Mid Upper Arm Circumference. 
2Mean ± SD 
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DISCUSSION 
In a recent systematic review of 5 published randomized, controlled 
maternal-zinc-supplementation trials,20 it was concluded that, although current 
available data did not provide enough evidence for routine zinc supplementation 
during pregnancy, supplementation may be beneficial in zinc-deficient populations 
in which LBW is highly prevalent. We therefore performed a randomized, double-
blind, placebo-controlled trial in a poor urban population of Dhaka. The 
prevalences of LBW (42.9%) and smallness for gestational age (74.6%) in our study 
population were very high, similar to data from other studies in rural1,3 and urban2 
Bangladesh and higher than observed in other developing countries.3 The median 
dietary intake of zinc was 6.5 mg/d, although an intake of 15 mg is recommended 
during the last 2 trimesters of pregnancy.24,25 Moreover, we assumed that only 20% 
of the dietary zinc was potentially available for absorption24 because it came 
mainly from cereals that are high in phytate and pulses, and because the intake of 
zinc and protein from animal products was low. 
After 3 mo of supplementation, serum zinc concentrations tended to be 
higher in the zinc-supplemented group than in the placebo group, but the 
difference was small. Increased blood zinc concentrations or a reduced number of 
low zinc values were reported after zinc supplementation in some13,17 but not 
all11,15 of the previous trials. It is recognized that the specificity of serum zinc as 
an indicator of body zinc status has limitations,24,37 and we believe that 
supplementation in our study was successful in improving maternal zinc status. 
Compliance with taking the supplements was good; the supplements were 
consumed between meals to avoid potential competition for absorption and the 
zinc tablets substantially increased the daily dietary zinc intake. 
Supplementation with 30 mg elemental Zn/d during the last 2 trimesters of 
pregnancy did not result in improved pregnancy outcomes. These findings were 
unexpected because our study was performed in a very malnourished population in 
which the dietary zinc intake was low and poorly bioavailable. Our 
supplementation provided twice the recommended dietary zinc intake for pregnant 
women, which is similar to or even higher than the dosages used in most of the 
other zinc-supplementation trials. Effects on birth weight and IUGR were observed 
in trials with use of dosages of 22.5 and 25 mg elemental Zn/d.16,17 
As expected in this highly mobile urban population, the dropout rate was 
substantial. More nulliparous women were lost to follow-up than were women who 
had previously given birth, which may have resulted in a lower number of LBW 
infants. However, because the percentages and reasons for women being lost to 
follow-up were not different between the zinc-supplemented and placebo groups, 
it is unlikely that the high dropout rate affected the outcome of our study. In 
addition, the final sample size of 410 infants was still sufficient to enable a 
difference in birth weight as small as 110 g to be detected. 
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Surprisingly, in our population only 4 women had serum zinc concentrations 
<9.18 umol/L, which was used as the reference point for zinc deficiency in other 
studies.13,38 Food intake may have contributed to the relatively high serum zinc 
concentrations observed in our study population because blood samples were taken 
during morning hours under nonfasting conditions. Serum zinc is known to vary by 
15-20% within individuals throughout the day, primarily as a result of food intake.37 
The amount of time between collection and separation is also known to influence 
final serum zinc concentrations of samples because zinc leaks from cells into 
serum.39 In our study, this delay of a maximum of 6 h may have caused an increase 
in serum zinc in some cases. Whether or not the relatively high serum zinc 
concentrations may reflect an adaptation to habitually low dietary zinc intakes in 
our study population is unknown. Inverse relations between dietary zinc supply and 
zinc status were observed in several studies,25 probably because of lower intestinal 
excretion of endogenous zinc.40 Serum zinc is known to be susceptible to 
contamination during sample collection, storage, and analysis. However, we 
believe that contamination is not a likely cause of the high serum zinc values 
observed in our study because special care was given to avoid contamination and 
because random contamination would not explain the systematically high values 
we observed. 
Even though the poor dietary intake and nutritional status of our study 
population indicated otherwise, the possibility that this population was not zinc 
deficient on enrollment and hence did not benefit from additional zinc 
supplementation must be considered. We therefore also analyzed only women with 
low serum zinc concentrations to assess whether the zinc status of our population 
affected the outcome of the study. In a trial among African American women who 
were already receiving a non-zinc-containing prenatal multivitamin or mineral 
tablet, Goldenberg et al.17 observed an increase in birth weight after zinc 
supplementation in women with low plasma zinc concentrations on enrollment. In 
our population, only 21 women had serum zinc concentrations comparable with the 
cutoffs used in Goldenberg's trial (<10.6 umol/L at 13 wk of gestation), and 
restricting analysis to those women resulted in no significant differences in mean 
infant birth weight [2360 ± 195 compared with 2375 ± 602 g in the zinc-
supplemented (n = 10) and placebo (n = 11) group, respectively], but the sample 
was small. 
We believe that the absence of any effect of zinc supplementation in our 
study population was most likely due to the concurrent existence of other nutrient 
deficiencies that reduced the bioavailability of zinc or limited fetal growth. The 
median intake of energy was 6.2 MJ/d, which is lower than the recommended 
maintenance requirements of 7.5 MJ/d for pregnant women with similar body 
weights.41 Maternal nutritional status was extremely poor at 4 mo of gestation, 
and most of the women undoubtedly had entered pregnancy in an already 
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disadvantaged nutritional state. The average weight gain between 4 and 8 mo of 
gestation was 4.9 kg, whereas in developing countries, weight gains of 1.5 kg/mo 
during the last 2 trimesters of pregnancy are recommended.42,43 A total of 132 
women (32.5%) had a decrease in MUAC during gestation, indicating that, instead 
of laying down fat stores for fetal growth later in pregnancy and for lactation and 
maternal recuperation, these women were actually depleting already-poor fat and 
lean tissue stores during gestation. Our data clearly show a population at high risk 
of having infants with LBW that is apparently not reversible with a single 
micronutrient supplement. 
In summary, zinc supplementation alone during the last 2 trimesters of 
pregnancy in very poor urban Bangladeshi women did not improve infant birth 
weight or gestational age despite the fact that supplementation resulted in a 
marginal improvement in maternal zinc status. It is possible that zinc 
supplementation earlier in gestation or before conception would have a positive 
effect. However, in most developing countries it is not feasible to identify 
pregnant women before 12 wk of gestation. The results of our study therefore 
indicate that public health interventions with zinc supplementation alone are 
unlikely to reduce the incidence of LBW in a developing country such as 
Bangladesh. 
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ABSTRACT 
Background: Infant malnutrition and mortality rates are high in less-developed countries 
especially in low birthweight infants. Zinc deficiency is also widely prevalent in these 
circumstances. 
Objective: The objective of this study was to assess the effect of daily zinc supplements 
given to pregnant mothers on their infants' growth and morbidity. 
Design: We did a double-blind, placebo-controlled, randomized trial in 199 and 221 
Bangladeshi infants, whose mothers took 30 mg daily elemental zinc or placebo, 
respectively, from 12 to 16 weeks' gestation until delivery. Infants were followed up until 
6 months of age. We obtained data for morbidity every week by mothers' recall. Infants' 
anthropometric measurements were done every month, and their serum zinc was assessed 
at 1 and 6 months of age. 
Results: Infants of mothers who received zinc during pregnancy had at age 6 months 
reduced risks compared with those in the placebo group for acute diarrhoea (risk ratio: 
0-84; 9556CI: 072,0-98), dysentery (0-36; 95S6CI: 0-25,0-84) and impetigo (0-53; 95%C\: 
0-34,0-82). These reductions were seen in low birthweight infants but not in those with 
normal birthweight. There were no differences in infant growth or serum zinc 
concentrations between treatment groups. 
Conclusions: Maternal zinc supplementation during pregnancy resulted in a reduction of 
the health risks in Bangladeshi low-birthweight infants, although this intervention did not 
improve birthweight. Whether zinc should be added to usual antenatal supplements in 
regions with high rates of low birthweight should be reviewed. 
INTRODUCTION 
Micronutrient deficiency, including zinc, contributes significantly to 
impaired growth, health, and development of children in less-developed 
countries.1 Zinc supplementation during infancy partly reverses the adverse effects 
of zinc deficiency, and is associated with a small improvement in growth,2 
improved immunity, and reduced morbidity due to infectious diseases.3 These 
effects were especially pronounced in low-birthweight (ie, <2500 g) infants, who 
might be vulnerable to the effects of zinc deficiency because of their reduced liver 
stores of hepatic zinc metallothionein.4,5 
Infants with a low birthweight have high rates of morbidity and mortality 
because of infectious diseases and impaired immunity, and are at increased risk of 
growth failure and abnormal cognitive development as neonates. They are also 
estimated to account for about a third of all deaths in the first year of life in less-
developed countries.6 The high prevalence of low birthweight, which is mainly 
attributable to intrauterine growth retardation in developing countries, is related 
to intergenerational cycles of malnutrition.7 Thus, the adverse effects of 
nutritional deprivation, and perhaps zinc deficiency might begin before birth and 
the most effective time for an intervention might, therefore, be the antenatal 
period. 
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Low maternal blood zinc concentrations during pregnancy are associated 
with an increased risk of low birthweight and preterm delivery in some8 but not all 
studies.9 Results of studies in developed countries of zinc supplementation and 
pregnancy outcome are also inconsistent.10 We have previously reported that zinc 
supplementation during pregnancy in a very poor, urban population of Bangladesh 
did not result in improved birth weights.11 In rhesus monkeys, low maternal plasma 
zinc concentrations were associated with reduced infant growth.12 Antenatal zinc 
deficiency in mice and rhesus monkeys resulted in reduced lymphoid organ sizes, 
IgG concentrations, and blood lymphocytes in the off-spring.13 Studies are required 
in man to investigate the relation between pregnancy and zinc status, prenatal 
zinc supplementation, and infant growth and health. 
We, therefore, did a study in infants from poor urban areas in Bangladesh, 
whose mothers received either daily zinc supplements or placebo during 
pregnancy, and assessed the effect of supplementation on the infants' growth and 
morbidity from infectious diseases during the first 6 months of life. The study was 
done in a population in whom the proportion of babies with low birthweight was 
43%.11 
SUBJECTS AND METHODS 
Study design and population 
We did our study in selected poor urban areas of Dhaka, characterized by a 
very high population density, poor housing, inadequate sewerage, and low 
socioeconomic status. The population is young and most people are illiterate.14 
Pregnant women were enrolled between 12 and 16 weeks' gestation, stratified by 
parity and randomly assigned to receive either daily zinc supplements or placebo 
until delivery. We used a computer-generated random letter to assign the mothers 
to each group. The codes remained unknown to investigators and participants until 
the study was completed. Singleton neonates were included in postnatal 
surveillance.11 Doctors measured weight and length, and calculated gestational age 
of the babies within 72 h after delivery.11 
We calculated gestational ages using date of last menstrual period as 
recalled by mothers at enrollment and with the Capurro method.15 We classified 
the babies as small or appropriate for gestational age using the tenth percentile of 
a US fetal growth curve as a cutoff,16 and recorded data on infant morbidity every 
week. Details of infant feeding were obtained every 2 weeks, and infants were 
classified as either exclusively (breastmilk only), predominantly (breastmilk and 
water or sugar water), or partly (breastmilk and other complementary fluids) 
breastfed, or not breastfed. We also recorded the age that complementary foods 
were introduced. 
A total of 410 singleton infants with known birthweights (low birthweight < 
2500 g. normal birthweight > 2500 g) were included in the postnatal surveillance. 
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We also included another ten infants, whose mothers had taken supplements and 
were followed up throughout pregnancy, but for whom valid birthweight 
measurements were not available. Thus, 199 infants of mothers on zinc 
supplements and 221 of mothers on placebo were enrolled. Sample-size 
calculations had indicated that a minimum of 360 infants (180 in each group) was 
needed to detect a 15% difference in mean weight gain during the first 6 months of 
life, a 15% difference in mean number of episodes of diarrhoea, or a 20% 
difference in mean serum zinc concentrations between the groups, with 80% power 
and a type I error of 5%. 
Supplements 
During pregnancy, mothers on zinc supplements received 30 mg elemental 
zinc per day. The placebo was a cellulose substance indistinguishable from the zinc 
supplement in both appearance and taste. All supplements were prepared in 
bubble packs of ten tablets each (ACME Ltd, Dhaka, Bangladesh) and two 
laboratories independently confirmed the zinc content of both tablets. Health-care 
workers gave the women a week's supply of zinc tablets or placebo, every week. 
The women were instructed to consume 1 tablet daily between meals with no 
other vitamin or mineral supplements. Consumption of iron and vitamin or mineral 
supplements was uncommon in this population.11 At baseline (12-16 weeks' 
gestation) only 11 (2%) women reported taking iron supplements and 45 (8%) 
reported taking other vitamin or mineral supplements during the past 14 days. 
According to general practice in Bangladesh, iron and folate supplements (200 mg 
ferrous sulphate and 200 ng folate per day) had been provided by the study team 
to women with a hemoglobin concentration of less than 90 g/L at 4 months' 
gestation (14 women, 2-5%) and 7 months gestation (40, 8-5%). Compliance with 
zinc or placebo treatment was 86%, as assessed by counting the remaining tablets 
at the next weekly visit, and by monthly unannounced checks in a 10% sub-sample. 
Blood analyses 
We took blood samples from non-fasting infants at 1 and 6 months of age by 
antecubital venipuncture in the morning using trace-mineral-free plastic syringes, 
stainless steel needles, and plastic tubes. We separated the serum within 6 h after 
samples were taken and stored serum at -20 °C. Before analysis we diluted the 
samples (1/12) with 003% polyoxyethylene 23 laryl ether and HN03 (10 mmol/L). 
Zinc concentration was measured by flame atomic absorption spectrophotometry. 
We established a standard curve with a commercial zinc reference (BDH 
Laboratory Supplies, London, UK), in concentrations of 0-1, 0-25, 0-5 and 10 mg/L, 
and used commercially obtained serum with known concentrations of zinc as a 
measure of quality control. The coefficient of variation of the measurements was 
always less than 5%. 
60 
Zinc supplementation durin$ pregnancy: growth and morbidity 
Anthropometry 
During monthly home visits, infant weight was measured to the nearest 10 g 
on beam-balance scales (Seca 725, Seca, Hamburg, Germany) that were daily 
calibrated against standard weights. Recumbent lengths were measured to the 
nearest 0-1 cm on a length board, and head, chest, and arm circumferences were 
measured to the nearest mm with numeral insertion tapes. We recorded for all 
indices the mean of two readings as the measured value. Anthropometric 
measurements were done by trained field workers. Intra-observer and inter-
observer variations were acceptable, with coefficients of variation less than 2% for 
all anthropometric indices. We defined underweight (low weight for age), stunting 
(low length for age) and wasting (low weight for length) as standard deviation 
scores (Z scores) of less than -200 compared with the US National Center for 
Health Statistics reference charts17 using EPI Info software (version 6-1, 1994, 
Centers for Disease Control, Atlanta, GA, USA). 
Morbidity assessment and outcome definitions 
During home visits trained non-medical interviewers asked detailed 
questions on the infant's history during the past week of respiratory infections, 
diarrhoea, fever, skin infections, and other illnesses. To distinguish impetigo from 
other skin diseases, interviewers asked mothers whether the infants had any signs 
of this disease, using photographs showing clinical signs of impetigo of various 
degrees of severity as a guide. Infants were examined for signs of dehydration 
during monthly visits. The respiration rate was recorded, and a second record was 
taken for infants with a respiration rate of more than 60 per min. 
The same trained fieldworkers obtained the data, which registered nurses 
checked manually and coded. Doctors examined infants who required medical 
treatment using standard treatment protocols, and referred them to appropriate 
health-care facilities if necessary. Information was recorded about standard infant 
vaccinations received through the expanded programme of immunisation or other 
sources. We defined an infant as having acute lower respiratory infection if 
reported symptoms included cough, difficult breathing, or both, with or without 
fever, lasting more than 1 day, and rapid breathing or chest indrawing. Upper-
respiratory-tract infection (URI) was diagnosed if the infant had reported 
symptoms of cough or difficult breathing, with or without fever for more than 1 
day, which was not associated with rapid breathing or chest indrawing, or a 
reported cough for more than 1 day with nasal discharge. Acute diarrhoea was 
defined as symptoms of unusually loose or unusually frequent stools, or both, as 
reported by the mother. If the stool contained blood the episode was classified as 
dysentery. Diarrhoea lasting for 14 days or longer was defined as persistent 
diarrhoea. 
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We calculated the actual number of surveillance days by subtracting the 
days on which no recall data were available from the total days of follow-up. When 
a mother had been absent for more than 15 days (two consecutive visits), recall 
data was only collected for the 14 days before the previous interview. Infants were 
classified as recovered if they were symptom free for at least 3 consecutive days. 
Statistical analysis 
We did a multiple stepwise regression to identify variables that contributed 
significantly to the variation in the different outcome variables and those that 
required adjustment as confounders in the multivariate analysis on the effect of 
zinc supplementation. Possible interactions between treatment and infant's 
birthweight, sex, or serum zinc status were assessed by introduction of separate 
interaction terms in the linear regression models. On the basis of these outcomes, 
separate models were used for subgroups of birthweight. 
We assessed differences in mean, total weight and length gain between 
infants of mothers who took zinc supplements or placebo using ANCOVA with the 
outcome variables (eg, total weight gain) as dependent variables and treatment 
group (zinc or placebo group) as independent variable. Baseline values were added 
as covariates (SPSS version 7.5). We tested differences in anthropometric indices 
and Z scores at 1, 2, 3, 4, 5, and 6 months of age, with ANCOVA for repeated 
measurements. 
To compare differences between treatment groups in frequency of diseases, 
we used a Poisson regression model with number of episodes as dependent 
variable, treatment group as independent variable and total days of actual 
surveillance as off-set term included in the model. We added potential 
confounders to the regression models as additional independent variables 
(epidemiological graphics estimation and testing package, EGRET, SERC, Seattle, 
WA98105, 1991). 
Duration of disease was calculated for all infants as percentage of actual 
surveillance days i l l . We used the non-parametric Kruskal-Wallis test to compare 
differences in duration of illness between infants from zinc and placebo groups. 
Since the distribution of length of illness was highly skewed, we used log-
transformed values in the multivariate regression models to enable control for 
covariates. Before log-transformation a constant was added to all duration values 
to eliminate zero values. P values less than 005 were regarded as statistically 
significant. 
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RESULTS 
After randomisation 139 women were lost to follow-up, including 7 twin births and 
19 infant deaths. Of the infants that were included in the follow-up after birth 22 
died and 13 were lost to follow-up because their families moved away from the 
study area. The mothers of two infants refused further participation in the study. 
No differences were recorded between the groups in numbers or reasons for not 
completing the study (figure 1). The maternal baseline characteristics were similar 
for infants lost to follow-up and those who completed follow-up (table 1). Mothers 
of infants who completed follow-up were significantly older (p=0016) at enrolment 
in the zinc supplement group than the placebo group (table 1). No other 
differences in baseline characteristics were seen between the two treatment 
groups. 184 infants in the zinc and 199 in the placebo group completed 6 months' 
follow-up (figure 1). Infants lost to follow-up were included in the analysis of 
morbidity for the days on which observations were available. 
All infants were breastfed throughout the study but the rate of exclusive 
breastfeeding was low because of early introduction of water given with 
breastmilk. At 24 weeks of age, 55 (13%) of all infants were exclusively or 
predominantly breastfed, and 353 (84%) were partly breastfed. 
559 women enrolled at 4 months gestation 
269 zinc 
supplemented 
55 women lost-to-follow-
up 
12 stillbirths/early neonatal 
deaths 
3 twins 
199 singleton Infants Include 
In postnatal surveillance 
15 (7.0%) infants 
lost-to-follow-up: 
-11 deaths 
- 3 out migrations 
- 1 refusal 
184 infants in zinc group 
completed follow-up at 6 months 
of age 
290 placebo 
supplemented 
58 women lost-to-follow-up 
7 stillbirths/early neonatal 
deaths 
4 twins 
221 singleton infants included 
in postnatal surveillance 
22 (10.0%) infants tost-to-
follow-up: 
-11 deaths 
-10 out migrations 
- 1 refusal 
199 infants in placebo group 
completed follow-up at 6 months of 
age 
Figure 1. Trial profile. 
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There was no relation between breastfeeding status at 1 or 6 months of age 
and main outcome variables in stepwise multiple regression analysis to identify 
potential confounding variables. There was a relation with age at water 
introduction for some variables and with that at complementary food introduction 
for other outcome variables. Therefore, those variables were controlled for in the 
multivariate analysis. No differences in infant serum zinc concentrations were 
seen at 1 month (15-1 (imol/L [SD 5-3] vs. 15-8 u.mol/L [5-5]) or at 6 months of age 
(11-4umol/L [2-5] vs. 11-7nmol/L [2-5]). 
Between birth and 6 months of age changes in weight (3-49 kg [077] vs. 3-56 
kg [0-77]), length (15-2 cm [20] vs. 15-4 cm [2-1]) and head circumferences (80 cm 
[1-2] vs. 8-1 cm [1-3]), did not differ between infants of mothers on zinc or 
placebo. Average weight increase (0-58 kg/month [0-13] vs. 0-59 kg/month [0-13]) 
and linear growth (2-5 cm/month [0-3] vs. 2-6 cm/month [0-4]) did not differ 
between infants from the zinc and placebo groups, respectively. 
Table 1. Selected baseline characteristics of 420 pregnant mothers. 
Maternal 
Characteristic 
Maternal age 
(years) 
Nulli-parae 
Socioeconomic 
status: 
-Poor 
-Very poor 
Body Mass Index 
(kg/m2) 
MUAC (mm) 
Hemoglobin (g/L) 
Serum zinc 
concentration 
(nmol/L) 
Zinc-supplement 
Lost to follow-
up (n=15) 
220 (4-8) 
31% 
25% 
56% 
19 2 (2-8) 
224 (27) 
113 (15) 
14-4 (2-8) 
Follow-up 
completed 
(n=184) 
23-8 (5-8) 
19% 
39% 
40% 
18 8 (2-5) 
227 (24) 
115 (15) 
16 1 (5-4) 
Placebo 
Lost to follow-up 
(n=22) 
23-5 (5-5) 
27% 
18% 
55% 
19 5 (3-4) 
231 (33) 
116 (12) 
150 (4-9) 
Follow-up 
completed 
(n=199) 
22-4 (5-5) 
24% 
41% 
35% 
19 1 (2-3) 
226 (23) 
116 (14) 
16-4 (6-1) 
Values are mean (SO) unless otherwise indicated; MUAC = mid upper arm circumference. 
At 6 months of age, Z scores for infants in the two groups were closely similar for 
mean length for age (-1-47 [0-91] vs. -1-41 [0-96]), weight for age (-1-36 [0-87] vs. -
1-28 [0-92]), and weight for length (-0-29 [0-77] vs. -0-28 [0-82]). There were no 
interactions with anthropometric outcomes and infant birthweight, sex, or serum 
zinc status. 
The 420 infants were followed up for a total of 65771 (93%) of a possible 
70560 days (31378 days in the zinc supplement and 34393 days in the placebo 
group). Infants of mothers taking zinc supplements had fewer episodes of acute 
watery diarrhoea, dysentery, and impetigo than those of mothers in the placebo 
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Table 2. Frequency of diseases for infants from zinc supplement and placebo groups 
during first 6 months of life. 
Disease 
Acute diarrhoea 
- Total episodes 
- Episode/infant 
- All infants" 
- LBW infants* 
" NBW infants1 
Persistent diarrhoea 
- Total episodes 
- Episode/infant 
- All infants" 
- LBW infants* 
- NBW infants' 
Dysentery 
- Total episodes 
- Episode/infant 
- All infants" 
- LBW infants* 
- NBW infants' 
Cough 
- Total episodes 
- Episode/infant 
- All infants" 
- LBW infants* 
- NBW infants' 
Acute lower respiratory 
infection 
- Total episodes 
- Episode/infant 
- All infants" 
- LBW infants* 
- NBW infants' 
Impetigo 
- Total episodes 
- Episode/infant 
- All infants" 
- LBW infants* 
- NBW infants' 
Zinc 
supplement 
267 
1-5 (1-9) 
1-4 (1-8) 
1-6 (1-9) 
49 
0.3 (0.7) 
0.2 (0.5) 
0.3 (0.8) 
7 
0.04 (0.2) 
0.04 (0.2) 
0.04 (0.3) 
668 
3.9 (1.9) 
4.2 (2.4) 
3.7 (1.7) 
106 
0.7 (1.2) 
0.6 (1.2) 
0.7 (1.1) 
30 
0.2 (0.6) 
0.1 (0.5) 
0.2 (0.7) 
Placebo 
346 
1-9 (2-1) 
2-2 (2-3) 
1-6 (1-9) 
49 
0.3 (0.6) 
0.3 (0.6) 
0.2 (0.6) 
22 
0.1 (0.4) 
0.1 (0.4) 
0.1 (0.4) 
768 
4.1 (1.8) 
3.9 (2.1) 
4.0 (1.8) 
134 
0.8 (1.3) 
1.5 (6.6) 
0.7 (1.0) 
61 
0.3 (0.8) 
0.3 (0.8) 
0.3 (0.8) 
RR (95% CI) 
0-84 (0-72;0-98) 
0-68 (0-53;0-87) 
104 (0-84; 129) 
1.13(0.76;1.68) 
0.88(0.46;1.71) 
1.47(0.86:2.50) 
0.36 (0.25;0.84) 
0.26 (0.07;0.99) 
0.46(0.14;1.44) 
0.95 (0.68;1.06) 
0.99(0.84:1.16) 
0.94(0.82;1.08) 
0.89 (0.69;1.15) 
0.97(0.64:1.45) 
0.87(0.62;1.24) 
0.53 (0.34;0.82) 
0.39 (0.18;0.85) 
0.64(0.37;1.10) 
P 
0.037 
0.002 
NS 
NS 
NS 
NS 
0.019 
0.049 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.005 
0.018 
NS 
RR = risk ratio estimated with Poisson regression adjusted for socioeconomic status, parity, baseline serum 
zinc, age at introduction of water. Values are in mean (SD) unless otherwise indicated."n=196 (zinc) and 214 
(placebo). * LBW= < 2500g birthweight (n=88 and 84).' NBW = > 2500g birthweight (n=106/129). Birtweight 
was unknown in three infants. 
group. For infants who were followed up for 15 days or longer the risk of these 
diseases was reduced by 16% for acute diarrhoea, 64% for dysentery, and 47% for 
impetigo (table 2). Infants of mothers on zinc had fewer days il l with dysentery 
and impetigo than those whose mothers were on placebo (table 3). Maternal zinc 
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supplementation had no effect on frequency and duration of cough or acute lower 
respiratory infections in the infants. 
When data were analysed separately for infants with low and normal 
birthweight (for whom birthweights were available) larger reductions were seen in 
low-birthweight but not normal-birthweight infants for the frequency of acute 
diarrhoea, dysentery, and impetigo in the zinc supplement than the placebo group. 
In low-birthweight infants of mothers receiving zinc, the risk of disease was 
reduced by 32% for acute diarrhoea, 74% for dysentery, and 61% for impetigo. By 
contrast, in normal-birthweight infants no differences in frequency of disease were 
seen between the zinc and placebo groups. 
Table 3. Proportion of days ill during first 6 months of life. 
Infant Morbidity 
Acute diarrhoea 
- A l l ' 
- LBW infants* 
- NBW infants ' 
Persistent diarrhoea 
- A l l " 
- LBW infants* 
- NBW in fants ' 
Dysentery 
- A l l ' 
- LBW infants* 
- NBW infants ' 
Cough 
- All* 
- LBW infants* 
- NBW infants ' 
Acute lower 
respiratory infection 
- A l l ' 
- LBW infants* 
- NBW infants ' 
Impetigo 
- A l l ' 
- LBW infants* 
- NBW infants' 
Proportion 
Zinc supplement 
Mean (SD) Median (range) 
4-8 (6.0) 
4-4(6.1) 
5-1 (6.0) 
3-2 (7.8) 
2-8 (6.7) 
3-6 (8.6) 
0-2(1.2) 
0-1 (1.0) 
0-2(1.4) 
37-6(24.1) 
39-5(25.1) 
35-4 (22.8) 
7-7(16.0) 
70(13.4) 
80(17.6) 
0-9 (3.2) 
0-6 (2.5) 
10(3.6) 
2.5 (0-0-29-7) 
1-5 (00-29-7) 
3-1 (0-0-24-8) 
00 (0-0-42-9) 
00 (0-0-30-3) 
00 (0-0-42-9) 
00 (0-0-10-5) 
00 (0-0-8-8) 
00 (0-0-10-5) 
32-5(0-0-91-8) 
36-4 (0-0-91-8) 
29-9 (0-0-91-1) 
00 (00-86-3) 
00 (0-0-60-5) 
00 (00-86-3) 
00 (0-0-24-1) 
00 (00-18-1) 
00 (0-0-24-1) 
of days i l l (%) 
Placebo 
Mean (SD) Median (range) 
50 (6.3) 
60(7.1) 
4-2 (5.6) 
2-9 (7.8) 
2-7 (6.2) 
2-6 (7.8) 
0-5 (2.0) 
10(2.3) 
0-4(1.6) 
37-7 (24.2) 
36-5(26.1) 
36-3 (22.9) 
8-8(15.4) 
10-8 (18.5) 
7-2(12.5) 
1-5 (4.4) 
1-8(5.4) 
1-4(3.6) 
2-9 (00 
3-5 (00 
2-3 (00 
0-0 (00 
00 (00 
00 (00 
00 ( 0 0 ; 
00 (00 
0-0 ( 0 0 ; 
36-3 ( 0 0 ; 
36-2 (00 
36-3 ( 0 0 ; 
00 ( 0 0 ; 
00 ( 0 0 ; 
00 (00 
0-0 (00 
00 ( 0 0 ; 
00 (00 
36-1) 
36-1) 
21-1) 
58-6) 
29-5) 
58-6) 
14-8) 
14-8) 
10-6) 
1000) 
; 96-5) 
1000) 
1000) 
1000) 
553) 
390) 
390) 
21-2) 
P 
NS 
0.008 
NS 
NS 
NS 
NS 
0.047 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.013 
0.047 
NS 
p values are from linear regression analysis with log transformed values, controlled for birtweight, gestational 
age, age at introduction of complementary food, maternal baseline body mass index, household socioeconomic 
status, maternal baseline serum zinc. "n=199 [zinc] and 221 [placebo]. *LBW = < 2500g (n=90 and 88 ) . ' NBW = 
£ 2500g (n=106 and 129). Only infants with known birthweight were included in subgroup analysis. 
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Likewise, low-birthweight infants in the zinc group had significantly fewer days ill 
with acute diarrhoea and impetigo than those in the placebo group, whereas no 
differences between the groups were seen in the normal-birthweight infants (table 
3). 
In low-birthweight infants born at term but with intrauterine growth 
retardation, we recorded significant reductions in zinc versus placebo groups for 
acute diarrhoea (risk ratio 0-59; 95%CI: 0-44-079), all diarrhoeal episodes (0-61; 
95%CI: 0-46-0-81) and impetigo (0-27; 95% CI: 0-10-0-76) whereas no differences 
between the groups were seen in preterm low-birthweight infants (< 37 weeks' 
gestation n=46), for acute diarrhoea (RR: 1-19 {0-68-2-10}, for all diarrhoea (1-10; 
0-66-1-83) or for impetigo (0-95; 0-22-4-10). 
DISCUSSION 
In our study population, zinc supplementation during the last two trimesters 
of pregnancy reduced the frequency and duration of acute diarrhoea, dysentery 
and impetigo especially in low-birthweight infants, but had no effect on infant 
growth during the first 6 months of life. Previously reported results from this study 
showed that prenatal zinc supplementation did not affect maternal weight gain 
during pregnancy or infant birthweight in this malnourished population.11 181 (43%) 
of our infants had low birthweight (< 2500g) and were, therefore, at increased risk 
of malnutrition and premature mortality mainly because of diarrhoea and 
respiratory tract infections.6'18 The improvements in morbidity were substantial, 
(32% and 74% reduced risk of acute diarrhoea and dysentery, respectively), and 
greater than the 18% reduction in frequency of diarrhoeal disease attributed to 
zinc supplementation during childhood.3 The reductions in our study were also 
larger than the 28% in number of days il l due to diarrhoea reported with infant zinc 
supplementation in an intervention study in low-birthweight, full-term infants in 
Brazil.4 
The improvements in morbidity in low-birthweight infants were due to 
reductions in intrauterine-growth-retarded and not preterm low-birtweight infants, 
although sample sizes for premature infants were too small for firm conclusions. 
Infants who are full-term with intrauterine growth retardation and those who are 
premature show different patterns of growth, morbidity, and mortality. 
Premature infants have better growth potential and gradually approach a normal 
weight.7 By contrast, intrauterine-growth-retarded infants who receive optimum 
feeding achieve a limited catch-up growth only in the first few months of life.19 
We noted effects on both frequency and duration of diarrhoeal diseases and 
impetigo, perhaps through enhancement of immune function in-utero, as 
suggested by results in animals. Antenatal zinc deprivation in rats resulted in low 
immunoglobulin serum concentrations, especially IgA, lgG2 and IgM in offspring at 6 
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months of age; these abnormalities can persist into adulthood.13 Maternal zinc 
status during pregnancy might also affect in-utero acquisition of antibodies, 
because of the importance of zinc in placental transport.20 
Zinc supplementation in infants and children is known to have beneficial 
effects on both prevalence and incidence of diarrhoeal diseases and pneumonia. 
These effects are thought to be attributable to improved immunity and intestinal 
mucosal regeneration and function, including decreased intestinal permeability.3 
The effects of zinc supplementation on impetigo might also be attributable to 
improved epidermal barrier function.21 
Maternal zinc supplementation in our study population had an effect on 
postnatal morbidity but not on infant birth weight or postnatal growth. Maternal 
protein and energy supplementation in East Java also benefited infant growth but 
did not affect birth weight.22 However, trials in Mexico23 and Jamaica24 of infant 
rather than prenatal zinc supplementation resulted in reduced infant morbidity 
and hospital admissions, but had no effect on infant growth. Results from a study 
in Peru also suggest that zinc supplementation during pregnancy has no effect on 
birthweight, but improves maternal and infant zinc status,25 and might have 
enhanced immunity, as shown by increased concentrations of immunoglobulins in 
cord blood. 
The effect of zinc on growth might be attributable to a direct role of zinc in 
protein synthesis and gene expression,2 but may also result secondarily from 
reductions in morbidity and an increase in appetite.26 In our study the 6-month 
follow-up might have been too brief to detect this effect. 
Findings from studies of zinc supplementation during childhood have shown 
a small effect on growth, especially in children with low height for age or low 
plasma zinc concentrations.2,26 By contrast, in undernourished populations in 
Mexico,23 Jamiaca,24 and Uganda,25 zinc did not have an effect on infant growth. 
Zinc might not have been the primary growth-limiting nutrient in these 
populations, or in our study population. 
Serum zinc concentrations at 1 and 6 months of age in our population were 
similar to those recorded in older infants and children in Ethiopia and Chile;26,28 
however, they were higher than those for children in India29 and for infants who 
were small for gestational age in Chile.5 Mothers in our study had high serum zinc 
concentrations during pregnancy. Although serum zinc is not a good measure of 
body zinc status,30 these concentrations suggest that our infants were not 
profoundly zinc deficient. This possibility could account for the absence of a 
growth effect of zinc in our population. Most infants in our study were 
predominantly or partly breastfed. In more-developed countries, zinc deficiency is 
rare in full-term breastfed infants during the first few months of life.31 
Our results suggest that infants of mothers supplemented with zinc during 
pregnancy are still born small, but might have a less compromised immune system 
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than those of mothers who are not supplemented. Low birthweight, therefore, 
might be mainly an indicator of risk rather than direct cause of morbidity and 
mortality. In this respect, a small neonate would not be as disadvantaged if it were 
not for the adverse health outcomes later in life that are associated with low 
birthweight.7 In intervention studies with the aim of reducing the frequency of low 
birthweight, investigators have restricted their assessments mainly to an effect on 
birthweight rather than the consequences of low birthweight.10 Our findings 
suggest that future antenatal intervention studies should continue observations 
beyond the neonatal period. 
Our results show a positive and clinically relevant effect of maternal zinc 
supplementation during pregnancy on infant morbidity, especially in low-
birthweight infants, and might potentially contribute to a reduction in the 
disadvantaged health outcomes of these infants. Our findings could have important 
implications for child health and survival programs in less-developed countries and, 
consequently, consideration should be given to the addition of zinc to regular 
antenatal supplements in regions with a high prevalence of low birthweight. 
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ABSTRACT 
Background: An essential role for zinc in development of the fetal immune system has 
been documented. However, the effect of antenatal zinc supplementation on infants' 
postnatal immune response to vaccinations is unknown. 
Objective: To evaluate the effect of zinc supplementation during pregnancy on immune 
response to tuberculin skin test and the combined diphtheria, tetanus toxoid and pertussis 
(DTP)-Haemophilus influenzae type-b (Hib)- conjugate vaccine in poor Bangladeshi 
infants. 
Design: We immunized 405 infants whose mothers were supplemented daily with 30mg 
elemental zinc or placebo beginning at 12-16 weeks gestation with the standard BCG 
vaccine at birth. A subcohort of 203 infants was in addition immunized at one month-
intervals with three doses of DTP-Hib vaccine starting at 9 weeks of age. The delayed 
hypersensitivity (PPD) skin test was performed in 345 infants at 24 weeks of age. Hib 
polysaccharide (PRP) antibodies were assessed for 91 infants at 4 and 24 weeks of age. 
Results: In infants born with low birth weight (LBW) a lower proportion of negative 
responses to PPD skin test were observed in the zinc (66.2%) compared to placebo (78.5%) 
group (p=0.07). No differences were observed in normal birth weight infants. There were 
no differences in proportion of infants above the protective thresholds for anti-PRP 
antibodies between zinc (81%) and placebo (89%) group. Geometric mean PRP antibody 
titres at 4 and 24 weeks of age were not different between groups. 
Conclusions: Zinc supplementation during pregnancy did not enhance immune response to 
Hib-conjugate vaccine but improved the delayed hypersensitivity immune responses to 
BCG-vaccine in Bangladeshi LBW infants. 
INTRODUCTION 
The response to childhood vaccinations varies in different populations. For 
example, the immune response to the pure polysaccharide Haemophilus influenzae 
type b (Hib) vaccine of Native American populations in the USA is known to be 
lower than in the general US population.1 Similarly, the immunogenicity of three 
doses of live attenuated, trivalent oral polio vaccine (TOPV) is lower in developing 
countries than in industrialized countries2 and the effect of prior bacillus 
Calmette-Guerin (BCG) vaccination on the tuberculin skin test is also known to 
vary in different populations.3 
Malnutrition and the occurrence of several micronutrient deficiencies are 
one important explanation for the depressed immune responses to vaccines in 
infants of developing countries. Undernourished infants have impaired immunity4 
and several micronutrients, of which zinc is among the most notable, are known to 
affect the immune system in characteristic ways.5 
The essential role for zinc in the non-immune and immune host defenses has 
been demonstrated.5,6 In zinc deficiency, impaired epithelial barrier functions, 
atrophy of lymphoid organs, a reduced number of T- and B-lymphocytes, and 
decreased macrophage functions have been observed,7 as well as depressed 
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antibody responses.8 A depressed delayed hypersensitivity reaction resulting in 
anergy6 and decreased CD4+ lymphocytes have been found in zinc deficient 
children which was reversed after zinc supplementation.9 
Maternal zinc deficiency during gestation may contribute to an impaired 
immune function in the offspring. In animal models perinatal zinc deficiency 
resulted in impaired development of the fetal immune system, including a reduced 
antibody response to certain bacterial antigens. These abnormalities might even 
persist into adulthood.5 Maternal zinc status may also affect in-utero acquisition of 
antibodies due to the role of zinc in placental transport.10 
Very little information exists on the effect of maternal zinc status or 
antenatal zinc supplementation in humans on infants' immune response. While 
there is a report of zinc supplementation during pregnancy in Peru, resulting in a 
35% increase of lgG3 levels in cord blood,11 we are not aware of any reports on the 
effect of maternal zinc supplementation on infants' postnatal immune response to 
childhood vaccines. 
We therefore evaluated the effect of maternal zinc supplementation in 
Bangladeshi urban poor women during the last two trimesters of pregnancy on 
humoral sero-response of their infants, using Haemophilus influenzae type b 
conjugate vaccine as a marker and on the tuberculin skin reaction to BCG as a 
marker for cell mediated immune response. 
SUBJECTS AND METHODS 
Study design and study population 
This study was a nested study within a community-based, randomized 
controlled trial, to evaluate the effect of zinc supplementation during pregnancy 
on birth weight and infant morbidity from infectious diseases.12,13 Details on the 
study population, intervention and data collection procedures have been reported 
elsewhere.12 The study was approved by the Ethical Review Committee of ICDDR,B 
and the Committee on Human Research of the Johns Hopkins School of Hygiene and 
Public Health. 
A total of 559 women from selected areas of Dhaka city slums were enrolled 
between 12 and 16 weeks gestation after obtaining written informed content. 
Enrolled mothers were stratified by parity and randomly assigned to two treatment 
groups, to receive either 30 mg elemental zinc per day (twice the RDA, as zinc 
acetate) or a cellulose placebo. Individual randomization was achieved by a 
computer-generated random letter assignment and the codes remained unknown 
to both investigators and participants until the study was completed. The 
supplements were prepared in bubble packs of ten tablets each (ACME Ltd, Dhaka) 
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and zinc content of both zinc and placebo tablets were independently confirmed 
by two different laboratories. Compliance with tablet consumption was 86%, as 
assessed by counting the remaining tablets in the bubble packs during 
unannounced home visits. Supplementation continued until delivery. 
A total of 420 singleton infants born to these women were included in the 
postnatal surveillance and followed to 24 weeks of age. Information on morbidity 
was collected weekly by mother's recall, infant anthropometrics were measured 
monthly and serum zinc was assessed at 4 and 24 weeks of age.13 Prior to the 
onset of the nested study, we had calculated required sample sizes to detect 
differences between treatment groups with 80% power and a type 1 error 5%. 
There was no prior data available on the immune response to H. influenzae type b 
vaccines in developing countries. We however assumed a lower immune response 
in the Bangladeshi infants and estimated that approximately 25% of Bangladeshi 
infants (25% less than the general US population) would have an antibody level of > 
0.15 ng/ml to PRP if they were given three doses of the vaccine. We also assumed 
that with zinc supplementation, their response would be the same as the US 
infants. Anticipating that 15% would not complete the follow-up a required sample 
size of 75 was calculated to be enrolled in each group. 
Immunization 
A total of 405 infants (194 in zinc, 211 in placebo groups respectively) were 
vaccinated with 0.05 ml reconstituted live freeze-dried vaccine of Bacille Calmette 
Guerin (BCG) by study physicians within 72 hours after birth. 
A subcohort of 203 infants (96 in zinc, 107 in placebo groups respectively) 
who had not yet reached the age of 12 weeks at the time of the onset of the 
nested study, were in addition vaccinated with the combined diphtheria, tetanus 
toxoid and pertussis (DTP)- Haemophilus Influenzae type b (Hib) vaccine 
(Diphtheria CRM, 97 protein conjugate), [TETRAMUNE® Wyeth-Lederle, NY] at 9, 
13 and 17 weeks of age (± 3 weeks). The second and third round of vaccinations 
were given at 4 week intervals (± 2 days). Infants were given the trivalent oral 
polio vaccine (TOPV) simultaneously. 
Post-vaccination safety surveillance was carried out from day 1 through day 
5 post-vaccination during home visits by trained study nurses. Data was collected 
and recorded daily on rectal temperature, local swelling and redness, generalized 
rash, seizures, general health of the infant, feeding history and any other 
unexpected reactions. 
Assessment of cell mediated immune response. 
Cell mediated immune response was tested at 24 weeks of age by delayed 
hypersensitivity skin test (DTH) using the purified protein derivate (PPD) test 
(Staten Serum Institute, Copenhagen, Denmark). Tuberculin solution (0.1 ml) was 
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applied by trained nurses to the volar surface of the forearm intradermal^ using 
an Omega glass PPD syringe with platinum needles. After 72 hours the size of the 
induration in millimeters developed was read as the transverse diameter. A 
cutaneous reaction was considered positive when an induration of > 5mm was 
observed.14 Six nurses were extensively trained and standardized in the 
administration and interpretation of PPD skin testing. Reproducibility of skin test 
reading was tested prior and during the study in hospitalized patients with 
tuberculosis attending the Institute of Chest Diseases, Chest Hospital, Dhaka. 
Variability between reading by the same nurse and between the different nurses 
was measured. Overall, Pearson correlation coefficients were high, ranging 
between 0.98 (p < 0.000) and 0.73 (p=0.03) and consistent with inter-rater 
agreements observed in similar studies.15 
Assessment of humoral immune response and serology 
Antibody response to H. influenzae b polysaccharide (polyribosylribitol 
phosphate (PRP)) was assessed pre-vaccination at 4 weeks of age and post-
vaccination at 24 weeks of age. Non-fasting blood specimens (5 ml) were obtained 
by antecubital venipuncture in the morning hours. Serum was separated a 
maximum of 6 hours after collection and stored at -20C until analysis. Antibodies 
to PRP were measured by enzyme linked immunosorbent assay (ELISA). All assays 
were performed at the laboratory of Wyeth Lederle Vaccines (NY, USA) using 
standard procedures.16 Geometric mean antibody titres were calculated as the 
antilog of the mean of the logarithms of titres. Mean paired differences between 
pre- and post-immunization titres and percentage of infants with PRP antibody 
levels > 0.15 ng/ml, associated with immediate protection,17 and > 1.0 u,g/ml, 
associated with long-term protection18 were calculated. 
Statistical methods 
Differences between groups in proportion of anergic infants from the 
Tuberculin skin test and proportion of infants with antibody titres above the 
protective thresholds before and after immunization were assessed with the Chi-
square test and Mac Nemar's test respectively. Differences between treatment 
groups in mean size of induration, geometric mean antibody titres and paired 
differences between pre and post immunization titres were assessed with the 
Mann-Whitney U-test. 
Analysis of Covariance (ANCOVA) and Logistic Regression Analysis were 
performed to control for potential confounders (SPSS7.5 FOR WINDOWS; SPSS Inc, 
Chicago). Separate models were made based on subgroups for birth weight and 
gender. P-values of <0.05 were considered statistically significant. 
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RESULTS 
Description of the study population. 
Of the 405 singleton infants (194 in zinc and 211 in placebo group) who were 
born to mothers from the trial of zinc supplementation in pregnancy and 
immunized with the BCG vaccine at birth, 39 (21 or 10.8% in zinc-supplemented 
and 18 or 8.5% in placebo- supplemented group) were lost-to-follow-up before the 
end of the study due to the following reasons: infant deaths (n=10), migration from 
the study area (n=11) or refusal to further participate (n=18). Reasons for lost-to-
follow-up were not different for infants from zinc and placebo groups. An 
additional 7 infants could not receive the PPD skin-test at 24 weeks of age because 
they were sick or absent at the time of the test. Therefore, 359 infants (167 zinc, 
192 placebo) were administered with the PPD skin test at 24 weeks of age. For 14 
infants, skin test readings could not be performed within 72 hours, thus, the final 
sample size for the effects on the tuberculin skin test consisted of 345 infants (163 
in zinc , 182 in placebo group). A comparison of baseline characteristics (table 1) 
revealed that infants included in the tuberculin skin test had significantly greater 
body weights and larger gestational age at birth compared to infants who were 
lost-to-follow-up. In the multivariate analysis we therefore controlled for infant's 
birth weight and gestational age. 
A sub-cohort of 203 infants (96 in zinc and 107 in placebo supplemented 
group) were eligible for inclusion in the Hib-immunization trial since they had not 
yet reached the age of 12 weeks. A total of 27 infants (16 or 16.7% in zinc 
supplemented and 11 or 10.3% in placebo group) were lost-to-follow-up before the 
end of the study for the following reasons: infants deaths (n=5), migration from 
the area (n=8), refusals (n=10) and infants who had received immunizations 
through another source (n=4). There were no differences between treatment 
groups in reasons for lost-to-follow-up. A total of 176 infants (80 in zinc and 96 in 
placebo group) completed the course of three doses of the combined diphtheria, 
tetanus toxoid and pertussis (DTP)- Haemophilus influenzae type b (Hib) vaccine 
and provided pre- and post-vaccination serum samples for immune assays. Median 
ages at pre- and post-immunization blood sampling were 4.0 and 24.1 weeks 
respectively and median ages at the three rounds of immunization were 9.6, 13.9 
and 18,1 weeks. Serum samples of 85 infants were insufficient for analysis 
resulting in a final sample of 91 infants (38 zinc, 53 placebo group) for analysis of 
Hib-response. 
Compared to infants who were lost-to-follow-up for the Hib assays, the 91 
infants who were included in the Hib-trial had significantly higher gestational ages 
at birth (table 1) and their mothers had significantly lower Body Mass Indexes (BMI) 
at baseline (i.e., 4 months gestation). We controlled for those variables in the 
multivariate analysis. 
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Table 1. Selected baseline and birth characteristics for mothers at 4 months gestation 
and infants included in analysis on immune response or lost-to-follow-up for analysis on 
immune response for 405 infants enrolled in BCC trial and 203 infants enrolled in DTP-Hib 
trial. 
Infants: 
Birthweight (g) 
LBW (%)2 
Gestational age 
(wk) 
IUGR (%)3 
Gender: male 
(%) 
Mothers: 
Age (yr) 
Nulliparous {%) 
Socioeconomic 
status 
Poor/very poor 
(%)A 
BMI5 
MUAC6 
Hemoglobin 
(g/L) 
Serum zinc 
(umol/L) 
Treatment: zinc 
(%) 
Infants lost for 
PPD skin test 
(n=64) 
2427 (484)1 
54.1 
38.0 (2.8) 
75.7 
57.3 
23.1 (5.6) 
24.0 
81.3 
18.9 (2.8) 
224 (27) 
112(13) 
15.1 (3.8) 
48.0 
1
 Values in mean (SD) 
2
 LBW= low birth weight (<2500 g) 
Infants included 
for PPD skin test 
(n=345) 
2558 (367)' 
40.6' 
39.0(2.1)' 
73.7 
53.3 
23.0 (5.5) 
21.7 
76.5 
19.0 (2.4) 
227 (23) 
115(13) 
15.5(4.6) 
47.2 
Infants lost for 
Hib-immune assay 
(n=112) 
2534 (404) 
43.1 
38.6 (2.3) 
71.9 
54.4 
23.0 (5.5) 
21.6 
79.0 
19.1 (1.6) 
228 (25) 
114(13) 
15.6 (4.7) 
48.9 
' IUGR = Intra Uterine Growth Retarded (<10% of fetal growth chart; 13) 
Based on an index of household assets (13) 
3
 BMI= Body Mass Index 
Infants included 
for Hib-immune 
assay (n=91) 
2536(351) 
42.7 
39.7(1.9)* 
82.0* 
52.7 
23.3 (5.7) 
24.2 
71.5 
18.4(1.9)* 
223(21) 
116(12) 
14.7(3.1) 
41.8 
' MUAC= Mid Upper Arm Circumference 
' Different from infants dropped for PPD (purified protein derivate) skin test (p<0.05) 
* Different from infants dropped for Hib {Haemophilus influenza type b)-immune assays (p<0.05) 
Effect of zinc supplementation on cellular immune response. 
At 24 weeks of age, 60.9% (210 of 345) of all infants showed a negative 
tuberculin skin response (induration of < 5 mm) in response to the PPD skin test. 
There were no differences in proportion of negative responses between treatment 
groups (zinc: 58.9%; placebo: 62.6%; table 2). A significantly higher percentage of 
infants born with low birth weights (LBW; <2500 g) showed negative skin responses 
compared to infants born with normal birth weights (NBW; 71.9% vs. 52.7% for LBW 
and NBW groups respectively, p<0.0001). 
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Anergic (%f 
All infants2 
LBW3 
NBW4 
Mean size of PPD-induration (mm)5 
All infants 
LBW 
NBW 
58.9 
66.2 
52.3 
11.7(0.4) 
11.7(0.6) 
11.8(0.5) 
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Table 2. Cellular immune response to tuberculin (PPD) skin test at 24 weeks of age for 
infants by birth weight in zinc and placebo groups. 
Zinc group Placebo group 
62.6 
78.5' 
53.0 
11.8(0.4) 
11.2(0.9) 
12.0(0.4) 
1
 Anergic - size of PPD induration < 5 mm "" ~~~ ~" 
2
 All infants (n=163/182) 
3
 Low birth weight infants (<2500 g, n=74/65) 
* Normal birth weight infants (n=87/116) 
5
 Mean size of induration of positive responses (SEM) 
" Different from zinc supplemented group (p=0.07; Logistic regression controlling for birthweight and 
gestational age) 
PPD=purified protein derivate tuberculosis 
When data were analysed separately for 139 LBW-infants, fewer infants in 
zinc compared to placebo group were not responsive to the tuberculin skin test 
(66.2% vs. 78.5%) with the difference being of marginal statistical significance 
(p=0.07). No differences in response to the tuberculin skin test were observed 
between treatment groups for the 203 normal birth weight infants, or for infants 
born premature (n=50) or at-term (n=295). The mean size of induration among the 
positive responses was 11.8 mm (SEM 0.4) and did not differ for LBW and NBW 
infants of zinc and placebo groups (table 2). 
Effect of zinc supplementation on response to Hib conjugate vaccine. 
Geometric mean PRP antibody titres before and after immunization and 
mean paired differences between titres pre- and post-immunization are shown in 
table 3. There were no statistically significant differences in geometric mean PRP 
titres at 24 weeks of age (post-immunization) between infants from zinc (6.78 
Ug/ml; 95% CI: 3.36;12.01) and placebo groups (10.15 ug/ml; 95% CI: 6.29;16.14). 
Table 3. Geometric mean PRP antibody titres pre- and post-immunization for infants in 
zinc and placebo group1 
Zinc group Placebo group 
(n=38) (n=53) 
Pre-immunization (ug/ml)2 0.22 (0.15;0.33) 0.21 (0.15;0.29) 
Post-immunization (ug/ml)3 6.78 (3.36;12.01) 10.15 (6.29; 16.14) 
1
 Geometric mean titres calculated as the antilog of the mean of the logarithms of values (values in brackets: 
95% confidence intervals) 
2
 Pre-immunization at 4 weeks of age 
3
 Post immunization at 24 weeks of age 
PRP=polyribosylribitol phosphate. 
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Figure 1. Proportion of infants with PRP antibody titres > 0.15 //g/m/ pre- and post-
immunization (and 95% confidence intervals) for zinc and placebo groups. 
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Figure 2. Proportion of infants with PRP antibody titres > 1.0 /jglml pre- and post-
immunization (and 95% confidence intervals) for zinc and placebo groups. 
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Nearly all infants (95% in zinc and 98% in placebo supplemented group, 
difference NS) achieved protective antibody titres correlated with immediate 
protection (>0.15 |ig/ml; figure 1). Furthermore, the large majority (81% in zinc 
and 89% in placebo group, difference NS) achieved titres > 1 u.g/ml associated with 
long-term protection (figure 2). No differences were observed between treatment 
groups in geometric mean PRP antibody titres for LBW (n=38) and NBW (n=51) 
infants but sample sizes were small. 
Infants from zinc supplemented mothers had significantly fewer days of 
fever (>38.0 C) during post-immunization safety surveillance compared to infants 
from placebo supplemented mothers (means (SEM): 0.98 (0.11) vs. 1.23 (0.12); 
p<0.05). No other differences in potential adverse effects following DTP-Hib 
immunization were observed between treatment groups (table 4). 
Table 4. Adverse events in the 5 days following immunization for three rounds of DTP-
Hib vaccine for infants in zinc and placebo group. 
Swelling/redness at injections site 
- n [%) 
- days 
Crying more than usual 
- n (X) 
- days 
Less active 
• n (%) 
• days 
Lethargic 
- n (X) 
- days 
Fever measured 
- n (%) 
- days3 
Zinc group 
(n=89) 
84 (94.6)1 
4.27 (0.27)2 
89 (100) 
4.01 (0.20) 
80 (90.2) 
2.57 (0.29) 
13 (14.1) 
0.21 (0.06) 
56 (62.9) 
0.98 (0.11) 
' Number (Proportion) of infants showing the event on at least one day 
Fever: rectal body-temperature > 38°C p < 0.05; Student's t-test 
Placebo group 
(n=94) 
90(96.1) 
3.95 (0.26) 
93 (99.0) 
3.97 (0.20) 
85 (90.2) 
2.36 (0.16) 
13(13.7) 
0.21 (0.07) 
66 (70.2) 
1.23 (0.12)' 
' Values in means (SD) 
DISCUSSION 
Zinc supplementation with 30 mg elemental zinc/day during the last two 
trimesters of pregnancy resulted in a positive albeit small effect on the response 
to the delayed hypersensitivity skin test on BCG vaccine at 24 weeks of age in 
infants born with low birth weight (LBW). No differences were observed among 
infants born with normal birth weights (NBW). There were no differences in 
antibody responses to the Haemophilus influenzae type b (Hib) vaccine between 
the groups. However, fewer days with fever were observed in the 5 days post-Hib-
vaccination in infants born to zinc-supplemented compared to placebo-
supplemented mothers. 
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We previously reported results from the same cohort of infants 
demonstrating that maternal zinc supplementation during pregnancy did not 
improve birth weight but reduced episodes of acute diarrhea, dysentery and 
impetigo during the first six months of life among LBW infants.13 The prevalence 
of LBW in Bangladesh is among the highest in the world and in our study a total of 
43% of all live births were LBW.12 LBW infants are known to be at-risk for impaired 
immunity and increased morbidity later in life.19 The results of this current study 
suggest that an improved cellular immunity might be a possible mechanism for the 
observed reductions in morbidity among LBW infants after maternal zinc 
supplementation. 
Beneficial effects of zinc supplementation on indicators of cellular immune 
response such as the delayed hypersensitivity skin response to PPD or CMI, number 
or functioning of circulating T-lymphocytes and thymus size have been reported 
previously in studies supplementing infants and children.9,20'23 Animal models of 
zinc deficiency suggest that improved delayed-type hypersensitivity after zinc 
repletion may be caused by a restored interaction between effector T-cells and 
macrophages.7 Zinc deficiency is also known to be associated with atrophy of 
lymphoid organs and a reduced number of T-lymphocytes in animal models, all of 
which respond positively to a repletion of zinc.5 
Zinc deficiency has in addition been shown to affect elements of the 
immunologic memory as reduced T-dependent and, to lesser extent, T-
independent antibody responses have been observed in zinc deficient mice.8 
Antenatal zinc deprivation in rats resulted in lower immunoglobulin serum 
concentrations, in particular IgA, lgG2 and IgM in the off-spring at 6 months of 
age.5 Evidence for an effect of zinc supplementation on humoral immune response 
in humans is less and not conclusive. Increased serum IgA and salivary IgA 
concentrations have been observed after zinc supplementation in two studies 
among Chilean infants.20,21 However, serum IgG and IgM concentrations were not 
affected by zinc supplementation among malnourished infants in Chile.20 Similarly, 
no effects of zinc supplementation on salivary IgA were observed in young rural 
Gambian children.24 
We observed a lower number of febrile days during the first five days post-
immunization after maternal zinc supplementation. Negative correlations between 
plasma zinc and number of febrile days have been observed previously in 
malnourished Chilean infants.20 These findings may be the result of a depressed 
acute phase response mediated by cytokines during zinc deficiency.25 Zinc 
repletion is expected to restore these functions. 
In our study we did not observe effects of maternal zinc supplementation on 
infants' antibody response to the Hib vaccine. The polysaccharide Hib-conjugate 
vaccine that we used in our study contains a T-dependent antigen (HbOC) that 
induces an anamnestic response after repeated infections and is predominantly of 
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the IgG class.16 We had anticipated a beneficial effect of zinc supplementation for 
this specific antigen since it is known that T-dependent B-lymphocytes are more 
affected by zinc deficiency than T-independent ones.5 Therefore our findings are 
somewhat unexpected. Our sample sizes were small and only sufficient to detect a 
difference of 4.6 (j.g/ml in PRP titres at 24 weeks or a difference of 74% in 
proportion of post-immunization titres above the protective threshold (s 1 ng/ml) 
between treatment groups assuming 80% power and a type I error of 5%. 
The Hib-conjugate vaccine that was used in this study has been shown to be 
more immunogenic than the unconjugated pure polysaccharide vaccine. In 
addition, the Hib conjugate vaccines, unlike the pure polysaccharide vaccines are 
known to reduce Hib carriage in the upper respiratory tract, especially among 
younger children in the US and The Gambia.26,27 The highly potent conjugate 
vaccine may have induced immune response in all our infants and therefore 
overcome any blunting of immune response resulting from zinc deficiency. 
In our population, geometric mean PRP antibody concentrations post-
immunization were 7.89 ng/ml which is substantially higher than levels observed in 
infants in developed countries such as the UK (3.65 ng/ml) after immunization 
with a similar conjugate vaccine.28 Although our sample sizes were small, it is 
possible that frequent exposure to the Haemophilus influenzae type b-antigen 
even at this young age, may have caused an anamnestic response if the child came 
in contact with the organism after receiving the primary series of the vaccine. 
Recent studies confirm that the incidence of invasive Haemophilus influenzae type 
b (Hib) diseases are high in South Asia with an estimated 50 cases per 100.000 
compared to 22-109 per 100.000 in pre-vaccination USA and Europe.29 Moreover, a 
700% increase in Hib incidence over the period 1987-1994 has been reported from a 
hospital in Bangladesh.30 We hypothesize therefore that high infection rates of 
Haemophilus influenzae type b in these settings may have contributed to the 
humoral immune response to the vaccine in nearly all our infants which may have 
masked any potential beneficial effects of zinc supplementation. 
Prior to immunization at the age of 4 weeks, 58% of our infants had PRP 
antibody concentrations of > 0.15 ng/ml compared to only 30% observed in UK 
infants of similar age.28 At 4 weeks of age, concentrations primarily reflect 
maternal Hib-specific immunoglobulins and the high maternal antibody 
concentrations in our population are another indication of a high degree of 
exposure to Hib organism. 
In conclusion, in our cohort of poor Bangladeshi infants we were not able to 
demonstrate an effect of maternal zinc supplementation on the immune response 
to Haemophilus influenzae type b vaccine. To our knowledge this study is the first 
to report the effect of maternal zinc supplementation on infant's immune response 
to vaccines, but our findings seem to be in contrast with the observed 
improvements in neonatal humoral immunity by increased cord-blood 
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immunoglobulin concentrations after zinc supplementation during pregnancy in a 
similar trial in Peru.11 Additional research is required to define the exact role of 
zinc in the development of the immune system in infants in developing countries. 
Finally, the findings of our current study suggest that an improved cellular 
immune response may have caused observed reductions in morbidity among infants 
born with LBW after maternal zinc supplementation during the last two trimesters 
in pregnancy.13 LBW infants are known to have impaired immunity and an 
increased burden of infectious diseases during infancy,19 and maternal zinc 
supplementation might be an effective way to reverse some of these 
disadvantageous outcomes. 
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ABSTRACT 
Background: Evidence for an effect of zinc supplementation on growth and morbidity in 
very young infants in developing countries is scarce and inconsistent. 
Objective: To assess the effect of zinc supplementation from 4 to 24 weeks of age on 
growth and morbidity in poor Bangladeshi infants. 
Design: Infants of Dhaka slums were enrolled at 4 weeks of age and randomly assigned to 
receive daily 5 mg elemental zinc (n=152) or placebo (n=149) until 24 weeks of age. 
Infants were followed weekly for information on compliance and morbidity while 
anthropometric measurements were performed monthly. Serum zinc was assessed at 
baseline and 24 weeks of age. 
Results: At 24 weeks of age serum zinc levels were higher in the zinc compared to placebo 
supplemented infants (13.3 (SD 3.8) vs. 10.7 (2.9)nmol/L;p<0.001). Significantly greater 
weight gains were observed in zinc group compared to placebo group for 43 infants who 
were zinc deficient (<9.18^mol/L) at baseline (3.15 (0.77) vs. 2.66 (0.80) kg, p<0.04). In 
the other infants no differences were observed in mean weight and length gains between 
4-24 weeks. Zinc-deficient infants also showed a reduced risk for incidence of Acute Lower 
Respiratory Infection (ALRI) after zinc supplementation (RR:0.30;95SSCI:0.10,0.92) whereas 
among the non-zinc deficient infants there were no differences between treatment 
groups. 
Conclusions: Improvements in growth rate and reduced incidence of ALRI were observed in 
zinc-deficient Bangladeshi infants after zinc supplementation. However, among non-zinc 
deficient infants there were no improvements in growth or morbidity, although zinc 
supplementation improved serum zinc status. 
INTRODUCTION 
Zinc deficiency has been associated with reduced growth, impaired 
immunity and increased prevalence and incidence of infectious diseases among 
infants and children in developing countries.1'3 Evidence for a causal relationship 
with morbidity has been provided by randomized controlled intervention trials in 
infants above 6 months of age and children in both industrialized and developing 
countries showing improved immune functions4,5 and reduced morbidity2 after zinc 
supplementation. These effects are thought to be more attributable to a 
correction of the zinc deficiency status that causes an impaired immunity and 
intestinal mucosal damage6 rather than to a pharmacologic effect of zinc7. 
Evidence for an effect of zinc supplementation on growth of children came from a 
recent meta-analysis concluding that zinc supplementation during childhood is 
responsible for a small but statistically significant effect on growth particularly 
among growth retarded children.1 
Most of the intervention trials studying the effect of zinc on growth or 
morbidity were performed in children above 6 months of age when the period of 
highest growth velocity has already passed. It has been hypothesized that earlier 
interventions might be more effective in preventing growth faltering and reducing 
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morbidity patterns among children at-risk.8 Unfortunately, only limited information 
is available on the effect of zinc supplementation in younger infants and the 
results are not conclusive. Beneficial effects on growth and morbidity were 
observed after zinc supplementation among low birth weight (LBW) and small for 
gestational age (SGA) infants in Brazil9 and Chile10 respectively. However, in India 
no effect of zinc supplementation on diarrheal morbidity was observed in children 
among 6-11 months of age in contrast to the strong beneficial effects observed 
among older children.11 Different prevalences of zinc deficiency among younger 
age groups caused by varying rates of prematurity, intrauterine growth retardation 
(IUGR), exclusivity of breast-feeding and early morbidity may explain the varying 
responses to zinc supplementation in very young infants. 
To investigate the effect of zinc supplementation on growth and morbidity 
from infectious diseases in infants below 6 months of age, we performed an 
intervention trial among 4-24 weeks old Bangladeshi infants living in Dhaka urban 
slums. Because the incidence of low birth weight among this population is as high 
as 43%, which is mostly (76%) due to IUGR12, a large proportion of these infants can 
be considered to have impaired immunity, increased morbidity and be at-risk of 
growth faltering later in life.13 
SUBJECTS AND METHODS 
Study population 
The study was performed in three selected areas of Dhaka city slums, in a 
representative sample of households from Dhaka's slum population.14 The slum 
areas are characterized by high population density, poor housing, multi-family 
latrines and water sources, poor sewerage and drainage facilities and irregular 
garbage collection. The population is relatively young and mostly illiterate.15 
Malnutrition is known to be widely prevalent and the prevalence of malnutrition 
among children of the urban slums is even higher than among children of the rural 
poor.16 
Singleton infants were eligible for inclusion in the study if they met entry 
criteria of age (4 ± 1 week) and residence, were in good general health without 
known underlying illnesses, were not included in any other intervention trial 
and/or had not received immunizations through other sources. A total of 301 
infants aged 3-5 weeks (152 in zinc and 149 in placebo supplemented groups) were 
identified through an established household-surveillance system and enrolled in 
the study between April and June 1997. Prior to enrollment, a written informed 
consent was obtained from the infant's parents. 
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The study was approved by the Ethical Review Committee of ICDDR,B and 
the Committee on Human Research of the Johns Hopkins School of Hygiene and 
Public Health. 
Study design 
Infants were randomly allocated to a liquid 5 mL daily dose with or without 
5 mg elemental zinc (as zinc acetate). Both liquids contained sucrose, flavors and 
preservatives, were indistinguishable in both appearance and taste and were 
prepared and coded by Opsonin Chemical Industries Ltd. Dhaka. The zinc content 
of both supplement and placebo was independently confirmed by two different 
laboratories. Health workers delivered a bottle containing a one-week supply of 40 
ml of the supplement at the houses of the participants and instructed mothers to 
give a daily dose to their infants using a marked dropper or feeding spoon. 
Compliance with supplement consumption was 85% (of total days) and the average 
daily consumption was 4.2 (SD 1.3) ml as assessed by measuring liquid levels at the 
weekly visits. Unannounced compliance checks between the regular visits were 
also performed monthly in a 10% subsample of the population. No differences in 
compliance were observed between the two treatment groups. The codes of the 
supplements were unknown to both participants and study staff and broken only 
after data editing and cleaning was completed. 
Prior to randomization, information was collected on household's socio-
economic status, demographic characteristics, maternal and infant anthropometry, 
characteristics of the delivery (place, duration, complications) and infant 
vaccination history. The infants were provided with the standard immunizations by 
the study nurses. The Bacille Calmette Guerin (BCG) vaccine was administered at 
enrollment and infants were immunized with the Trivalent Oral Polio vaccine 
(TOPV) and the combined diphtheria, tetanus toxoid and pertussis (DTP)-
Haemophilus Influenza type B (hib) vaccine (TETRAMUNE, Wyeth Lederle Vaccines, 
NY, USA) at 8, 12 and 16 weeks of age (± 2 weeks). A subsample of 171 infants who 
had not yet reached the age of 4 months ± 15 days at the time of arrival of the 
vaccine, received in addition the 7-valent Pneumococcal conjugate vaccine (Wyeth 
Lederle Vaccines, NY, USA) at 4 weeks (± 2 weeks) intervals.17 
Infants' serum zinc was determined at 4 and 24 weeks of age. Infants were 
followed weekly for assessment of compliance and morbidity of diarrheal and 
respiratory diseases. Information on infant feeding practices was collected every 2 
weeks and infants were classified as either exclusively, predominantly (infant 
receiving breast milk and water/sugar water), or partially breastfed or not 
breastfed at all. The age of introduction of complementary foods was also 
determined. Anthropometric measurements (weight, length, arm-, head- and 
chest-circumference) were performed monthly until the infants were 6 months old. 
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Data collection procedures 
During monthly home visits, infant weight was measured to the nearest 10 g 
on beam-balance scales (Seca 725) that were regularly calibrated against standard 
weights. Recumbent lengths were measured to the nearest 0.1 cm on a length 
board and head-, chest- and arm circumferences were measured to the nearest 
millimeter using numeral insertion tapes. The mean of two measurements was 
recorded as the observed value for all indices. Intra- and inter-observer variations 
were assessed and found to be acceptable with coefficients of variation below 2% 
for all anthropometric indices. Underweight (low weight-for-age), stunting (low 
length-for-age) and wasting (low weight-for-length) were defined as standard 
deviation scores (Z-scores) of < -2.00 compared with the US NCHS reference 
charts using EPI Info software (version 6.1, 1994, CDC, Atlanta, GA, USA).18 
A detailed history during the past week of respiratory infections, diarrhea, 
fever and other illnesses was recorded during weekly home visits. Infants were 
investigated for signs of dehydration during monthly visits. Infants who required 
medical treatment were examined by study physicians following standard 
treatment protocols and referred to appropriate healthcare facilities if necessary. 
All data were collected by the same trained fieldworkers and manually checked 
and coded by registered nurses. 
Acute lower respiratory infection (ALRI) was defined as a history of cough 
and/or difficult breathing, with or without fever, lasting more than 1 day and 
accompanied by at least one of the following symptoms: rapid breathing or chest 
indrawing. Upper respiratory tract infection (URI) was defined as a) history of 
cough or difficult breathing, with or without fever, for more than one day not 
associated with rapid breathing or chest indrawing, or b) cough for more than one 
day with nasal discharge. 
Acute diarrhea was defined as unusually loose and/or unusually frequent 
stool according to the mother's perception. If the stool contained blood the 
episode was classified as dysentery. Persistent diarrhea was defined as diarrhea 
lasting for 14 days or more. 
The number of actual surveillance days was counted by subtracting the days 
on which no recall data were available from the total days of follow-up. When a 
mother had been absent for more than 15 days (2 consecutive visits), recall data 
was only collected for the 14 days prior to the first interview after the period of 
absence. An episode of illness was considered resolved if the child was free of 
symptoms for at least 3 consecutive days according to definitions used in similar 
studies.2-11 
Specimen collection and laboratory procedures 
At 4 and 24 weeks of age, non-fasting blood specimens were obtained by 
antecubital venipuncture in morning hours for serum zinc determination using 
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trace mineral-free plastic syringes, stainless steel needles and plastic tubes. Serum 
was separated at a maximum of 6 hours after collection and stored at -20C until 
analysis. Prior to analysis, the serum samples were diluted (1:12) with 0.03% poly-
oxyethylene 4 lauryl ether (Brij 30) and HNO3 (10 mmol/L). Zinc concentration was 
measured using flame atomic absorption spectrophotometry19 (AA-6501S Atomic 
Absorption Flame Emission Spectrophotometry, Shimadzu, Japan). A standard 
curve was established using a commercial zinc reference (BDH Laboratory Supplies, 
UK) in concentrations of 0.1, 0.25, 0.5 and 1.0 mg/l. Commercial serum with 
known concentrations of zinc were used as a measure of quality control. The 
coefficient of variation of the measurements was always < 5%. 
Statistical methods 
Prior to the main analysis, potential confounders that contributed 
significantly to the variation in outcome variables, were identified by a multiple 
stepwise regression. Possible interactions between treatment group and infant's 
sex, baseline nutritional status or serum zinc status were evaluated by introducing 
separate interaction terms in the linear regression models. Significant interactions 
between treatment and baseline serum zinc and between treatment and gender 
were observed for some of the outcome variables. We therefore created separate 
models based on subgroups for gender and baseline serum zinc < or > 9.18 (imol/L. 
The cut off for zinc deficiency was selected according to the literature.2 
Differences in mean and total weight and length gain between zinc- and 
placebo-supplemented infants were assessed using Analysis of Covariance 
(ANCOVA) and selected baseline values were added as covariates (SPSS7.5 FOR 
WINDOWS; SPSS Inc, Chicago). The covariates had been selected prior to the 
ANCOVA through a multiple stepwise regression identifying variables that 
contributed significantly to the variation in outcome variable. Differences in 
anthropometric indices and Z-scores at 1, 2, 3, 4, 5 and 6 months of age were 
tested using ANCOVA for repeated measurements. 
Differences between groups in incidence of diseases were assessed with 
Poisson regression models (Epidemiological GRaphics Estimation and Testing 
Package, EGRET, SERC, Seattle, WA98105, 1991) including number of episodes as 
dependent, treatment group as independent and total days of actual surveillance 
as off-set term in the model.20 Potential confounders were added to the regression 
models as additional independent variables. 
Longitudinal prevalence of diseases was calculated for each individual as 
percentage of actual surveillance days with illness. The non-parametric Mann-
Whitney U test was used to compare differences in longitudinal prevalence 
between infants from zinc and placebo groups. Log transformed values of 
prevalence were used in the multivariate regression models since the distribution 
of longitudinal prevalence was highly skewed. Prior to the log-transformation a 
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constant ('one') was added to all values to enable log-transformation of the zero-
values. P values of <0.05 were considered statistically significant. Results are 
presented as means (standard deviations) unless otherwise indicated. 
Table 1. Baseline characteristics of infants in zinc and placebo groups 
Age (months) 
Gender: male (%) 
Socio-economic status2: 
-Poor 
-Very poor 
Weight (kg) 
Length (cm) 
MUAC (mm) 
Head circumference (cm) 
Serum zinc (nmol/L) 
Zinc-supplemented1 
(n=152) 
0.89 (0.13) 
41% 
41% 
30% 
3.47 (0.48) 
51.3 (2.3) 
104 (9) 
35.6 (1.4) 
11.9 (2.9) 
Placebo-supplemented1 
(n =149) 
0.90 (0.12) 
48% 
44% 
34% 
3.44 (0.50) 
51.1 (2.1) 
104 (9) 
35.6 (1.3) 
11.7 (3.0) 
'Values in means (SD) 
2
 Based on an index of household assets (12) 
MUAC, mid upper arm circumference. 
None of the differences statistically significant 
RESULTS 
During the course of the study a total of 31 infants (10%) were lost-to-
follow-up (14 (9%) in the zinc supplemented and 17 (11%) in the placebo group; 
NS). Fifteen out of the 31 infants either permanently or temporarily out-migrated, 
8 infants died during the study period, 4 parents refused further participation and 
4 infants had received immunizations through other sources and were excluded 
from further participation. There were no differences in reasons for lost-to-follow-
up between the two treatment groups. Infants who were lost-to-follow-up from 
the study still contributed to the analysis for morbidity for the number of days on 
which there were observations. 
A total of 270 infants (138 in the zinc and 132 in the placebo group) 
completed the study until 24 weeks of age. This final sample size was sufficient to 
detect the following differences with 80% power and type I error of 5% between 
zinc and placebo groups for the main outcome variables: 1.2 ujnol/L (10%; SD 3.5) 
for serum zinc at 24 weeks of age, 0.24 kg (9%; SD 0.7) for increase in body weight 
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Table 2. Changes in anthropometric indicators between 4 and 24 weeks of age by 
baseline serum zinc status for infants in zinc and placebo groups. 
Weight growth (kg) 
-All infants11 
-Serum zinc < 9.18 u,mol/L3 
-Serum zinc > 9.18 n m o l / l / 
Weight growth (g/kg/month) 
-All infants 
-Serum zinc < 9.18 u.mol/L3 
-Serum zinc > 9.18 umol/L4 
Linear length growth (cm) 
-All infants2 
-Serum zinc < 9.18 umol/L3 
-Serum zinc > 9.18 nmol/L4 
Change in head circumference (cm) 
-All infants2 
-Serum zinc < 9.18 u,mol/L3 
-Serum zinc > 9.18 umol/L" 
Change in chest circumference (cm) 
-All infants2 
-Serum zinc < 9.18 u.mol/L3 
-Serum zinc > 9.18 umol/L4 
Change in MUAC (cm) 
-All infants2 
-Serum zinc < 9.18 umol/L3 
-Serum zinc > 9.18 umol/L4 
Zinc-supplemented1 
2.85 (0.73) 
3.15(0.77) 
2.79(0.71)* 
131 (29) 
144 (29) 
128 (28)* 
11.5 (1.9) 
12.5 (2.0) 
11.3 (1.8)* 
5.1 (1.1) 
5.9 (1.0) 
5.0 (1.1)* 
6.8 (2.1) 
7.8 (2.1) 
6.6 (2.0)* 
2.5 (1.1) 
2.9 (1.2) 
2.5 (1.0) 
Placebo-supplemented1 
2.79 (0.72) 
2.66 (0.80)" 
2.81 (0.72) 
129 (29) 
130(33) 
128 (28) 
11.4 (2.1) 
11.5 (2.2) 
11.4 (2.1) 
5.2 (1.1) 
5.1 (1.2)' 
5.2 (1.1) 
6.6 (2.1) 
6.7 (2.4) 
6.6 (2.1) 
2.6 (1.0) 
2.5 (1.1) 
2.6 (1.0) 
Values in mean (SD). 
2
 All infants, n=138/133 for zinc and placebo groups respectively. 
3
 Baseline serum zinc < 9.18 umol/L (n=21/16). 
4
 Baseline serum zinc > 9.18 nmol/L (n=117/115) 
' Different from value in zinc supplemented group; p < 0.05 (ANCOVA control for gender, baseline length-for-
age-Z-score, baseline infant weight, baseline serum zinc, household income). 
* Different from value in serum zinc < 9.18 umol/L group; p < 0.05 (ANCOVA control for gender, baseline 
length-for-age-Z-score, baseline infant weight, baseline serum zinc, household income). 
MUAC, mid upper arm circumference 
between 4 and 24 weeks of age and 0.7 episodes/child/6 months (12%; SD 0.2) for 
incidence of acute diarrhea. Baseline characteristics of infants in zinc and placebo 
group were not different (Table 1). At baseline a total of 43 infants (14%) had 
serum zinc levels < 9.18 umol/L (22 (15%) in zinc and 21 (14%) in placebo group; 
NS). 
Serum zinc 
At 24 weeks of age, serum zinc concentrations in the zinc supplemented 
infants were significantly higher compared to infants in the placebo group (13.3 
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[3.8] vs. 10.7 [2.9] (xmol/L; p < 0.001). Serum zinc concentrations significantly 
decreased between 4 and 24 weeks in the placebo group (-1.1 [4.1] nmol/L) 
whereas they increased in the zinc supplemented infants (1.5 [4.7] nmol/L, p-
value of difference < 0.001). At 24 weeks of age a total of 28 (22%) infants in the 
placebo group were zinc deficient (serum zinc < 9.18 (xmol/L) compared to 12 (9%) 
infants in the zinc group (p<0.005). 
Assessment of growth 
No differences were observed for changes in weight, length and head 
circumferences between 4 and 24 weeks of age for infants from zinc and placebo 
groups respectively (Table 2). Mean weight and length at 24 weeks of age were 
6.33 (0.94) kg and 62.7 (2.6) cm for infants supplemented with zinc and 6.23 (1.01) 
kg and 62.5 (2.7) cm respectively for placebo supplemented infants (difference 
US). Mean length-for-age, weight-for-age and weight-for-length Z-scores between 
4 and 24 weeks of age were not different between treatment groups (data not 
shown). 
LAZ 
-A— placebo 
Normal zinc (> 9.18 ^ ol/L) 
Month of age 
Figure 1. Mean length-for-age Z-scores (LAZ) between 1 and 6 months of age for infants in 
zinc and placebo supplemented groups. 
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WAZ 
Month of age 
Different from zinc supplemented group; p < 0.05 
zinc 
—•— placebo 
Normal zinc (2 9.18 timol/L) 
Low zinc (< 9.18 umol/L) 
Figure 2. Mean weight-for-age Z-scores (WAZ) between 1 and 6 months of age for infants 
in zinc and placebo supplemented groups. 
WLZ 
Month of age 
* Different from zinc supplemented group; p < 0.05 
Normal zinc (> 9.18 nmol/L) 
Low zinc (< 9.18 nmol/L) 
Figure 3. Mean weight-for-length (WLZ) Z-scores between 1 and 6 months of age for 
infants in zinc and placebo supplemented groups. 
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When data were analyzed separately for infants with (n=43) or without 
(n=257) zinc deficiency at baseline (serum zinc values < 9.18 |xmol/L), significant 
differences were observed after zinc supplementation for total weight gain 
between 4 and 24 weeks of age and weight at 24 weeks of age (6.52 (0.85) vs. 5.82 
(0.99) kg in zinc and placebo groups respectively; p<0.05) in 43 infants that were 
zinc deficient at baseline (Table 2). A similar trend was observed for total length 
gain but this difference did not reach statistical significance. Weight-for-age and 
weight-for-length Z-scores at 4, 5 and 6 months of age were significantly higher in 
zinc supplemented infants compared to the placebo supplemented infants (Figure 
1-3). After zinc supplementation significantly greater changes in weight, length, 
head-, and chest-circumferences were observed in infants that were zinc deficient 
compared to their non-zinc deficient counterparts (Table 2). No differences were 
observed in placebo infants or between treatment groups in infants with normal 
baseline serum zinc values (> 9.18 u,mol/L; Table 2 and Figure 1-3). 
Table 3. Longitudinal prevalence of morbidity between 4 and 24 weeks of age for infants 
in zinc and placebo groups 
Morbidity 
Acute diarrhea 
- All infants2 
- Serum zinc < 9.18 umol/L3 
- Serum zinc > 9.18 umol/L4 
Persistent diarrhea 
- All infants 
- Serum zinc < 9.18 umol/L 
- Serum zinc > 9.18 umol/L 
Dysentery 
- All infants 
- Serum zinc < 9.18 umol/L 
- Serum zinc > 9.18 umol/L 
Cough (URI)5 
- All infants 
- Serum zinc < 9.18 umol/L 
- Serum zinc > 9.18 (xmol/L 
ALRI6 
- All infants 
- Serum zinc < 9.18 umol/L 
- Serum zinc > 9.18 umol/L 
5.9 
5.8 
6.0 
4.2 
4.3 
4.2 
0.7 
0.0 
0.8 
36.9 
38.5 
36.6 
7.6 
5.8 
7.9 
Percentage of days i l l 
Zinc group1 
4.8 (0.0-37.0) 
5.2 (0.0-26.4) 
4.4 (0.0-37.0) 
0.0 (0.0-48.1) 
0.0 (0.0-30.8) 
0.0 (0.0-48.1) 
0.0 (0.0-18.6) 
0.0 (0.0-0.0) 
0.0 (0.0-18.6) 
35.3 (0.0-100.0) 
40.6 (0.0-100.0) 
33.8 (0.0-91.8) 
0.0 (0.0-93.9) 
0.0 (0.0-69.4) 
0.0 (0.0-93.9) 
Placebo group1 
5.8 
6.7 
5.6 
4.7 
3.1 
5.0 
1.1 
0.2 
1.3 
35.1 
38.5 
34.1 
7.5 
8.0 
7.4 
3.6 (0.0-33.3) 
4.1 (0.0-26.5) 
3.6 (0.0-33.3) 
0.0 (0.0-86.4) 
0.0 (0.0-28.0) 
0.0 (0.0-86.4) 
0.0 (0.0-73.0) 
0.0(0.0-4.1) 
0.0 (0.0-73.0) 
32.2 (0.0-94.6) 
44.6 (2.00-94.6) 
29.1 (0.0-89.8) 
0.0 (0.0-87.2) 
0.0 (0.0-45.5) 
0.0 (0.0-87.2) 
First column: mean % of days il l ; second column: median (range) 
2
 All infants (n=152/149) only children included with >= 15 days follow-up 
3
 Baseline serum zinc < 9.18 umol/L (n=22/21). 4 Baseline serum zinc £9.18 nmol/L (n=130/127) 
5URI, upper respiratory infection 6ALRI= acute lower respiratory infection. 
None of the differences statistically significant (Linear regression with log transformed values). 
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In male infants, total weight gain between 4 and 24 weeks of age (3.21 
(0.68) vs. 2.99 (0.62) kg in zinc and placebo groups) was higher in the zinc 
supplemented compared to placebo supplemented infants. However, this 
difference was not statistical significant after controlling for confounding variables 
in the multivariate analyses. No differences in growth were observed between 
treatment groups among female infants or among different subgroups based on 
infant's nutritional status. 
Morbidity 
No differences were observed between the two treatment groups for percentage of 
days ill and number of episodes of diarrheal and respiratory diseases (Table 3 and 
4). However, when data were analyzed separately for zinc-deficient children 
(baseline serum zinc < 9.18jamol./L), fewer number of episodes with acute lower 
respiratory infections (ALRI) were observed in the zinc supplemented (0.3 [0.7] 
episodes/child/6months) compared to the placebo supplemented infants (0.9 [1.3] 
episodes/child/6months; RR: 0.30; 95%CI:0.10;0.92). No significant differences 
were observed between zinc and placebo groups for infants with normal baseline 
serum zinc values (> 9.18nmol./L; Table 4). 
There were no differences in the effect of zinc on morbidity for infant's 
gender. 
DISCUSSION 
Zinc supplementation with 5 mg elemental zinc/day between 4 and 24 
weeks of age did not improve infant growth nor reduced morbidity from diarrheal 
and respiratory diseases in Bangladeshi infants with normal serum zinc values. 
However, in infants with low serum zinc concentrations (<9.18 \imoUL) at 
baseline, beneficial effects on growth in terms of a significant greater weight gain 
and improved though not significant linear growth and on morbidity in terms of 
significant fewer number of episodes of Acute Lower Respiratory Infections (ALRI) 
were observed after zinc supplementation. These findings were somewhat 
unexpected since we had anticipated a beneficial effect of zinc supplementation 
on growth and morbidity among all infants in this deprived population. The study 
was performed among young infants below 6 months of age who are at high risk for 
growth faltering and/or contracting diseases, in a population where zinc deficiency 
is thought to be common. 
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Table 4. Incidence of diseases between 4 and 24 weeks of age for infants in zinc and 
placebo supplemented groups. 
Total surveillance days 
Acute diarrhea 
• Total # episodes 
- Episode/child/6mth2 
-All infants3 
•Serum zinc < 9.18 umol/L4 
-Serum zinc i 9.18 nmol/L5 
Persistent diarrhea 
- Total # episodes 
- Episode/child/6mth2 
-All infants3 
-Serum zinc < 9.18 umol/L4 
-Serum zinc > 9.18 nmol/L5 
Dysentery 
- Total # episodes 
- Episode/child/6mth2 
-All infants3 
-Serum zinc < 9.18 umol/L4 
-Serum zinc > 9.18 umol/L5 
Cough (URI)7 
- Total # episodes 
- Episode/child/6mth2 
-All infants3 
-Serum zinc < 9.18 umol/L4 
-Serum zinc > 9.18 umol/L5 
ALRI8 
- Total # episodes 
- Episode/child/6mth2 
-All infants3 
-Serum zinc < 9.18 umol/L4 
-Serum zinc > 9.18 umol/L5 
Zinc group 
20547 
244 
2.1 (2.0) 
2.1 (2.0) 
2.1 (2.1) 
40 
0.4 (0.8) 
0.4 (0.7) 
0.4 (0.9) 
10 
0.09 (0.3) 
0.0 (0.0) 
0.1 (0.3) 
511 
3.4(1.7) 
4.5(2.1) 
4.6 (2.0) 
75 
0.7(1.2) 
0.3 (0.7) 
0.7(1.3) 
Placebo group 
20238 
216 
2.0(2.1) 
2.6 (2.1) 
1.9 (2.1) 
38 
0.4(1.5) 
0.3 (0.6) 
0.5 (1.6) 
13 
0.12 (0.4) 
0.1 (0.3) 
0.1 (0.5) 
500 
3.4(1.5) 
4.5 (1.9) 
4.6 (2.2) 
74 
0.7(1.2) 
0.9 (1.3) 
0.7 (1.2) 
R R ^ C . I . ) 1 
1.13(0.94;1.36) 
0.87 (0.60; 1.72) 
1.14(0.93;1.39) 
1.17(0.74;1.83) 
1.58 (0.31 ;7.96) 
1.04(0.64;1.69) 
0.72(0.31;1.66) 
N.A.6 
0.77(0.33;1.78) 
1.00(0.89;1.14) 
0.95(0.65;1.39) 
1.01 (0.88;1.15) 
0.99(0.71;1.37) 
0.30 (0.10;0.92)' 
1.10(0.77;1.56) 
1
 RR= rate ratio estimated with Poisson regression with 95% CI in parentheses, adjusted for baseline infant 
weight, length, socio-economic status, problems during delivery reported, delivery duration, age introduction 
of water. 
2
 Values in mean (SD) 
3
 All infants (n=150/149) only children included with >= 15 days follow-up 
""Baseline serum zinc < 9.18 nmol/L (n=22/21). 
5
 Baseline serum zinc > 9.18 umol/L (n=128/127) 
6
 N.A.= Not applicable, could not calculate RR due to empty cells 
7
 URI, upper respiratory infection. 
8
 ALRI, Acute Lower Respiratory Infection. 
" p < 0.05 
We believe that a lack of effect in the apparently non-zinc deficient infants 
(based on serum zinc concentrations > 9.18 u.mol/L) may be due to one or more of 
the following reasons: (a) zinc might not have been the primary growth-limiting 
nutrient for these predominantly breastfed infants, (b) the age of these infants did 
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not allow us to demonstrate an effect of zinc supplementation on morbidity due to 
the low incidence of diseases among this young age group and the fact that at this 
age predominantly breastfed infants have probably not yet developed a zinc 
deficiency, and (c) the dosage we provided may not have been sufficient. 
We provided 5 mg elemental zinc per day, the recommended daily 
allowance for this age group.21 Since the infants in our study were pre-dominantly 
breast-fed during most of the study period, most of the dietary zinc intake was 
from breastmilk and differences between zinc and placebo supplemented infants in 
dietary zinc intake, other than the supplement, were therefore thought to be 
random and due to natural variability in breastmilk zinc.22 Compliance with 
supplement-consumption was good and we observed significant improvements in 
serum zinc values in the zinc supplemented but not in the placebo supplemented 
group, indicating that the zinc supplementation was successful in improving the 
zinc status of these infants. 
We do not know whether a higher dosage of zinc would have given different 
results in our population. Positive effects of zinc supplementation on growth or 
morbidity of infants or children have been observed in studies using higher23'26 but 
also similar27,28 or even lower dosages10 than used in our study. A significantly 
higher mortality was observed among severely malnourished children in Bangladesh 
receiving a high-dose (6 mg/kg bodyweight/day) zinc treatment, suggesting that 
some caution is warranted in supplementing malnourished children with high 
dosages of zinc.29 
The lack of effect on growth in the general, i.e., non-zinc deficient 
population as observed in our study after zinc supplementation is in contrast with 
findings of other studies among the same age group showing improvements in 
growth after supplementation with 3 and 5 mg elemental zinc/day in Chile and 
France respectively.10,28 Beneficial effects of zinc supplementation on linear and 
ponderal growth have also been observed among older infants, both in well and 
malnourished populations.1,23 However, some studies among older children in 
malnourished populations24,27,30 were not able to show an effect of zinc 
supplementation on growth. It has been hypothesized that zinc was probably not 
the primary limiting nutrient to growth in these populations31 and single nutrient 
interventions might therefore not improve growth in populations with multiple 
nutrient deficiencies.32 
We believe that the very young age of our population is the most likely 
explanation for a lack of effect of zinc supplementation as observed among the 
general population of infants in our study. Firstly, we supplemented infants 
between 4 and 24 weeks of age and the overall burden of morbidity in this age 
group was low. A stronger reduction in morbidity after zinc supplementation has 
been observed in older compared to younger age groups11,25 possibly due to the 
higher incidence of diseases in older age groups where exposure to antigens is 
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usually higher and the protective effect of maternal antibodies is waning. 
However, reductions in morbidity after zinc supplementation have been observed 
even during the first six months of life in a study among low birth weight (LBW) 
infants in Brazil.9 The dosage used in this study was similar to our dosage but the 
supplementation in the Brazilian study started at birth and continued for 12 weeks 
only. 
Secondly, in our study we observed statistically significant differences in 
growth and morbidity after zinc supplementation among infants that were zinc 
deficient at baseline. These findings and the fact that at 4 weeks of age only 14% 
of our population had serum zinc concentrations < 9.18 jxmol/L, suggest that most 
infants of this age had not yet developed a zinc deficiency. At 24 weeks of age, 
almost all infants in our study (96%) were still pre-dominantly or partially breast-
fed. In developed countries zinc deficiency is known to be relatively rare among 
term breast-fed infants during the first months of life33 due to large concentrations 
of highly bio-available zinc in early breastmilk and utilization of hepatic 
metallothionein as a source of zinc during the first months of life.34 The results of 
our study indicate that similar mechanisms may also occur in less affluent societies 
in breast-fed children below 6 months of age although more research is required to 
confirm this. 
In conclusion, zinc supplementation with daily 5 mg elemental zinc between 
4 and 24 weeks of age improved zinc status, but did not improve growth or reduce 
morbidity in poor Bangladeshi infants, who were not zinc deficient at 4 weeks of 
age. However, improvements in growth and morbidity were observed in infants 
with low serum zinc values at 4 weeks of age suggesting that zinc supplementation 
might be beneficial in some infants who are zinc deficient at this very early age. 
We previously reported results from another study in the same population 
showing that zinc supplementation during pregnancy with 30 mg elemental 
zinc/day during the last two trimesters reduced morbidity from diarrheal diseases, 
particularly among low birth weight infants during the same age period.12,35 The 
differences in results between our two studies indicate that compared to infant 
supplementation, zinc supplementation during pregnancy might perhaps be a more 
effective way to reduce some of the increased health risks associated with low 
birth weight or zinc deficiency in infants below 6 months of age. 
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ABSTRACT 
Background: Zinc deficiency is known to impair immunologic functions. However, the 
effect of zinc supplementation on the immune response to polysaccharide vaccines is not 
known. 
Objective: To determine the immunogenicity of the heptavalent PNC vaccine in poor 
Bangladeshi infants and to assess the effect of zinc supplementation on immune response 
to PNC and other childhood vaccines. 
Design: We immunized 301 infants with the standard BCG vaccine at 4 weeks of age and 
the combined diphtheria, tetanus toxoid and pertussis (DTP)- Haemophilus Influenzae type 
b (Hib) vaccine from 9 weeks of age. The infants were supplemented with daily 5mg zinc 
or placebo from 4-33 weeks of age. A subcohort of 241 infants was in addition immunized 
with the heptavalent PNC vaccine at 18 ± 1 weeks of age. Response to delayed 
hypersensitivity (PPD) skin test and antibody response to Hib and each of the seven PNC 
serotypes were assessed at 4, 24 and 33 weeks of age. 
Results: After three doses of PNC, geometric mean titres for the pneumococcal serotypes 
ranged from 3.68 to 13.34 ng/ml. Titres at 24 weeks of age were significantly higher for 
infants who had received PNC compared to infants who had only received DTP-Hib. There 
were no severe adverse events related to vaccination. Zinc supplementation resulted in 
higher titres for serotypes 9V and 23F but had no effect on other serotypes nor on 
response to DTP-Hib. Zinc had a marginal negative effect on response to PPD skin test. 
Conclusions: A heptavalent PNC vaccine proved to be safe and immunogenic in Bangladeshi 
infants. Zinc supplementation enhanced the immune response of two Pneumococcal 
serotypes (9V and 23F). 
INTRODUCTION 
Acute lower respiratory infections (ALRIs) are estimated to cause the death 
of 4 million under-5 year-olds annually in the world and most of these deaths are 
due to pneumonia, accounting for up to 30% of all deaths in children <5 years of 
age from developing countries.1,2 Streptococcus pneumoniae (the pneumococcus) 
is the most important cause of bacterial pneumonia in young children.3 
The pure pneumococcal polysaccharide vaccines currently licensed in the US 
and many other countries worldwide, are immunogenic in children above 2 years of 
age and in adults, but not in infants below 2 years of age in whom the incidence of 
pneumonia-related death is highest. To overcome this problem new vaccines have 
been developed in which the T-independent capsular polysaccharide is covalently 
conjugated to a T-dependent protein carrier.4 A recently developed heptavalent 
pneumococcal conjugate vaccine (Prevanar; Wyeth-Lederle-PNCRM7) was found to 
be safe, immunogenic and highly efficacious in preventing invasive disease in US 
infants beginning at 2 months of age.5,6 This vaccine contained saccharides of 
pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. 
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There is only limited data from developing countries regarding the immune 
responses of infants to this pneumococcal conjugate vaccine. In a pilot trial in the 
Gambia a pentavalent pneumococcal conjugate vaccine was found to be safe and 
immunogenic but sample sizes were small (n= 30) and the vaccine contained only 
five pneumococcal serotypes.7 If the 7-valent pneumococcal conjugate vaccine is 
to be used routinely in developing countries it is important to know if the immune 
responses are similar to infants in developed countries. If the antibody responses 
are found to be lower, it is important to know if the impaired immune responses 
can be overcome through supplementation with micronutrients that are known to 
affect the immune system, such as zinc. Zinc plays an essential role in the non-
immune and immune host defenses8 and beneficial effects on immunity and 
morbidity have been demonstrated in infants and children after zinc 
supplementation.9'11 However, the effect of zinc supplementation in infants on the 
immune response to vaccines is not known. 
We assessed the immunogenicity of a heptavalent pneumococcal conjugate 
vaccine in infants from a very poor, urban area in Bangladesh where ALRI is 
estimated to account for 23% of all childhood mortality12 and evaluated the effect 
of zinc supplementation during 4-33 weeks of age on the immune response to this 
vaccine. 
SUBJECTS AND METHODS 
Study design and study population 
This study was a nested study within a community-based, randomized 
controlled trial, to evaluate the effect of zinc supplementation on growth and 
morbidity from infectious diseases among infants aged 4 to 24 weeks. Details on 
the study population, intervention and data collection procedures have been 
reported elsewhere.13 The study was approved by the Ethical Review Committee of 
ICDDR,B and the Committee on Human Research of the Johns Hopkins School of 
Hygiene and Public Health. 
Singleton infants living in three selected areas of Dhaka city slums were 
eligible for inclusion in the study if they met the entry criteria of age (4 ± 1 week), 
were in good general health without known underlying illnesses, were not included 
in any other intervention trial and/or had not received immunizations through 
other sources. A total of 301 infants aged 4±1 week (152 in zinc and 149 in placebo 
supplemented groups) were identified through an established household-
surveillance system and enrolled in the study between April and June 1997 after 
obtaining written informed consent from the parents. Infants were randomly 
allocated to a liquid 5 mL daily dose sucrose liquid with or without 5 mg elemental 
zinc (as zinc acetate). Both liquids contained sucrose, flavors and preservatives, 
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were indistinguishable in both appearance and taste and were prepared and coded 
by Opsonin Chemical Industries Ltd. Dhaka. The zinc content of both supplement 
and placebo was independently confirmed by two different laboratories. 
Compliance with supplement consumption was 85% and the average daily 
consumption was 4.2 ± 1.3 ml as assessed by measuring liquid levels at weekly 
visits combined with unannounced compliance checks between the regular visits. 
No differences in compliance were observed between the two treatment groups. 
The codes of the supplements were unknown to both participants and study staff 
and broken only after data editing and cleaning was completed. Supplementation 
started at 4 ± 1 weeks of age and continued until the end of data collection at 24 ± 
1 or 33 ± 2 weeks of age respectively. Due to a delayed arrival of the 7-valent 
pneumococcal conjugate vaccine, only 241 infants who at that time had not yet 
reached the age of 4 months ± 15 days were eligible for pneumococcal 
immunization. For these infants supplementation and compliance monitoring 
continued until 33 weeks of age to allow for a final blood sampling at least one 
month after the third dose of the vaccine. 
Infants were followed weekly for assessment of compliance and morbidity of 
diarrheal and respiratory diseases. Anthropometric measurements (weight, length, 
arm-, head- and chest-circumference) were performed monthly until the infants 
were 6 months old. Infants' serum zinc was determined at 4 and 24 weeks of age.13 
Immunization 
At enrollment 0.05 ml reconstituted live freeze-dried vaccine of Bacille 
Calmette Guerin (BCG) was administered and infants were immunized with the 
Trivalent Oral Polio vaccine (TOPV) and combined diphtheria, tetanus toxoid and 
pertussis (DTP)- Haemophilus Influenzae type b (Hib) vaccine (Diphtheria CRM, 97 
protein conjugate), [TETRAMUNE® Wyeth-Lederle, NY] at 9, 13 and 18 weeks of age 
(± 3 weeks). A total of 241 infants who had not yet reached the age of 4 months ± 
15 days at the time of the arrival of the vaccine, received in addition the 7-valent 
pneumococcal conjugate vaccine (Prevanar; PNC, Wyeth Lederle Vaccines, NY, 
USA) at 18, 24 and 28 weeks (± 4 weeks). The pneumococcal conjugate vaccine 
contained 2 ng each of saccharides of the following serotypes: 4, 9V, 14, 18C, 19F 
and 23F and 4 ng of 6B coupled to a protein carrier (CRM197). The second and 
third round of vaccinations were given at 4 week intervals (± 2 days). When 
possible the pneumococcal conjugate vaccine was administered conjointly with the 
TETRAMUNE vaccine intramuscularly into the opposite leg. Vaccines not given 
concomitantly were given at least 2 weeks apart. All immunizations were given by 
study nurses. 
Post-vaccination safety surveillance was carried out during home visits from 
day 1 through day 5 post-vaccination by trained study nurses. Data was collected 
and recorded daily on rectal temperature, local swelling and redness, generalized 
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rash, seizures, general health of the infant, feeding history and any other 
unexpected reactions. 
Assessment of immune response to H. Influenza type b and Pneumococcal 
conjugate vaccine. 
Antibody response to H. Influenzae b polysaccharide (polyribosylribitol 
phosphate (PRP)) was assessed pre-vaccination at 4 weeks of age and post-
vaccination at 24 weeks of age. Immunogenicity of the 7-valent pneumococcal 
conjugate vaccine was assessed pre-vaccination at 4 weeks of age, after the 
second dose of vaccination at 24 weeks of age and one month after the third dose 
at 29 weeks of age. Non-fasting blood specimens (5 ml) were obtained by 
antecubital venipuncture in the morning hours. Serum was separated a maximum 
of 6 hours after collection and stored at -20C until analysis. Antibodies (IgG) to 
PRP and to the seven pneumococcal vaccine serotypes were measured by enzyme 
linked immunosorbent assay (ELISA). All assays were performed at the laboratory 
of Wyeth Lederle Vaccines (NY, USA) following standard procedures.14 The study 
codes were not known to the laboratory personnel until all assays were completed. 
Geometric mean antibody titres were calculated as the antilog of the mean of the 
logarithms of titres. Mean paired differences between pre- and post immunization 
titres and percentage of infants with antibody levels > 0.15 ng/ml and > 1.0 ng/ml 
were determined. 
Assessment of immune response to tuberculin skin test. 
Immune response to the BGC vaccine was tested at 24 weeks of age by 
delayed hypersensitivity skin test (DTH) using the purified protein derivate (PPD) 
test (Staten Serum Institute, Copenhagen, Denmark). Tuberculin solution (0.1 ml) 
was applied by trained nurses to the volar surface of the forearm intradermal^ 
using an Omega glass PPD syringe with platinum needles. After 72 hours the 
transverse diameter of the induration developed was read in millimeters. A 
cutaneous reaction was considered positive when an induration > 5mm was 
observed.15 Six nurses were extensively trained and standardized in the 
administration and interpretation of PPD skin testing. Inter-rater agreements as 
assessed prior and during the study in hospital patients were found to be 
satisfactory with Pearson correlation coefficients ranging between 0.98 (p < 0.000) 
and 0.73 (p=0.03) and consistent with inter-rater agreements observed in similar 
studies.16 
Statistical methods 
Results are presented as means and standard deviation except when 
otherwise stated. Differences between groups in proportion of infants with an 
induration of < 5 mm from the tuberculin skin test and proportion of infants with 
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antibody titres above the protective thresholds before and after immunization 
were assessed with the Mac Nemar's test. Differences between groups in mean size 
of induration, geometric mean antibody titres and paired differences between pre-
and post- immunization titres were assessed with the Mann-Whitney U-test and the 
Wilcoxon paired signed rank sum-test respectively. Separate models were made 
based on subgroups for baseline serum zinc < or > 9.18 (j.mol/L. The cut-off for zinc 
deficiency was selected according to the literature.11 
Analysis of Covariance (ANCOVA) and Logistic Regression Analysis were 
performed to control for potential confounders (SPSS7.5 FOR WINDOWS; SPSS Inc, 
Chicago). P-values of <0.05 were considered statistically significant and P-values of 
<0.09 were considered marginally significant. 
RESULTS 
Description of the study population. 
Of the 301 infants enrolled and immunized with BCG vaccine at enrollment, a total 
of 33 (11%) infants (15 or 10% in zinc group and 18 or 12% in placebo group, 
difference NS) were lost-to-follow-up before 24 weeks of age. Eight infants had 
died, 15 infants had migrated from the study area, the parents of six infants 
refused to further participate and four infants had received immunizations through 
other sources and were excluded from further participation. Reasons for lost-to-
follow-up were not different for infants from zinc and placebo group. The PPD 
skin test could not be administered in an additional 10 infants (4 in zinc and 6 in 
placebo group) at 24 weeks of age because they refused, were sick or not available 
at the time of the test. For 13 infants readings (10 in zinc and 3 in placebo group) 
could not be performed within the required 72 hours and the final sample size for 
the effects on the tuberculin skin test therefore consisted of 245 infants (123 in 
zinc, 122 in placebo group). 
For the assessment of immune response to the combined diphteria, tetanus 
toxoid and pertussis (DTP)- Haemophilus influenza type b (Hib) vaccine, an 
additional ten infants were lost-to-follow-up because they had not received three 
doses of vaccinations (n=3) or because their caretakers refused the final blood 
sampling (n=7). A total of 258 infants (133 in zinc, 125 in placebo group) 
completed the course of three doses of the DTP-Hib vaccine and provided pre- and 
post-vaccination serum samples for immune assays. Thirty of these infants (15 in 
zinc and 15 in placebo group) had only received the DTP-Hib vaccine, whereas the 
remaining 228 infants had received one or two doses of the 7-valent pneumococcal 
PNC) vaccine in addition. Median ages at pre- and post-immunization blood 
sampling were 4.0 and 24.0 weeks respectively and median ages at the three 
rounds of immunization were 8.7, 13.7 and 18.3 weeks. Serum samples of 76 
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Table 1. Selected baseline characteristics for infants included in analysis on immune 
response and infants lost-to-follow-up for analysis on immune response for 301 infants 
enrolled in Hib trial and 241 infants enrolled in Pneumococco trial. 
Age infant (months) 
Gender: male (%) 
Weight (kg) 
Length (cm) 
Z-scores: 
Length-for-age 
Weight-for-age 
Weight-for-length 
Serum zinc (u,mol/L) 
Age mother (yrs) 
Weight mother (kg) 
Parity: 
primiparae (%) 
Socio-
economicstatus: 
poor/very poor (%) 
Infants lost for 
Hib trial 
(n=119) 
0.88 (0.12) 
49.6 
3.39 (0.48) 
51.1 (2.2) 
-1.07 (0.95) 
-0.87 (0.76) 
-0.25 (0.58) 
12.0 (2.9) 
25.6 (6.2) 
44.0 (6.4) 
26.1 
81.5 
Infants included 
in Hib trial 
(n=182) 
0.91 (0.12)* 
41.2 
3.49 (0.49) 
51.3 (2.1) 
-0.99 (0.86) 
-1.04 (0.75)* 
-0.41 (0.78)* 
11.7 (3.0) 
23.9 (5.5)v 
44.4 (6.4) 
25.3 
69.8 
Infants lost for 
PnC trial (n=135) 
0.89 (0.12) 
48.1 
3.46 (0.50) 
51.0 (2.2) 
-1.10 (0.91) 
-0.93 (0.76) 
-0.23 (0.64) 
12.1 (3.0) 
24.8 (6.1) 
43.8 (6.3) 
23.0 
79.2 
Infants included 
in PnC trial 
(n=106) 
0.88 (0.13) 
39.6 
3.43 (0.47) 
51.1 (2.1) 
-1.05 (0.86) 
-0.93 (0.76) 
-0.31 (0.57) 
11.3 (2.6)* 
24.6 (5.8) 
44.5 (6.5) 
27.4 
71.7 
1
 Values in mean (SD) 
2
 LBW= low birth weight (<2500 g) 
3IUGR = Intra Uterine Growth Retarded (<10% of fetal growth chart; 13) 
4
 Based on an index of household assets (13) 
5
 BMI= Body Mass Index 
' MUAC= Mid Upper Arm Circumference 
' Different from infants lost-to-follow-up for Pneumococco assays test (p<0.05) 
v
 Different from infants lost-to-follow-up for Hib (Haemophilus influenza type b)-immune assays (p<0.05) 
* Different from infants dropped for Hib {Haemophilus influenza type b)-immune assays (p<0.06) 
infants were insufficient for analysis resulting in a final sample of 182 infants (95 
zinc group, 87 placebo group) for analysis of Hib-response. Compared to infants 
who were lost-to-follow-up for the Hib assays, the 182 infants who were included 
in the Hib-trial had statistical significant higher weight for age Z-scores at 
enrollment and their mothers were significantly younger (table 1). We controlled 
for those variables in the multivariate analysis. 
A total of 241 infants (121 in zinc supplemented group and 120 in placebo 
supplemented group) received the first dose of the PNC vaccine in addition to the 
combined diphteria, tetanus toxoid and pertussis (DTP)-Haemophilus influenzae 
type b (Hib) vaccine. Of these 241 infants, 8 (7%) in zinc and 15 (13%) in placebo 
group, difference NS, were lost-to-follow-up before the final blood drawing at 33 
weeks of age for the following reasons: 3 infants died, 6 infants migrated out of 
the study area, 10 refused to further participate in the study and 4 infants did not 
complete the three-dose course of the PNC vaccine. There were no differences for 
reasons of lost-to-follow-up between zinc and placebo group. Median ages at the 
final post-three dose blood sampling was 32.7 weeks and median ages at the three 
113 
Chapter 7 
rounds of immunization were 18.1, 23.9 and 28.9 weeks. Of the 218 infants who 
provided a final blood sample after the third vaccine dose, a total of 112 serum 
samples were insufficient for analysis and pneumococcal antibody titres at 33 
weeks of age are therefore known for 106 infants (53 in zinc and 53 in placebo 
group). Antibody titres of these 106 infants were compared with titres of 30 
infants (15 in zinc and 15 in placebo group) who had not received the PNC vaccine 
The 106 infants with known PNC antibody titres had statistical significant lower 
serum zinc concentrations at enrollment compared to the infants who were lost-to-
follow-up (table 1) and we therefore controlled for baseline serum zinc in the 
multivariate analysis. 
Immunogenicity of pneumococcal conjugate vaccine 
Geometric mean antibody titres for the seven pneumococcal serotypes for infants 
who received only the DTP-Hib vaccine compared to infants who received both the 
DTP-Hib and the PNC vaccines are shown in table 2. Prior to immunization at 4 
weeks of age, there were no differences in titres between the groups. Geometric 
mean antibody titres declined significantly (p<0.001 Wilcoxon paired-rank test) at 
24 weeks of age for all seven serotypes in infants who had only received the DTP-
Hib vaccine. At 24 weeks of age, 71 (42%) infants had received the first PNC dose 
only while 100 (58%) infants had received two doses of PNC. 
Geometric mean antibody titres for all seven serotypes were significantly 
higher at 24 weeks of age (P < 0.001; Mann-Whitney U test) for infants that had 
received two PNC doses compared to the titres of infants that had just received 
one PNC dose at that time (table 2). For infants that had received one PNC dose 
at 24 weeks of age, geometric mean titres had increased between 4 and 24 weeks 
of age for serotypes 4, 9V and 18C whereas only the increase in serotype 4 was 
statistically significant. A similar but more pronounced pattern was observed for 
infants who had received two PNC doses at 24 weeks of age (table 2). In these 
infants, geometric mean titres increased significantly for serotypes 4, 9V, 18C and 
23F between 4 and 24 weeks. After three doses of the PNC vaccine geometric 
mean titres for all seven serotypes had increased further. The geometric mean 
titres ranged from 3.68 to 13.34 ng/ml with the highest titres for serotypes 6B and 
14 and the lowest for serotype 9V. 
Comparisons between groups were only possible at 24 weeks of age, after 
all three doses of DTP-Hib vaccine and one or two doses of the PNC vaccine. 
Geometric mean titres for all seven PNC serotypes were significantly higher in 
infants that had received two or even only one dose of PNC at 24 weeks of age 
compared to infants who had only received the DTP-Hib vaccine. 
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Table 2. Geometric mean titres to each pneumococcal serotype pre- and post-
immunization for infants receiving the Pneumococcal conjugate vaccine combined with 
Tetramune and infants receiving only the Tetramune vaccine1. 
Pneumococco sero-type Tetramune only 
(n- 30) 
PnC conjugate and Tetramune 
(n= 106) 
6B 
9V 
14 
Pre-immunization2 
Post-1 dose immunization3 
Post- 2 dose immunization4 
Post-3 dose immunization5 
Pre-immunization 
Post-1 dose immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
Pre-immunization 
Post-1 dose immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
Pre-immunization 
Post-1 dose immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
18C 
Pre-immunization 
Post-1 dose immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
19F 
Pre-immunization 
Post-1 dose immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
23F 
Pre-immunization 
Post-1 dose immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
0.67 (0.42; 1.09) 
0.07 (0.04;0.13) 
-do-
2.73 (1.76;4.24) 
0.26 (0.17;0.40) 
-do-
1.37 (0.93;2.00) 
0.19 (0.11;0.32) 
-do-
3.23 (2.17;4.80) 
0.26 (0.15;0.44) 
-do-
0.79 (0.52;1.18) 
0.09 (0.05;0.15) 
-do-
3.16 (2.11;4.74) 
0.49 (0.30;0.82) 
-do-
1.06 (0.73;1.54) 
0.14 (0.08;0.24) 
-do-
0.60 (0.49;0.74) 
4.92 (3.41; 7.10)"# 
8.19 (6.38;10.52)"# 
8.61 (7.51;9.86) 
2.37 (1.97;2.86) 
0.56 (0.40;0.78)*' 
1.25 (0.83;1.89)" 
13.34 (11.14;15.98) 
1.34 (1.15;1.57) 
0.94 (0.67;1.33)" 
2.30 (1.73;3.05)"# 
3.68 (3.20;4.24) 
3.32 (2.73;4.04) 
1.02 (0.70; 1.39) ' 
2.13 (1.44;3.16f 
10.23 (8.57;12.21) 
0.93 (0.77; 1.12) 
0.73 (0.50; 1.07)" 
1.73 (1.17;2.56)"# 
5.14 (4.39;6.02) 
2.89 (2.41;3.47) 
1.00 (0.71;1.40)"' 
3.33 (2.34;4.74)" 
5.75 (4.77;6.92) 
1.06 (0.89;1.25) 
0.68 (0.48;0.98)" 
1.65 (1.08;2.51)"* 
6.65 (5.52;8.01) 
1
 Geometric mean titres calculated as the antilog of the mean of the logarithms of values (values in brackets: 
95% confidence intervals) 
2
 Pre-immunization at 4 weeks of age 
3
 Post-1 dose immunization at 24 weeks of age (n=71), after 1 doses of PnC vaccine and 3 doses of Tetramune 
vaccine 
4
 Post-2 dose immunization at 24 weeks of age (n=100), after 2 doses of PnC vaccine and 3 doses of Tetramune 
vaccine. 
5Post- 3 dose immunization at 33 weeks of age (n=106), after 3 doses of PnC vaccine 
* Titre differs from Tetramune only group (p<0.01; ANCOVA, control for age infant at enrollment, age mother, 
prevalence of upper respiratory infection between 4-24 weeks of age) 
" Titre differs from Tetramune only group (p<0.005; ANCOVA, control for age infant at enrollment, age 
mother, prevalence of upper respiratory infection between 4-24 weeks of age) 
# Titre increased compared to titre pre-immunization (p< 0.001; Wilcoxon signed-rank test) 
' Titre decreased compared to titre pre-immunization (p < 0.001; Wilcoxon signed-rank test). 
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Figure 1. Proportion of infants with Pneumococcal antibody titres > 1.00 jus/ml 
After the third dose of PNC vaccine, all infants had received protective 
antibody levels ( > 1 ng/ml) for serotype 4 whereas nearly all had received the 
protective threshold for the other serotypes: 6B (99%), 9V (97.1%), 14 (99%), 18C 
(98.1%), 19F (95.2%) and 23F (97.1%) (figure 1). At 24 weeks of age, for all seven 
serotypes significantly higher proportions of infants who had received two or even 
one dose of the PNC vaccine had reached the protective thresholds compared to 
infants who had only received the DTP-Hib vaccine (p < 0.001; Logistic Regression). 
Prior to immunization at 4 weeks of age, no differences in proportions above 
protective thresholds were observed between groups (figure 1). 
Effect of zinc supplementation on response to pneumococcal conjugate vaccine. 
At 4 weeks of age, prior to immunization and prior to the onset of 
supplementation there were no differences in geometric mean titres for the seven 
PNC serotypes between infants from zinc and placebo group (table 3). After one or 
two doses of the PNC vaccine at 24 weeks of age there seem to be higher titres in 
the zinc compared to the placebo group for serotype 23F (1.88 |ag/ml; [95% CI: 
1.09;3.2] vs. 1.02 ng/ml; [95% CI: 0.65; 1.62] for zinc and placebo group 
respectively; p < 0.08) but the difference was small and only of marginal statistical 
significance. After three doses of the PNC vaccine at 33 weeks of age significantly 
higher titres were observed in zinc compared to placebo group for serotype 9V 
(4.09 ng/ml; [95% CI: 3.27;5.10] and 3.33 ^ig/ml; [95% CI: 2.79;3.96] for zinc and 
placebo group respectively; p < 0.05). There were no differences between zinc and 
placebo groups for the other pneumococcal serotypes. 
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Table 3. Geometric mean tit res and % above 'protective' thresholds to each 
pneumococcal serotype pre- and post-immunization for infants from zinc- and placebo-
supplemented sroups. 
Pneumococcal sero-type 
4 
Pre-immunization2 
Post-2 dose immunization3 
Post-3 dose immunization4 
6B 
Pre-immunization 
Post-2 dose immunization 
Post-3 dose immunization 
9V 
Pre-immunization 
Post-2 dose immunization 
Post-3 dose immunization 
14 
Pre-immunization 
Post-2 dose immunization 
Post-3 dose immunization 
18C 
Pre-immunization 
Post- 2 dose immunization 
Post-3 dose immunization 
19F 
Pre-immunization 
Post-2 dose immunization 
Post- 3 dose immunization 
23F 
Pre-immunization 
Post-2 dose immunization 
Post-3 dose immunization 
Zinc group 
GMT1 
0.74 (0.55;1.00) 
7.64 (5.31;10.99) 
8.78 (6.99;11.02) 
2.45 (1.81;3.31) 
0.98 (0.59;1.64) 
13.94(10.83;17.93) 
1.47 (1.13;1.92) 
2.13 (1.40;3.23) 
4.09 (3.27;5.10) 
2.94 (2.18;3.98) 
1.59 (0.94;2.70) 
11.44 (9.25;14.14) 
0.98 (0.75;1.27) 
1.57 (0.91;2.72) 
5.47 (4.21;7.09) 
3.35 (2.52;4.46) 
2.45 (1.53;3.93) 
5.79 (4.32;7.75) 
1.26 (0.94; 1.70) 
1.88 (1.09;3.24) 
6.64 (4.79;9.21) 
(n=53) 
%> 
0.15 
meg 
85.9 
100 
98.9 
100 
98.9 
100 
100 
100 
94.6 
100 
98.9 
100 
94.6 
98.1 
%> 
1.0 
meg 
35.9 
100 
81.5 
100 
63.0 
100 
84.8 
100 
46.7 
96.2 
83.7 
94.2 
56.5 
94.2 
Placebo group 
GMT 
0.69 (0.50;0.94) 
8.18 (6.32;10.59) 
8.44 (7.20;9.90) 
2.90 (2.14;3.93) 
1.02 (0.65;1.61) 
12.79 (9.80;16.69) 
1.46 (1.12;1.91) 
1.41 (0.99;2.00) 
3.33 (2.79;3.96)* 
3.45 (2.48;4.78) 
1.39 (0.90;2.15) 
9.17 (6.87;12.21) 
1.18 (0.87;1.59) 
1.00 (0.64;1.56) 
4.84 (4.00;5.86) 
3.63 (2.69;4.89) 
2.06 (1.40;3.05) 
5.70 (4.47;7.28) 
1.30 (1.00;1.68) 
1.02 (0.65; 1.62)* 
6.66 (5.48;8.10) 
(n=53) 
%> 
0.15 
meg 
88.4 
100 
98.8 
100 
98.8 
100 
97.7 
100 
94.2 
100 
100 
100 
97.7 
100 
%> 
1.0 
meg 
38.4 
100 
82.6 
98.1 
61.6 
98.1 
82.6 
98.1 
51.2 
100 
86 
96.2 
54.7 
100 
1
 GMT= Geometric mean titres calculated as the antilog of the mean of the logarithms of values (values in 
brackets: 95% confidence intervals) 
2
 Pre-immunization at 4 weeks of age;3 Post-2 dose immunization at 24 weeks of age; * Post-3 dose 
immunization at 33 weeks of age 
* Titre differs from zinc group (p<0.05; ANCOVA); #Titre differs from zinc group (p<0.08; ANCOVA) 
No differences were observed between zinc and placebo supplemented 
infants post-immunization at 33 weeks of age for all seven pneumococcal serotypes 
for proportion of infants who had reached the "protective" thresholds of > 0.15 
Hg/ml or > 1 u.g/ml (table 3). 
Safety 
Adverse events observed after the PNC and DTP-Hib immunization during 
the five days post-immunization safety follow-up were usually mild and occurred 
less often than after only the DTP-Hib immunization (table 4). Following the PNC 
immunization, infants had significantly fewer days with local reactions at the 
injection site (3.71 ± 2.08 days) during the five days post-immunization for all 
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three rounds of immunization combined, compared to the DTP-Hib immunization 
(4.87 ± 2.81 days, p < 0.01; table 4). During the five days following the PNC 
vaccination fewer days of systemic reactions were reported: crying more than 
usual (2.64 ± 2.19 vs. 3.89 ± 2.37 days for PNC and DTP-Hib only groups 
respectively, p<0.005) or less active (1.30 ± 1.38 vs. 2.41 ± 1.89 days for PNC and 
DTP-Hib only groups respectively, p < 0.005). There was a small and marginal 
statistically significant (p < 0.06) difference in number of days with fever (>38.0 
°C) after receiving the PNC vaccination (0.88 ± 1.05 days) compared to after 
receiving only the DTP-Hib vaccination (1.26 ± 1.09 days). 
Overall, ten infants were hospitalized, one infant was admitted in the out-
patient ward and one infant visited the emergency room within one month of 
receipt of a dose of the PNC vaccine. The reasons for hospitalization were: acute 
diarrhea (n=6), dysentery (n=2), persistent diarrhea and broncho pneumonia (n=1), 
septicemia and diarrhea (n=1) and Salmonella type B enteritis (n=1). All were 
Table 4. Adverse events in the 5 days following immunization combined for three rounds 
of DTP-Hib and Pneumococco vaccine for infants receiving Tetramune only or both the 
vaccines in zinc and placebo group. 
Swelling/redness at 
injections site 
- %1 
-days2 
Crying more than usual 
• % 
• days 
Less active 
-% 
- days 
Lethargic 
•% 
• days 
Fever measured3 
• % 
- days2 
1
 Values in means (SD) 
Tetramune only 
Zinc group 
(n=15) 
15 (100) 
5.40 (2.24) 
15 (100) 
3.63 (1.77) 
13 (86.7) 
2.67 (1.88) 
1 (6.7) 
0.17 (0.53) 
11 (73.3) 
1.23 (1.14) 
Fever: rectal body-temperature > 38°C 
Placebo group 
(n=15) 
13 (86.7) 
5.11 (3.03) 
14 (95.8) 
4.51 (2.98) 
12 (80.0) 
2.92 (2.40) 
1 (6.7) 
0.54 (1.15) 
9 (60.0) 
1.10 (1.23) 
Pneumococcal and Tetramune 
Zinc group 
(n=113) 
112 (99.1) 
3.84 (2.07) 
102 (90.3) 
2.73 (2.01) 
81 (71.7) 
1.33 (1.23) 
14 (12.4) 
0.20 (0.59) 
69 (61.1) 
0.96 (1.05) 
Placebo group 
(n=105) 
96 (91.4)* 
3.57 (2.10)* 
91 (86.7)* 
2.55 (2.35)* 
70 (66.7)' 
1.26 (1.53)' 
12 (11.4) 
0.15 (0.46) 
52 (49.5)° 
0.80 (1.06)" 
* Values in zinc and placebo groups combined differ from zinc and placebo group combined titres in Tetramune 
only group (p < 0.005, Chi-square test or Student's t-test) 
# Values in zinc and placebo groups combined differ from zinc and placebo group combined titres in 
Tetramune only group (p < 0.05, Chi-square test or Student's t-test) 
A
 Values in zinc and placebo groups combined differ from zinc and placebo group combined titres in 
Tetramune only group (p < 0.06) 
o Values in placebo group of PNC group differ from zinc group (p < 0.07; Student's t-test) 
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considered by the investigator to be not related or remotely related to the study 
vaccine with the exception of one case who was judged to be possibly related to 
the study vaccine. This infant had developed diarrhea one day after the PNC 
vaccination and was hospitalized five days later with acute diarrhea. The infant 
recovered completely and was discharged from the hospital after five days. A total 
of three infants died at home within one month upon receipt of the PNC vaccine 
due to severe malnutrition, diarrhea associated with fontanel swelling and 
respiratory tract infection. All deaths occurred more than one week after the 
vaccination and were judged to be not related or remotely related to the study 
vaccine. 
There were no major differences between infants from zinc and placebo 
groups in adverse effects following DTP-Hib immunization or PNC immunization. 
The proportion of infants with fever on any day during the post-immunization 
Table 5. Cellular immune response to tuberculin (PPD) skin test at 24 weeks of age for 
infants by birth weight in zinc and placebo groups. 
Size of induration < 5 mm (%) 
All infants2 
Serum zinc < 9.18 umol/L3 
Serum zinc > 9.18 umol/L4 
Mean size of PPD-induration (mm)5 
All infants 
Serum zinc < 9.18 umol/L 
Serum zinc > 9.18 umol/L 
Zinc group 
65.0 
81.8 
61.4 
10.21 (0.53) 
11.00 (2.08) 
10.77 (0.50) 
Placebo group 
55.7* 
72.2 
53.4 
10.35 (0.39) 
9.33 (0.88) 
10.56 (0.41) 
1
 Anergic = size of PPD induration < 5 mm 
2
 All infants (n=123/122) 
3
 Baseline serum zinc < 9.18 umol/L (n=22/18) 
4
 Baseline serum zinc > 9.18 umol/L (n=101/103) 
5
 Mean size of induration of positive responses (SEM) 
" Different from zinc supplemented group (p=0.09; Logistic regression controlling for birthweight and 
gestational age); PPD=purified protein derivate tuberculosis 
safety surveillance following the PNC immunization was higher in the zinc (61.1%) 
compared to the placebo group (50.0%) but the difference was small and only of 
marginal statistical significance (p < 0.07). 
Effect of zinc supplementation on immune response to DTP-Hib vaccine and 
Tuberculin skin test. 
At 24 weeks of age, 60.4% (148 of 245) of all infants showed an induration of 
< 5 mm after the PPD skin test which was considered a negative response. The 
proportion of infants with a negative response to the tuberculin skin test was 
higher in the zinc (65.0%) compared to the placebo group (55.7%; table 5) but the 
difference was small and only marginally significant (p < 0.09). A significantly 
higher percentage of infants with baseline serum zinc values below 9.18 umol/L 
119 
Chapter 7 _ ^ _ _ _ _ _ ^ ^ _ ^ _ _ ^ _ _ ^ _ _ ^ _ _ ^ ^ _ _ _ ^ ^ _ _ ^ ^ ^ _ _ _ ^ ^ ^ ^ _ _ ^ _ ^ _ 
had a negative response on the skin test compared to infants with higher serum 
zinc values at baseline (79.4% vs. 57.6% for < 9.18 vs. £ 9.18 umol/L respectively, 
p<0.01). No differences in response to the tuberculin skin test were observed 
between treatment groups for 40 infants with low (<9.18 umol/L) and for 204 
infants with higher baseline serum zinc values (table 5). The mean size of 
induration among the positive responses was 10.3 mm (SEM 0.5) and not different 
for infants of zinc and placebo groups (table 5). 
Geometric mean PRP antibody titres before and after immunization are shown in 
table 6. There were no significant differences in geometric mean PRP titres at 24 
weeks of age (post-immunization) between infants from zinc (6.96 ng/ml; 95% CI: 
Table 6. Geometric mean PRP antibody titres pre- and post-immunization for infants in 
zinc and placebo group' 
Zinc group Placebo group 
(n= 95) (n= 87) 
Pre-immunization (jig/ml)2 0.28 (0.21 ;0.36) 0.29 (0.22;0.37) 
Post-immunization (ug/ml)3 6.96 (4.34;11.15) 9.72 (6.43; 14.70) 
1
 Geometric mean titres calculated as the antilog of the mean of the logarithms of values (values in 
brackets: 95% confidence intervals) 
2
 Pre-immunization at 4 weeks of age 
3
 Post immunization at 24 weeks of age 
PRP=polyribosylribitol phosphate. 
4.34;11.15) and placebo groups (9.72 ug/ml; 95% CI: 6.43;14.70). Nearly all infants 
(94% in zinc and 95% in placebo supplemented group, difference NS) achieved 
protective antibody titres correlated with immediate protection (>0.15 ug/ml; 
figure 2) and a large majority (81% in zinc and 89% in placebo group, difference NS) 
in addition achieved titres > 1 ug/ml associated with long-term protection (figure 
2). 
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Pre-immunization Pre-immunization Post-immunization Post-immunization 
(>0.15mcg) (>1.00mcg) (>0.15mcg) (>1.00mcg) 
Figure 2. Proportion above protective thresholds for PRP antibody titres 
DISCUSSION 
Immunization with the 7-valent pneumococcal conjugate (PNC) vaccine was 
acceptably safe and resulted in significant rises in antibody titres of all 7 serotypes 
when administered to 4 to 7 month old Bangladeshi infants. Local and systemic 
reactions during the five days post-immunization were usually mild and occurred 
less often than after vaccination with the DTP-Hib vaccine. There were no severe 
adverse events resulting in hospitalization or death that were thought to be 
related to the vaccination. The mortality rate in this cohort of infants (3/240 or 
1.3% in three months of follow-up) was similar to infant mortality rates observed in 
other studies in Bangladeshi infants.13,17 The national infant mortality rate for 
Bangladesh is 79/1000 or 7.9%.18 
As far as we are aware this is the first trial reporting on the immunogenicity 
of the heptavalent PNC vaccine in a developing country. A pentavalent 
Pneumococcal conjugate vaccine, containing serotypes 6B, 14, 18, 19F and 23F 
proved to be safe and immunogenic in a pilot study in the Gambia.7 In the US the 
same heptavalent PNC vaccine that was used in our study was found to be safe, 
immunogenic and highly efficacious in preventing invasive disease and otitis media 
in US infants and young children.5,6 In this study the first dose of PNC vaccine was 
given at 2 months of age compared to approximately 4 months of age in our study. 
After three doses of vaccination, geometric mean titres (GMT) in our study 
were high and ranged from 3.68 (ig/ml for serotype 9V to 13.34 ng/ml for serotype 
6B. The concentrations observed in these Bangladeshi infants were substantially 
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higher than the titres observed in US infants (ranging from 0.98 ng/ml for serotype 
9V to 3.48 ng/ml for serotype 14)6 and higher than titres observed in Gambian 
infants after three doses of a pentavalent PNC vaccine (ranging from 2.49 ng/ml 
for serotype 19 to 7.59 ng/ml for serotype 14).7 It is possible that frequent 
exposure to the S. Pneumoniae in our population may have caused a booster 
response if the child has come into contact with the organism after receiving the 
primary series of the vaccine. A booster dose of the PNC vaccine at 12 to 15 
months of age resulted in increases in titres that were greater than the increases 
observed after the primary three-dose series in US children.6 Serotype 6B in 
particular showed a remarkable booster response whereas in previous studies it 
was one of the least immunogenic serotypes after the primary series of 
vaccination. In our study, serotype 6B yielded the highest antibody titres after 
three doses of the vaccine. It has been hypothesized that since the PNC vaccine 
employs a T-dependent immune response, it effectively induces T cell memory and 
primes for an anamnestic response to all 7 vaccine serotypes.6 Our findings suggest 
that the anamnestic responses may vary for the different serotypes with serotype 
6B being particularly responsive. Antibody responses to the different 
pneumococcal polysaccharides are known to be serotype specific with serotype 14 
being the most immunogenic and 9V being the least immunogenic in most studies 
after the primary series of vaccination.5'6,7,19'20 The results of our study are 
consistent with these findings with the remarkable exception of the response to 
serotype 6B. An interesting finding especially since serotype 6B is the most 
common pneumococcal serotype in developing countries and thought to be 
responsible for 14% of all invasive diseases.21 The frequent exposure to this 
serotype probably primed the immune system and may have enhanced a booster 
response. It is also possible that the better immune response to 6B is a result of 
the twofold higher concentration of this antigen in the vaccine compared to the 
other serotypes. 
Antibody levels associated with protection against pneumococcal serotypes 
are not known but it has been hypothesized that a minimum antibody titre after 
the primary series associated with long term protection against invasive disease is 
in the range of 0.15 to 0.5 ng/ml.5 In our study all infants had reached antibody 
concentrations of > 0.15 ng/ml and more than 95% of the infants in addition had 
reached antibody concentrations of > 1.0 ng/ml for all seven serotypes after three 
doses of the PNC vaccine. Thus, the vaccine is likely to provide a long-term 
protection against invasive pneumococcal diseases associated with one of the 
seven vaccine serotypes. Unfortunately the current heptavalent vaccine is 
estimated to cover only 52% and 25.5% of the serogroups responsible for invasive 
pneumococcal diseases in developing countries21 and Bangladesh22 respectively. It 
has been suggested that an effective vaccine for global use should preferably 
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contain the following nine serotypes: 1, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Such 
a formula would cover 50.5% of the serotypes occurring in Bangladesh.22 
Supplementation with 5 mg elemental zinc per day from 4 weeks to 33 
weeks of age resulted in significantly higher titres for serotype 9V after three 
doses of the PNC vaccine compared to titres in infants who had received a 
placebo. After one or two doses of the PNC vaccine there were higher albeit only 
marginal statistically significant titres in the zinc compared to placebo group for 
serotype 23 F. There were no differences between zinc and placebo groups for the 
occurrence of adverse events during five days post-immunization nor for the 
antibody response to the DTP-Hib vaccine. Contrary to expectations, zinc 
supplementation resulted in a more negative response to the delayed 
hypersensitivity tuberculin skin test but the effect was small and only of marginally 
statistical significance. 
Zinc deficiency has been associated with reduced numbers of T-and B-
lymphocytes, impaired epithelial barrier functions, atrophy of lymphoid organs and 
decreased macrophage functions resulting in a depressed delayed hypersensitivity 
reaction.8 In infants and children most of these abnormalities have been responsive 
to zinc supplementation.9,10,23,24 We therefore had anticipated a beneficial effect 
of zinc supplementation on the antibody response to childhood vaccines. In our 
study the high immunogenicity of the PNC vaccine in all infants may have masked 
any potential beneficial effects of zinc supplementation. Indeed, the two 
serotypes that were responsive to zinc supplementation in our study (9V and 23F) 
were among the least immunogenic of all seven serotypes. 
Previously reported findings from our study demonstrated a beneficial effect 
of zinc supplementation on the incidence of reported Acute Lower Respiratory 
Tract Infections (ALRI) but only in infants that had been defined zinc deficient 
(serum zinc < 9.18 nmol/L) upon enrollment.13 The biological pathways for this 
observed effect are as yet unclear. The PNC vaccine may have been protective 
against at least some of the ALRI infections that were caused by the S. Pneumonia 
of one of the seven vaccine serotypes. A higher immunogenicity to some of the 
serotypes after zinc supplementation may have resulted in a more effective 
protection against the disease in some cases but this hypothesis is obviously 
preliminary and requires confirmation through controlled trials investigating the 
efficacy of the PNC vaccine against invasive pneumococcal diseases in developing 
countries and defining the exact role of zinc in this process. 
In conclusion, a heptavalent pneumococcal conjugate vaccine proved to be 
safe and immunogenic when administered to infants from a poor urban community 
in Bangladesh. The efficacy of the vaccine in preventing invasive diseases and the 
effect of micronutrient supplementation on this efficacy are yet to be determined. 
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Chapter 8 
In this thesis two intervention studies are described to evaluate the impact 
of zinc supplementation on infant's intra-uterine and postnatal growth, gestational 
age duration, morbidity and immune response. In the first study, 559 pregnant 
women from Dhaka city slums were either supplemented with daily 30 mg 
elemental zinc or received a placebo starting from 12-16 weeks gestation until 
delivery. In the second study, a separate cohort of 301 four-week old infants from 
the same study-area were supplemented daily with 5 mg elemental zinc or placebo 
until 24 weeks of age. 
In this chapter the findings of both studies will be evaluated and discussed, 
the effects of the two interventions will be compared and possible policy 
implications and recommendations for future research will be discussed. Prior to 
evaluating the effects of the interventions, this chapter will first reflect on the 
general zinc status of our study population as estimated from dietary intake data 
and blood zinc analysis. 
ZINC STATUS AND ZINC DEFICIENCY DURING PREGNANCY IN URBAN 
BANGLADESH. 
Dietary intake 
The pregnant women enrolled in the intervention study were at-high risk for 
inadequate energy and zinc intakes (Chapter 2). Median intakes of energy (6065 
kJ/d) and zinc (6.1 mg/d) were low at 4 months gestation although intakes 
increased between 4 and 8 months of pregnancy by 11% and 23% for energy and 
zinc, respectively. Median dietary zinc intakes of 8 to 14 mg/day have been 
reported from pregnant women in the US and UK1 while intakes of 6 to 7 mg/day 
were observed in studies in Brazil,2 Malawi,3 and Peru.4 The intakes observed in 
Bangladesh were therefore comparable with intakes observed in other less 
industrialized countries and lower than intakes reported from developed countries. 
Zinc requirements during pregnancy to meet increased physiological 
demands are influenced by usual zinc intakes, possible changes in fractional zinc 
absorption and/or endogenous zinc excretion during pregnancy and the bio-
availability of zinc from the diet. In animals and humans, regulation of zinc 
absorption and endogenous intestinal excretion are the primary means to maintain 
zinc homeostasis at varying levels of zinc intakes.5 In populations with habitually 
low zinc intakes, conservation of endogenous zinc is thought to be more critical in 
maintenance of zinc homeostasis than changes in absorption but there are 
important limitations of adaptation mechanisms in situations of extremely low or 
chronically low intakes.6 
The increased physiological zinc requirements during pregnancy may be 
partly met by an increased fractional absorption.7 However, the changes in 
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fractional absorption during human gestation are modest and less than the 
significant increases that occur during early human lactation.6,8 Estimates of zinc 
requirements during pregnancy do therefore not yet take into account these 
possible metabolic adaptations.7,9 
Bioavailability of zinc in the diet is influenced by the food source as well as 
other components of the diet that inhibit or promote absorption of zinc. 
Phytate:zinc ratios above 15 are associated with suboptimal zinc status.10 
Unfortunately, in our study we were not able to estimate phytate:zinc molar 
ratio's, because the phytate concentrations of many of the foods consumed in this 
population were not known. However, most (74%) of the daily zinc intake came 
from cereals (rice) and pulses and total protein accounted for 12.1% of the daily 
energy intakes (Chapter 2) while the intake of animal protein was considered 
negligible. Based on these dietary characteristics, we classified the zinc in this diet 
to be of low bioavailability according to WHO guidelines,30 and assumed that only 
15-20% of the dietary zinc in our population was available for absorption. 
Thus assuming a poor bio-availability of dietary zinc, we used the 
probability approach,11 to estimate the proportion of women at risk for inadequate 
dietary zinc intakes (Chapter 2). As expected, the percentage at risk for 
inadequate intakes was high: 98% and 89% for normative and basal requirements7 
respectively. 
Serum zinc concentrations 
In contrast to these low dietary zinc intakes, mean serum zinc 
concentrations at 4 and 7 months gestation were higher than expected in our 
population (15.3 [SD 4.3] and 15.2 [SD 4.3] nmol/L respectively). At 4 weeks 
gestation only four women had blood zinc concentrations < 9.18 nmol/L (Chapter 
3), the cut-off used as the reference for zinc deficiency in other studies.12,13 In 
adults, a normal range for serum zinc is considered to be between 10.7-15.3 n 
mol/L,14 similar to values observed in children, and these values usually tend to 
decline during pregnancy. Lower plasma zinc concentrations in pregnant women 
compared to non-pregnant controls of comparable age have been observed as early 
as 2 months gestation.15 At 19 weeks gestation, serum zinc concentrations of 9.7 
(SD 1.5) nmol/L were observed in low-income women in the US16 whereas average 
plasma concentrations at 10-24 weeks gestation were 10.6 (SD 2.1) and 8.1 (SD 
2.3) nmol/L in Peru17 and Malawi18 respectively. Several possible explanations for 
the higher than expected serum zinc concentrations in our study were discussed 
(Chapter 3). These included an increase due to food intake,14 the delay of up to 6 
h between collection and separation of samples,19 and possible contamination 
during sample collection or analysis. The relatively high serum zinc concentrations 
in our population may also reflect an adaptation to habitually low dietary zinc 
intakes6 since inverse relationships between dietary zinc supply and zinc status 
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were observed in several studies.7 However, this would not explain the 
discrepancies between serum zinc concentrations observed in our study population 
and the concentrations reported from populations with similar dietary zinc 
intakes.17,18 
The limitations of plasma/serum zinc as an indicator for body zinc status are 
well known,7,20 although it is still considered the best available indicator for 
assessment of zinc status on a population level.20 Because low dietary intakes of 
poorly available zinc were observed in our population despite the relatively high 
serum zinc concentrations, while acknowledging the difficulties with the 
interpretation of serum zinc values, it was assumed that the study described in this 
thesis was performed in a population of pregnant women with suboptimal zinc 
status. 
ZINC STATUS AND ZINC DEFICIENCY DURING INFANCY IN URBAN BANGLADESH. 
Dietary intake 
All infants enrolled in this intervention trial were breast-fed for the entire 
duration of the study but the rate of exclusive breastfeeding was low due to early 
introduction of water provided along with breast milk. This practice is very 
common in Bangladesh and has been reported before.21 Infants receiving 
breastmilk and water only were classified as "predominantly" breast-fed and 
infants receiving breast milk and other complementary fluids and foods were 
classified as "partially" breast-fed. Using these standard definitions, 16% of all 
infants were exclusively or predominantly breast-fed (breast milk and water) and 
80% were partially breast-fed at 24 weeks of age {Chapter 6). Breastmilk was 
therefore the primary source of dietary zinc in these infants. Unfortunately, we 
did not assess breastmilk zinc concentrations in our population. In developed 
countries, the average zinc intake during lactation is thought to be sufficient to 
ensure adequate breastmilk zinc concentrations and milk zinc output during the 
first months of lactation.22 However, compared to the concentrations observed in 
western women, lower breastmilk zinc concentrations at comparable time points 
during lactation have been observed in some23 but not all24 studies on milk zinc 
concentrations of women in developing countries. 
Serum zinc concentrations. 
Average serum zinc concentrations at 1 and 6 months of age in the non-
supplemented infants enrolled in our intervention study were 11.7 (SD 3.0) and 
10.7 (SD 2.9) nmol/L respectively {Chapter 6). These concentrations are 
comparable to concentrations observed in older infants and children in Ethiopia25 
and Chile,26 but higher than concentrations found in older infants and children in 
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India27 and small-for-gestational-age infants in Chile.28 In addition to the 
possibilities already discussed for the high maternal serum zinc concentrations, 
breastfeeding practices may have contributed to the relatively higher serum zinc 
concentrations among the infants in this study. In developed countries, zinc 
deficiency is relatively rare among term breast-fed infants during the first months 
of life.29 A high bioavailability of zinc from human milk together with efficient 
conservation of endogenous zinc by the gastrointestinal tract ensures that dietary 
zinc intakes from human milk are adequate during the first 6 months of life despite 
declining breastmilk zinc concentrations.30 
Because at 4 weeks of age only 4% of the infants in this study had serum zinc 
concentrations below the cut-off value for zinc deficiency (9.18 ^mol/L), similar 
mechanisms may have protected infants in this study from developing zinc 
deficiencies {Chapter 6), at least for the duration of this study. However, the 
situation may be different for the period after 6 months of age. Available data of 
zinc intakes of infants older than 6 months of age in Peru and Mexico suggest that 
many infants and young children in developing countries are unlikely to meet their 
zinc requirements and are at-risk of suboptimal zinc status.31 
THE EFFECTS OF ZINC SUPPLEMENTATION DURING PREGNANCY ON PREGNANCY 
OUTCOME, GROWTH, MORBIDITY AND IMMUNE RESPONSE. 
Supplementation with 30 mg elemental zinc/day during the last two 
trimesters of pregnancy did not improve birth weight or gestational age (Chapter 
3) nor did it have an impact on postnatal growth during the first six months of life. 
However, it resulted in reduced morbidity from diarrheal diseases and impetigo in 
infants born with low birth weight (LBW; Chapter 4). This observed reduction was 
probably due to an improved cellular immunity or a less compromised immune 
function. A positive albeit small effect on response to the delayed hypersensitivity 
skin test on BCG vaccine at 24 weeks of age was observed in LBW infants whose 
mothers had received zinc during pregnancy (Chapter 5). 
We are not aware of previous studies that report effects of zinc 
supplementation during pregnancy beyond the neonatal period. Most trials of 
maternal zinc supplementation have been performed in developed countries and 
have limited their assessments mainly to an effect on birth weight. The results of 
these trials have been inconsistent.32"34 
However, a similar double-blind, placebo-controlled randomized trial has 
recently been performed in Peru,4,17 and the findings from that trial are 
remarkably comparable to ours. In Peru, 1295 women were enrolled between 10 
and 24 weeks of gestation and randomly assigned to prenatal supplements of 60 mg 
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iron and 250 ng folate with or without 15 mg zinc. The infants were followed until 
one year of age. In the Peruvian study, zinc supplementation during pregnancy did 
not improve birth weight or gestational age even though it increased maternal 
serum zinc and infant cord blood zinc. However, zinc supplementation did seem to 
affect fetal neurobehavioral activity as measured by fetal movements and heart 
rate35 and resulted in increased concentrations of immunoglobulins in cord-blood 
and a reduced number of febrile episodes in the infants during the first six months 
of life.36 Recently reported findings of the Peruvian study suggest that infants 
whose mothers were supplemented with zinc during pregnancy had better growth 
in the second half year of life, despite the absence of an effect on intra-uterine or 
early postnatal growth (Zavaleta N, personal communication). Because infants 
were not followed beyond six months of age, those findings could not be confirmed 
in the current study in Bangladesh. 
The findings of the study described in this thesis are consistent with other 
studies showing effects on both prevalence and incidence of diseases after zinc 
supplementation in infants and children, and are thought to reflect the prominent 
role of zinc in both immune and non-immune host defense mechanisms.37 Work 
with animal models indicate a role of perinatal zinc status in optimal development 
of the fetal immune system. Reduced lymphoid organ size, gamma globulin 
concentrations and blood lymphocytes numbers have been observed in off-spring 
born to zinc deficient mice and rhesus monkeys. Antenatal zinc deprivation in rats 
resulted in lower serum immunoglobulin concentrations, in particular IgA, lgG2 and 
IgM in the off-spring at 6 months of age. These abnormalities may persist into 
adulthood.38 Maternal zinc status during pregnancy may also affect in-utero 
acquisition of antibodies due to the role of zinc in placental transport of 
immunoglobulins.1 It is therefore conceivable that the reduction in morbidity in 
the LBW infants (Chapter 4) was the result of an improved immune system 
{Chapter 5) or perhaps a less compromised immune system in LBW infants during 
gestation. 
The observation of a lack of effect on intra-uterine or postnatal growth 
despite reductions in morbidity, has been discussed extensively (Chapter 4). 
Although it is appreciated that growth and morbidity are related clinical features, 
it is believed that in relation to the effect of zinc the two should be considered as 
separate outcomes. Different biological pathways may explain the role and effect 
of zinc in the two outcomes. The effect of zinc on growth may be due to a direct 
effect of zinc on protein synthesis and gene expression,39 but there can also be an 
indirect impact of zinc on growth through reductions in morbidity and increased 
appetite.25 In our population a growth effect of zinc might not have been observed 
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because of the time-lag between the observed reductions in morbidity and a 
possible beneficial effect on growth. 
Predictors for an effect of zinc on growth in children are low height-for-age 
and zinc deficiency defined as low plasma zinc concentrations.39 Zinc 
supplementation among 6-21 month old infants in Ethiopia resulted in more 
pronounced effects on weight and length velocities in stunted compared to non-
stunted supplemented infants.25 Similar predictors might be relevant in the 
context of intrauterine growth,33 such that, zinc supplementation during pregnancy 
might exert a beneficial effect on intrauterine growth primarily in populations that 
are zinc deficient and at high risk for poor fetal growth. A clinically and 
statistically significant effect on birth weight and head circumference was 
observed in a maternal zinc supplementation trial in Alabama in which only women 
with low plasma zinc concentrations on enrollment were selected.40 The effects 
were more pronounced in women with a relatively low Body Mass Index (BMI < 26 
kg/m2). In children however, studies in malnourished populations in Mexico,41 
Jamaica,42 and Uganda43 all failed to show an effect of zinc supplementation on 
growth. It has been suggested that zinc might not be the primary growth limiting 
nutrient in otherwise nutritionally deprived children.44 Also in our population of 
pregnant women zinc might not have been the primary intrauterine growth limiting 
nutrient. This is suggested by the lack of a growth effect in our study and by the 
low total energy intakes during pregnancy. In addition, higher energy, but not zinc 
intakes during pregnancy were related to larger maternal weight gains and a 
reduced risk of premature deliveries (Chapter 2). 
THE EFFECTS OF ZINC SUPPLEMENTATION DURING INFANCY ON INFANT 
GROWTH, MORBIDITY AND IMMUNE RESPONSE. 
Supplementation with 5 mg elemental zinc/day between 4 and 24 weeks of 
age improved growth and reduced the incidence of ALRI in infants who were zinc-
deficient (< 9.18 nmol/L) at 4 weeks of age. However, among zinc sufficient 
infants there were no effects on growth or morbidity, even though zinc 
supplementation improved zinc status (Chapter 6). The biological pathways for this 
effect in zinc-deficient infants are still to be clarified. Zinc supplementation 
resulted in a higher anti-body response to some serotypes (9V and 23F) of the 7-
valent pneumococcal conjugate vaccine (PNC) but it had no effect on other 
serotypes nor on the response to the combined diphtheria, tetanus toxoid and 
pertussis (DTP)-Haemophilus influenzae type-b (Hib)- conjugate vaccine while a 
small, marginally significant (p < 0.09) negative effect on the response to PPD skin 
test was observed (Chapter 7). 
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This study was one of the first to supplement very young infants (< 6 months 
of age). Most intervention trials assessing the effect of zinc on growth or morbidity 
have been conducted in children older than 6 months of age,37,39 i.e., beyond the 
period of maximal growth velocity. Immunologically, the period between birth and 
six months of age is characterized by waning passive immunity from maternal 
antibodies and continued development of the infants immune system and immune 
response. It has been hypothesized that interventions with zinc earlier in infancy 
might therefore be more effective in preventing growth faltering and reducing 
morbidity patterns among children at risk.45 Infants supplemented before 6 months 
of age in Chile and France,28,46 had improved growth while a reduced morbidity but 
no effect on growth was observed after zinc supplementation during the first six 
months of life among LBW infants in Brazil.47 In contrast, greater reductions in 
morbidity after zinc supplementation have been observed in older compared to 
younger age groups.27 In our study, zinc supplementation between 4 and 24 weeks 
of age did not affect growth or morbidity in those infants who were not zinc 
deficient at 4 weeks of age while the effects on the immune response were not 
clear. Despite the rationale for a stronger effect in this young age group, an 
alternative hypothesis (Chapter 6) is that younger infants in fact, will have a 
reduced response to zinc compared to older infants. It is known that compared to 
older infants, the overall burden of morbidity in the 0-6 months age group is low. 
Moreover, most of these infants presumably do not yet develop a zinc deficiency as 
suggested in our study by a prevalence of only 14% with serum zinc concentrations 
< 9.18 (imol/L at 4 weeks of age and by the lack of a physiologic response in 
growth and morbidity to zinc supplementation among the non-zinc deficient 
infants. The observation that serum zinc concentrations in the placebo group were 
declining between 4 and 24 weeks of age, while the proportion of zinc-deficient 
infants increased from 14 to 22% (Chapter 6) indicate that the zinc status of these 
infants was deteriorating over time. After 6 months of age, these infants might 
therefore be at-risk for sub-optimal zinc status and interventions with zinc might 
have a greater impact beyond this age. 
ZINC NUTRITION THROUGHOUT THE LIFE CYCLE. 
In this thesis interventions with zinc are described during two critical phases 
of the life-cycle, i.e., pregnancy and early infancy. Comparisons of the results 
between the two studies might provide useful information for future research and 
policy implications, although it is recognized that comparisons between different 
studies are difficult to interpret. The two cohorts of pregnant women ("the 
pregnancy cohort") and infants ("the infant cohort") came from the same study 
area but might nevertheless have been different in essential baseline 
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characteristics. Although socio-economic characteristics were not different 
between the two cohorts, mothers of infants in the infant cohort were found to be 
older and had better nutritional status (weight, length) at one and six months post-
partum compared to mothers in the pregnancy cohort. Likewise, infants in the 
infant cohort had a better nutritional status at one and six months of age than 
infants in the pregnancy cohort. The two cohorts therefore were not completely 
comparable. Based on these differences, one probably would have predicted a 
greater effect of zinc on growth in the more malnourished pregnancy cohort, since 
low nutritional status is considered a predictor for a growth-effect of zinc. 
However, this was not observed in our studies. 
Effects on growth 
Supplementation with zinc during pregnancy did not improve intra-uterine 
or postnatal growth or pregnancy duration whereas supplementation with zinc in 
the infants improved linear and ponderal growth, but only in those infants (14% of 
the population) who were zinc-deficient at baseline. To better understand the 
effect of maternal zinc supplementation in the zinc-deficient population data of 
pregnant women and their infants with low serum zinc concentrations were 
segregated and analyzed. As reported previously (Chapter 3), only 21 (4%) of the 
pregnant women had low baseline serum zinc concentrations (< 10.6 nmol/L) and 
no effect on birth weight was observed in these women. However, surprisingly 
similar findings were observed between the two infant cohorts when subsequently 
data were segregated and analyzed of the 20 (6%) infants born to study women, 
who were zinc deficient (<9.18 nmol/L) at one month of age. The fourteen zinc-
deficient infants whose mothers received zinc during pregnancy had significantly 
greater weight gains during the first six months of life compared to the six zinc-
deficient infants in the placebo group (3.61 [SD 0.80] kg vs. 1.91 [SD 2.28] kg in 
zinc and placebo groups respectively, p < 0.05) even after controlling for 
nutritional status at birth, gestational age and gender. The small sample sizes are 
acknowledged, but nevertheless the consistency in the observations between the 
two studies provides valuable information. Both antenatal and postnatal zinc 
supplementation may benefit growth but the effects are restricted to infants who 
for some reason are zinc-deficient in early infancy. For most infants however, zinc 
supplementation did not benefit growth, and possible explanations for this finding 
which will have potential implications for future policy and research were already 
discussed. 
First, zinc might not have been the primary growth-limiting nutrient for 
these women and infants. In that respect, supplementation with multiple 
micronutrients in addition to zinc, might be more effective. One concern related 
to the use of multiple micronutrient supplementation has been the potential 
negative effects of interactions between different nutrients when provided 
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simultaneously in one supplement.48 Although there is evidence of interactions 
among several micronutrients at the metabolic level49 very little is known about 
the significance of these interactions for pregnancy outcomes. Prenatal iron 
supplements for instance impaired zinc absorption in pregnant women in Peru, but 
the inclusion of zinc in the supplements reduced the potential inhibitory effects of 
iron.50 Adding zinc to the iron/folate supplement did not effect hemoglobin 
levels51 and led to higher zinc concentrations in pregnant women.17 Use of a 
multivitamin/mineral prenatal supplement beginning in the first or second 
trimester of pregnancy was associated with twofold reductions in risk of LBW and 
preterm delivery in low-income US women.52 The supplement used in this study 
contained, among others, 25 mg zinc, 1 mg folic acid and 65 mg iron. 
Unfortunately, to date, no controlled intervention trials have examined the effects 
of multi-micronutrient supplements during pregnancy in less-developed countries 
where multiple micronutrient deficiencies are common.49 Several trials are 
currently underway, including a multi-country trial co-ordinated by UNICEF,53 
which will provide important information on the effect of multiple micronutrient 
supplementation on pregnancy outcomes. 
Secondly, the relatively limited duration of the studies in Bangladesh might 
have prevented the observation of an effect on growth. As previously discussed, 
the observed reductions in morbidity might yield a potential indirect effect of zinc 
on growth beyond 6 months of age. In rural Bangladesh, episodes of dysentery in 
particular have been associated with lower annual weight and height gains among 
children under five years of age.54 In addition, the timing of the antenatal 
interventions might not have been optimal for a growth-effect. Several studies 
have indicated that maternal pre-pregnancy weight is the most important 
predictor for infant birth weight,55,56 and interventions aimed at improving 
maternal nutritional status prior to conception might therefore be more effective. 
Data from studies in East Java, Pakistan and Guatemala further suggest that 
interventions with nutritional supplements should evaluate overall change in 
maternal nutritional status across a full reproductive cycle, in conjunction with 
changes in birth weight and nutritional status between two siblings born during 
that cycle,57,58 while taking into account that differential effects might occur, 
depending on initial maternal nutritional status.59 
Effects on morbidity 
Maternal supplementation with 30 mg elemental zinc/day during the last 
two trimesters of pregnancy reduced morbidity from diarrheal diseases and 
impetigo, particularly among LBW infants (n= 176, 43%; Chapter 3). By contrast, 
infant zinc supplementation did not have an effect on morbidity in most infants, 
except for a lower incidence of Acute Lower Respiratory Infections (ALRI) after 
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zinc supplementation in infants that were zinc-deficient at 4 weeks of age. 
Unfortunately, birth weight information was not available for these infants and the 
interaction of infant zinc supplementation and low or normal birth weight could 
not be assessed. However, the effect of infant zinc supplementation for various 
levels of infant's nutritional status at 4 weeks of age could be assessed, but no 
differences in effects on morbidity were observed (Chapter 6). 
Zinc plays a distinct and essential role in the development of the immune 
system38 and it is believed that supplementation with zinc during pregnancy most 
likely benefited the immune system of the infants born with LBW, whose immune 
systems would otherwise have been compromised. Compared to infant 
supplementation, supplementation with zinc during pregnancy might therefore be 
a more effective way to reduce certain critical health risks associated with LBW in 
this population. 
The prevalence of LBW in Bangladesh is the highest in the world,60 and in 
our study 43% of all live births were LBW (Chapter 3), mostly (76%) due to 
intrauterine growth retardation (IUGR). These figures are comparable to 
prevalences of LBW and IUGR observed in other studies in Bangladesh.61,62 Infants 
born with IUGR are known to be at-risk for impaired immunity, increased morbidity 
and mortality and abnormal cognitive development later in childhood and 
adulthood.63,64 The findings of this study indicate that birthweight and LBW may 
be considered primarily an indicator of risk rather than a direct cause of morbidity 
and mortality (Chapter 4). In this regard, being born too small would not be so 
disadvantageous if it were not for the adverse health outcomes later in life that 
are associated with LBW. Intervention studies aiming to reduce incidences of LBW 
should therefore continue to observe infant outcomes beyond the neonatal period. 
The findings described in this thesis indicate that maternal zinc 
supplementation during pregnancy may contribute to a reduction in the 
disadvantaged health outcomes of LBW infants. This could potentially lead to 
important changes in health and nutritional status throughout the life-cycle of 
these infants. These findings suggest that zinc supplementation during pregnancy 
might enhance the development of the fetal immune system in infants born with 
LBW which subsequently leads to a reduced morbidity from infectious diseases in 
these infants. Potentially, this could result into an improved health and growth 
beyond six months of age and, eventually, in a healthier and better nourished 
child, adolescent, and woman of child-bearing age. Evidence from other studies 
suggest that zinc supplementation during childhood might further improve the 
child's growth and health. It was hypothesised in this discussion that 
supplementation with zinc during other critical phases of the life cycle, i.e., 
adolescence might perhaps result in an improved pre-pregnancy nutritional status 
and eventually in improved pregnancy weight gains and birth weights. 
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Figure 1. Zinc nutrition throughout the life cycle. 
In an attempt to describe the potential role of zinc throughout the life 
cycle, the ACC/SCN life-cycle conceptual framework as described in Chapter 1, 
was modified (figure 1), adding the findings of this study, the evidence provided by 
some other studies and the hypotheses described in this discussion which should be 
investigated in future research. 
SUMMARY OF CONCLUSIONS. 
The aim of the first study described in this thesis was to evaluate the effect 
of supplementation with 30 mg elemental zinc/day during the last two trimesters 
of pregnancy in poor urban women from Bangladesh (Chapter 1). Based on the 
findings of this study, it was concluded that antenatal zinc supplementation did 
not improve intra-uterine or postnatal growth but resulted in a reduced morbidity 
from diarrhoeal diseases and impetigo in the infants during the first six months of 
life, particularly in infants born with LBW. These effects were most likely due to 
improved cellular immunity in these infants as indicated by a higher proportion of 
positive responses to the PPD skin test at 6 months of age. 
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The second study aimed to evaluate the effects of supplementation with 5 
mg elemental zinc/day in Bangladeshi infants from 4 to 24 weeks of age (Chapter 
1). The conclusions of this study were that zinc supplementation improved linear 
and ponderal growth and reduced morbidity from Acute Lower Respiratory 
Infections (ALRI) but only in infants that were zinc deficient (serum zinc < 9.18 
|imol/L) at 4 weeks of age. In most infants however, supplementation with zinc did 
not have any effect on growth or morbidity. There was no clear effect of zinc 
supplementation on infant's immune response. Zinc improved the antibody 
response to certain Pneumococcal serotypes whereas a small but negative effect 
on the response to the PPD skin test was observed. 
POLICY IMPLICATIONS 
Even though issues related to a potential interaction between 
micronutrients and programmatic issues regarding the distribution of and 
compliance to antenatal supplements still need to be resolved, child health and 
survival programs in developing countries should consider the inclusion of zinc in 
antenatal multiple micronutrient supplements especially in regions with a high 
prevalence of LBW (Chapter 4). In the study described in this thesis pregnant 
women were supplemented with daily 30 mg elemental zinc and no apparent 
adverse effects related to this dosage were observed. In Peru, pregnant women 
were supplemented with 15 mg zinc/day added to an iron/folate supplement and 
similar beneficial effects on infant morbidity were observed36 whereas no evidence 
for potential adverse effects on iron status were reported.51 A dosage of 15 mg 
zinc/day, the current recommended daily allowance,65 therefore seems to be a 
reasonable safe and effective dose for most women in developing countries. 
More research is required to enable formulation of policy directions 
regarding the use of zinc supplements in infants during the first months of life. 
Zinc might be beneficial in infants that are zinc-deficient at a very young age and 
supplementation of these infants could be considered. Because appropriate or 
feasible screening techniques to identify zinc deficiency are lacking in most 
developing country settings, universal zinc supplementation remains the only 
option. However, there are several concerns related to the universal 
supplementation of very young, exclusively breast-fed infants in countries like 
Bangladesh. First, supplementing breast-fed infants under less hygienic conditions 
should preferably be avoided. A better strategy to prevent zinc deficiency might 
perhaps be to enhance the promotion of exclusive breast-feeding until the age of 
six months. Information from our study suggest that breast-feeding might protect 
most of these infants from developing a zinc deficiency before the age of six 
months (Chapters 4 and 6). Secondly, there is uncertainty regarding the most 
appropriate dosage of zinc for supplementing malnourished infants below six 
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months of age. In the study described in this thesis infants were supplemented 
with daily 5 mg elemental zinc which is the recommended daily allowance for this 
age group.65 No evidence for any adverse side effects related to the zinc 
supplement was found in our study but the higher proportion of negative responses 
to the PPD skin test in zinc compared to placebo supplemented infants {Chapter 
7), suggesting a potential negative effect on cellular immunity warrants further 
research. In addition, a statistically significant lower score on the Mental 
Development Index (MDI) of the Bailey scale was observed in the zinc-
supplemented infants at 13 months of age in an addendum to our study66 and more 
research is required to explain these findings. Finally, a significantly higher 
mortality was observed among severely malnourished children in Bangladesh 
receiving a high-dose (6 mg/kg bodyweight/day) zinc treatment,67 probably due to 
an inhibitory effect of zinc on copper absorption, suggesting that caution is 
warranted in supplementing malnourished children with high dosages of zinc.68 
FUTURE RESEARCH 
Future research on the role of zinc during pregnancy should include: 
• Studies on the efficacy and efficiency of antenatal multiple-micronutrient 
supplements, including zinc in a dosage of at least 15 mg/day while taking into 
account possible interactions with protein/energy intakes. Potential interactions 
between nutrients when provided in one tablet should also be evaluated in these 
studies. 
• Intervention studies with zinc and/or multiple micronutrients, with the aim 
to improve maternal nutritional status prior to conception, preferably in regions 
where maternal undernutrition is common. In particular, interventions during 
phases of the lifecycle when growth is accelerated (i.e., in adolescence) should be 
explored. 
• Studies on the exact role of zinc in the development of the immune system 
• More research on the effects of maternal zinc supplementation on cognitive 
and motor development in infants born with LBW versus NBW and in zinc-deficient 
versus non-zinc deficient infants. 
• All proposed studies on the effect of maternal zinc and/or multiple 
micronutrient supplements should include assessments of breast milk zinc and 
continue observations beyond the neonatal period, and preferably throughout a 
full reproductive cycle. 
Future research on the role of zinc during infancy should include: 
• Studies on the interaction between breastfeeding practices, breastmilk zinc 
concentration, maternal dietary zinc intake and infant zinc status during the first 
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six months of life and beyond in a developing country setting. In particular, it 
should be explored why certain infants become zinc-deficient at a very early age 
whereas others do not. 
• Studies on the effect of zinc supplementation in infants should preferably be 
able to distinguish between effects in infants born with LBW and infants born with 
NBW. 
• Research on guidelines for effective and safe dosages of zinc for infants 
below six months of age in undernourished populations. 
• More research on the effects of infant zinc supplementation on cognitive 
and motor development in infants born with LBW versus NBW and in zinc-deficient 
versus non-zinc deficient infants. 
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Zinc deficiency may be widely prevalent in many developing countries, but 
was not recognized as a public health problem until recently. Zinc deficiency has 
been associated with reduced growth and development, impaired immunity and 
increased morbidity from infectious diseases. As a constituent of over 200 metallo-
enzymes in the human body, zinc is known to play an important molecular role in 
processes of gene replication, activation and repression, as well as DNA 
transcription and translation and protein synthesis. The physiological role of zinc 
during periods of rapid growth and development emphasises its importance during 
the periods of gestation, fetal life, and early infancy. 
The first study described in this thesis aimed to evaluate the effect of zinc 
supplementation during the last six months of pregnancy on pregnancy outcome, 
infant growth, morbidity from infectious diseases and immune response to 
childhood vaccines during the first six months of life. The aim of the second study 
was to evaluate the effect of zinc supplementation between 1 and 6 month of age 
in infants on infant growth, morbidity from infectious diseases and immune 
response to childhood vaccines during the study period. The studies were 
performed in a population at high risk of growth faltering and increased morbidity 
in the urban slum areas of Dhaka, Bangladesh; an area where the prevalence of 
low birth weight (LBW) is high and zinc deficiency is assumed to be common. 
In the first study, a total of 559 women were enrolled between 12 and 16 wk 
of gestation, stratified by parity and randomly assigned to receive 30 mg elemental 
zinc/d (n=269) or placebo (n=290). Supplementation continued until delivery. 
Serum zinc was estimated at baseline and 7 mo of gestation. Dietary intake by 
means of a 24 h recall and anthropometric measurements were assessed monthly 
from 4 to 8 months of gestation. Weight, length, and gestational ages of 410 
singleton infants were measured within 72 h of birth. Infants were followed until 6 
mo of age. Information on infant's morbidity from infectious diseases was 
collected weekly by mother's recall. Infant anthropometrics were measured 
monthly and serum zinc was assessed at one and six months of age. A total of 383 
infants (184 from zinc group and 199 from placebo group) completed the entire 6 
months of follow-up. The infants had been immunized with the standard Bacille 
Calmette Guerin (BCG) at birth. A subcohort of 203 infants were in addition 
immunized at one month-intervals with three doses of the combined diphtheria, 
tetanus toxoid and pertussis (DTP)-Haemophilus influenzae type-b (Hib)- conjugate 
vaccine starting at 9 weeks of age. The delayed hypersensitivity (PPD) skin test 
was performed in 345 infants at 24 weeks of age. Hib polysaccharide (PRP) 
antibodies were assessed for 91 infants at 4 and 24 weeks of age. 
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The pregnant women enrolled in the intervention study were at-high risk for 
inadequate caloric and zinc intakes. Median intakes of energy (6065 kJ/d) and zinc 
(6.1 mg/d) were low and more than 85% of the women were estimated to be at-
risk for inadequate dietary zinc intakes {Chapter 2). No significant effect of zinc 
treatment was observed on infant birth weight (2513 {SD: 390} compared with 2554 
{SD: 393} g in zinc and placebo groups respectively), or on gestational age, infant 
birth length, head-, chest- or arm circumference (Chapter 3). However, compared 
to infants of the placebo group, infants of mothers receiving zinc during pregnancy 
showed significantly reduced risks for incidence of acute diarrhea (RR: 0-84; 95%CI: 
072,0-98), dysentery (RR: 0-36; 95%CI: 0-25,0-84) and impetigo (RR: 0-53; 95%CI: 
0-34,0-82) between 0 and 6 months of age. The reductions were observed in LBW 
infants (n=176, 43%) whereas no significant differences were found in normal birth 
weight infants. There were no differences in infant growth or serum zinc 
concentrations between treatment groups (Chapter 4). In infants born with LBW a 
lower proportion of negative responses to PPD skin test were observed in the zinc 
(66.2%) compared to placebo (78.5%) group (p=0.07). No differences were observed 
in normal birth weight infants. There were no differences in proportion of infants 
above the protective thresholds for anti-PRP antibodies between zinc (81%) and 
placebo (89%) group. Geometric mean PRP antibody titres at 4 and 24 weeks of age 
were not different between groups (Chapter 5). We conclude that supplementation 
with 30 mg elemental zinc/day during the last two trimesters of pregnancy in poor 
urban women from Bangladesh, did not improve intra-uterine or postnatal growth 
but resulted in a reduced morbidity from diarrheal diseases and impetigo, only in 
infants born with LBW during the first six months of life. These effects were most 
likely due to improved cellular immunity in these infants as indicated by a higher 
proportion of positive responses to the PPD skin test at 6 months of age. 
In the second study, a separate cohort of 301 infants was enrolled at 4 
weeks of age and randomly assigned to receive daily 5 mg elemental zinc (n=152) 
or placebo (n=149) until 24 weeks of age. Infants were followed weekly for 
information on compliance and morbidity while anthropometric measurements 
were performed monthly. Serum zinc was assessed at baseline and 24 weeks of 
age. Infants were immunized with the standard BCG vaccine at 4 weeks of age and 
with the combined DTP-Hib vaccine from 9 weeks of age. A subcohort of 241 
infants was additionally immunized with the heptavalent pneumococcal conjugate 
(PNC) vaccine at 18 ± 1 weeks of age. Response to delayed hypersensitivity (PPD) 
skin test and antibody response to Hib and to each of the seven PNC serotypes 
were assessed at 4, 24 and 33 weeks of age. 
At 24 weeks of age serum zinc levels were higher in the zinc compared to 
placebo supplemented infants (13.3 {SD 3.8} vs. 10.7 {SD 2.9} ^mol/L; p<0.001). 
Significantly greater weight gains were observed in zinc group compared to 
placebo group for 43 infants that were zinc-deficient (<9.18nmol/L) at baseline 
146 
—— Summary 
(3.15 {SD 0.77} vs. 2.66 {SD 0.80} kg, p<0.04). In the other infants no differences 
were observed in mean weight and length gains between 4-24 weeks. Zinc-
deficient infants also showed a reduced risk for incidence of Acute Lower 
Respiratory Infection (ALRI) after zinc supplementation (RR:0.30; 95%CI:0.10-0.92) 
whereas among the non-zinc deficient infants there were no differences between 
treatment groups (Chapter 6). After three doses of PNC, geometric mean titres for 
the pneumococcal serotypes ranged from 3.68 to 13.34 ng/ml. Titres at 24 weeks 
of age were significantly higher for infants who had received PNC compared to 
infants who had only received DTP-Hib. There were no severe adverse events 
related to vaccination. Zinc supplementation resulted in higher titres for serotypes 
9V and 23F but had no effect on other serotypes nor on response to DTP-Hib. Zinc 
had a marginal negative effect on response to PPD skin test (Chapter 7). We 
conclude that supplementation with 5 mg elemental zinc/day from 4 to 24 weeks 
of age improved linear and ponderal growth and reduced the incidence of ALRI, 
but only in infants that were zinc-deficient at 4 weeks of age. In most infants 
however, zinc did not have any effect on growth or morbidity. There was no clear 
effect of zinc supplementation on infant's immune response. 
In Chapter 8 we evaluated and compared the findings of the two 
interventions. We concluded that zinc supplementation during early infancy might 
benefit post-natal growth but the effects are restricted to infants who for some 
reason are zinc deficient at a very early age. For most infants of this young age 
however, zinc supplementation did not benefit growth and several explanations for 
this finding were discussed. First, zinc might not have been the primary growth-
limiting nutrient for these women and their infants. Secondly, the limited duration 
of the studies might have prevented us from observing a growth-effect of zinc, in 
particularly any potential secondary effects on growth through the observed 
reductions in morbidity. Supplementation with zinc during pregnancy reduced 
morbidity from diarrheal diseases and impetigo among LBW infants. By contrast, 
infant zinc supplementation did not have an effect on morbidity in most infants, 
except for a lower incidence of ALRI in infants that were zinc-deficient at 4 weeks 
of age. The differences in results between our two studies indicate that, compared 
to infant supplementation, zinc supplementation during pregnancy might be a 
more effective way to reduce some of the increased health risks associated with 
LBW or zinc deficiency in infants below 6 months of age. 
The prevalence of LBW in Bangladesh is the highest in the world and infants 
born with LBW are known to be at-risk for impaired immunity, increased morbidity 
and mortality and abnormal cognitive development. Our findings indicate that 
maternal zinc supplementation during pregnancy may contribute to a reduction in 
some of these disadvantaged health outcomes. Therefore child health and survival 
programs should consider the inclusion of zinc in antenatal multiple micronutrient 
supplements especially in regions with a high prevalence of LBW. 
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Alhoewel lage zinkinnemingen veel voorkomen in ontwikkelingslanden, 
worden de consequenties voor de gezondheid pas sinds kort onderkend. Eerder 
werd een verband gevonden tussen zinkdeficientie en een verminderde groei en 
ontwikkeling, aantastingen van het immuunsysteem en een verhoogde kans op 
infectieziekten. Zink is een bestanddeel van meer dan 200 metaalenzymen in het 
lichaam en speelt als zodanig een belangrijke moleculaire rol in diverse cellulaire 
processen zoals genreplicatie, -activering en -onderdrukking, DNA transcriptie en 
eiwitsynthese. De fysiologische rol van zink tijdens groei en ontwikkeling 
benadrukken het belang van zink tijdens de zwangerschap, foetale groei en de 
eerste levensmaanden. 
De eerste interventiestudie die in dit proefschrift wordt beschreven had tot 
doel om het effect te evalueren van zinksuppletie tijdens de laatste zes maanden 
van de zwangerschap op het geboortegewicht, de zwangerschapsduur, de groei van 
het kind, de ziektedruk en de reactie van het immuunsysteem op vaccinaties 
tijdens de eerste zes maanden van het leven. De tweede interventiestudie 
evalueerde het effect van zinksuppletie tussen de eerste en zesde levensmaand op 
de groei van het kind, ziektedruk en de reactie van het immuunsysteem op 
vaccinaties tussen de eerste en zesde levensmaand. De studies zijn uitgevoerd in 
een bevolkingsgroep met een hoog risico op verminderde groei en infectieziekten, 
in een sloppenwijk van Dhaka, Bangladesh; een gebied waar veel kinderen een te 
laag geboortegewicht (low birthweight; LBW, < 2500 g) hebben en waarvan 
verondersteld wordt dat zinkdeficientie er veel voorkomt. 
In de eerste studie werden 559 vrouwen geworven die minimaal twaalf en 
maximaal zestien weken zwanger waren. De vrouwen werden ingedeeld naar 
pariteit, en vervolgens ad-random toegewezen aan de interventie of 
controlegroep. Vanaf de dag van werving tot aan de bevalling kreeg de 
interventiegroep 30 mg elementair zink per dag (n=269) en de placebogroep 
(n=290) een cellulose-placebo. Aan het begin van het onderzoek en bij zeven 
maanden zwangerschap werd het serumzink bepaald. ledere maand werd de 
voedingsinneming van de vrouwen bepaald middels een 24h recall en werden nun 
gewicht, de lengte en armomtrek gemeten. Binnen 72 uur na de geboorte werden 
het gewicht, lengte en arm-, borst-, en hoofdomtrek van 410 zuigelingen gemeten. 
Tevens werd de zwangerschapsduur vastgesteld. De zuigelingen werden hierna 
gevolgd tot de leeftijd van zes maanden. ledere week werd de moeder gevraagd 
naar symptomen van infectieziekten bij de zuigeling gedurende de week 
voorafgaand aan het interview. De zuigelingen werden maandelijks gewogen en 
gemeten, en bij een en zes maanden werd het serumzink bepaald. Na zes maanden 
waren er nog 383 zuigelingen in het onderzoek (184 in de zink- en 199 in de 
placebogroep). Alle zuigelingen waren bij de geboorte gevaccineerd met het 
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standaard Bacille Calmette Guerin (BCG) vaccin. Vanaf de leeftijd van 9 weken 
waren 203 van deze kinderen met maandelijkse intervals tevens gevaccineerd met 
3 doseringen van het gecombineerde diphterie, tetanus, en kinkhoest (DTP)-
Haemophilus influenza type-b (Hib)-conjugaat vaccin. Bij 24 weken werd de 
tuberculine (purified protein derivate; PPD) huidtest uitgevoerd in 345 zuigelingen. 
Hib-polysacchariden-(PRP)-antilichamen werden gemeten bij 91 zuigelingen op de 
leeftijd van 4 en 24 weken. 
De zwangere vrouwen die aan dit onderzoek meededen, hadden een hoog 
risico op inadequate inneming van energie en zink. De mediaan innemingen van 
energie (6065 kJ/dag) en zink (6,1 mg/dag) waren laag en meer dan 85% van de 
vrouwen had een verhoogd risico op inadequate zinkinneming (hoofdstuk 2). Er 
werd geen behandelingseffect gevonden van zink op het geboortegewicht (2513 ± 
390 en 2554 ± 393 gram in zink en placebogroepen respectievelijk), noch op de 
zwangerschapsduur, geboortelengte, of op hoofd-, borst- of armomtrek {hoofdstuk 
3). Echter, zuigelingen van moeders die zink hadden gekregen tijdens de 
zwangerschap hadden een significant verlaagd risico vergeleken met zuigelingen in 
de placebogroep op het voorkomen tijdens de eerste zes levensmaanden van acute 
diarree (RR: 0,84; 95% betrouwbaarheidsinterval (BTH): 0,72-0,98), dysenterie (RR: 
0,36; 95% BTH: 0,25-0,84) en impetigo (RR: 0,53; 95% BTH: 0,34-0,82). De 
gereduceerde risico's werden alleen geobserveerd in de LBW-zuigelingen en niet in 
zuigelingen met een normaal (> 2500 g) geboortegewicht. Er werden geen 
verschillen gevonden tussen de twee interventiegroepen in groei van de zuigeling 
noch in serumzink concentrates (hoofdstuk 4). In de LBW zuigelingen werd een 
lager percentage negatieve readies op de PPD-huidtest geobserveerd in 
zuigelingen uit de zinkgroep (66,2%) vergeleken met de placebogroep (78,5%; 
p=0,07). Bij zuigelingen met een normaal geboortegewicht werden geen 
verschillen tussen de twee interventiegroepen gevonden. Tevens werden er geen 
verschillen gevonden in het percentage zuigelingen met PRP-antilichaam-
concentraties boven het beschermende niveau tussen zink (81%) en placebogroep 
(89%). De gemiddelde PRP-antilichaam-concentraties bij 4 en 24 weken waren niet 
verschillend tussen de twee groepen (hoofdstuk 5). 
Uit deze bevindingen concluderen wij dat suppletie met 30 mg elementair 
zink per dag tijdens de laatste twee trimesters van de zwangerschap bij arme 
vrouwen uit de sloppenwijken van Bangladesh geen verbetering liet zien van de 
foetale of de postnatale groei. De suppletie resulteerde wel in een lager risico op 
diarree en impetigo tijdens de eerste zes levensmaanden, met name in LBW 
zuigelingen. Het hogere percentage positieve readies op de PPD-huidtest op de 
leeftijd van zes maanden in deze groep kinderen geeft aan dat deze effecten 
waarschijnlijk werden veroorzaakt door een verbeterde cellulaire immuniteit. 
In de tweede studie werd een nieuw cohort van 301 zuigelingen geworven 
op de leeftijd van 4 weken en ad-random toegewezen aan dagelijks 5 mg 
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elementair zink (n=152) of placebo (n=149) tot de leeftijd van 24 weken. De 
zuigelingen werden iedere week bezocht om informatie te verzamelen over het 
volgen van het onderzoeksprotocol en de ziektedruk terwijl iedere maand het 
gewicht, en de lengte, hoofd-, borst-, en armomtrek werden gemeten. Aan het 
begin van het onderzoek en met 24 weken werd het serumzink bepaald. De 
zuigelingen werden gevaccineerd met het standaard BCG-vaccin op de leeftijd van 
4 weken en met het gecombineerde DTP-Hib-vaccin vanaf de leeftijd van 9 weken. 
241 van deze kinderen kregen bovendien nog het heptavalent Pneumococcal 
conjugaat (PNC) vaccin vanaf de leeftijd van 18 ± 1 week. De reactie op de PPD-
huidtest en de hoeveelheid antilichamen voor Hib en elk van de zeven 
Pneumococcal serotypen werden bepaald op de leeftijd van 4, 24 en 33 weken. 
Op de leeftijd van 24 weken waren de serumzink concentrates hoger in de 
zuigelingen die zinksuppletie hadden ontvangen vergeleken met de zuigelingen die 
de placebo hadden gekregen (13,3 ± 3,8 vs. 10,7 ± 2,9 |amol/L; p<0,001). Een 
significant grotere gewichtstoename werd geobserveerd in de zinkgroep 
vergeleken met de placebogroep bij 42 zuigelingen die aan het begin van het 
onderzoek "zinkdeficient" waren, dat wil zeggen een serum zink concentratie 
hadden van < 9,18 nmol/L (3,15 ± 0,77 vs. 2,66 ± 0,80 kg, p < 0,04). Voor de 
overige kinderen waren er geen verschillen tussen de interventie en controlegroep 
in gemiddelde gewicht- en lengtetoename tussen 4 en 24 weken. Na zinksuppletie 
hadden zuigelingen die zinkdeficient waren tevens een verminderd risico op het 
voorkomen van acute ontstekingen aan de lagere luchtwegen ofwel acute lower 
respiratory infections (ALRI) (RR:0,30; 95% BTH: 0,10-0,92) terwijl er geen 
verschillen werden aangetroffen tussen de twee zink en placebogroep bij 
zuigelingen die niet zinkdeficient waren (hoofdstuk 6). Na drie doseringen met het 
PNC-vaccin, lagen de gemiddelde Pneumococcal-serotypen-antilichaam 
concentrates in de orde van 3,6 tot 13,3 ng/ml. Op de leeftijd van 24 weken 
waren de concentrates significant hoger in de zuigelingen die het PNC-vaccin 
hadden ontvangen vergeleken met de zuigelingen die alleen het DTP-Hib-vaccin 
hadden gekregen. Er werden geen ernstige bijwerkingen geconstateerd na de PNC 
vaccinatie. Zinksuppletie resulteerde in hogere concentrates antilichamen voor de 
serotypen 9V en 23F maar er was geen effect voor de overige serotypen noch voor 
de reactie op de DTP-Hib vaccinatie. Zinksuppletie had een marginaal negatief 
effect op de reactie op de PPD-huidtest (hoofdstuk 7). 
Uit de bevindingen van deze studie concluderen wij dat suppletie met 5 mg 
elementair zink per dag op de leeftijd van 4 tot 24 weken, de lengte- en 
gewichtsgroei verbeterde en het voorkomen van ALRI verminderde, maar alleen in 
zuigelingen die zinkdeficient waren op de leeftijd van 4 weken. Echter, de meeste 
zuigelingen lijken geen baat te hebben bij zinksuppletie voor wat betreft de groei 
en ziektedruk. Er was geen duidelijk effect van zinksuppletie op de immuunreactie 
van de zuigelingen. 
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In hoofdstuk 8 evalueren en vergelijken we de bevindingen van de twee 
studies. We concluderen dat zinksuppletie tijdens de vroege zuigelingentijd 
voordelen kan hebben op de postnatale groei van de zuigelingen maar alleen in 
zuigelingen die om de een of andere reden al zinkdeficient zijn op een heel jonge 
leeftijd. Echter, voor de meeste zuigelingen op deze jonge leeftijd gaf 
zinksuppletie geen effect op de groei. Het is mogelijk dat zink niet het 
belangrijkste limiterende nutrient was voor de groei in deze vrouwen en kinderen. 
Bovendien kan de relatief korte duur van onze studies ervoor gezorgd hebben dat 
wij een groeieffect van zink niet aan konden tonen en dit geldt met name voor een 
mogelijk secundair effect op de groei via de geobserveerde reducties in de 
ziektedruk. Zinksuppletie tijdens de zwangerschap verminderde de ziektedruk van 
diarree en impetigo, met name in kinderen met een te laag geboortegewicht. Deze 
bevindingen staan in contrast tot de effecten van zinksuppletie tijdens de vroege 
kindertijd. Hierbij werden bij de meeste kinderen geen effecten waargenomen op 
de ziektedruk, behalve bij kinderen die op de leeftijd van 4 weken zinkdeficient 
waren. In deze zuigelingen werd een lagere incidentie van ALRI waargenomen. De 
contrasterende resultaten van deze twee studies suggereren dat zinksuppletie 
tijdens de zwangerschap wellicht een effectieve manier is om bepaalde 
gezondheidsrisico's te verminderen die geassocieerd zijn met LBW of met 
zinkdeficientie. 
Het percentage LBW kinderen in Bangladesh is het hoogste ter wereld. Deze 
kinderen hebben een verhoogd risico op aantastingen van het immuunsysteem, een 
verhoogde ziektedruk en verhoogde sterfte en een verminderde cognitieve 
ontwikkeling. Onze bevindingen suggereren dat preventieprogramma's in 
ontwikkelingslanden op het gebied van kindergezondheid en -sterfte dienen te 
overwegen om zink toe te voegen aan multi-micronutrienten supplementen voor 
zwangere vrouwen, met name in gebieden waar LBW veel voorkomt. 
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nogmaals bedankt voor al je werk aan de cover van het proefschrift. 
Carola: al weer een mijlpaal in onze vriendschap! Eindelijk kun je dan paranimf 
voor mij zijn. Ik ben heel erg blij dat onze vriendschap stand heeft gehouden 
ondanks dat we op verschillende continenten waren de afgelopen jaren. 
En dan natuurlijk Karst, mijn diep-Fries, zonder wie ik dit proefschrift nooit 
begonnen en geeindigd was en zonder wie ik sowieso nooit in Bangladesh terecht 
was gekomen....ik ben heel blij met je! Sinds twee jaar is Julia er en heeft alle 
cliche's waargemaakt. Ze vroeg en kreeg de aandacht die ze verdiende tijdens het 
schrijven van dit proefschrift en zorgde zo voor de nodige afleiding. Later zal ze 
het hopelijk allemaal begrijpen waarom mama steeds achter de computer moest. 
Voorlopig zijn Tinky Winky en Bert en Ernie veel belangrijker en dat hoort ook zo! 
Ik kijk erg uit naar ons nieuwe avontuur samen in Nederland 
Saskia 
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